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Abstract 
Human skin, the largest organ in the body, is consistently exposed to outside elements, 
making it one of the body’s most vulnerable organs. Factors that contribute to deterioration of 
the cosmetic appearance of the skin include disease, injury, the environment, age, and genetic 
conditions. In some cases, physical damage to the skin may result in scarring of the skin. The 
cosmetic industry consistently seeks new products to improve skin appearance and conditions. A 
Worcester Polytechnic Institute (WPI) team has discovered that fibrin, an insoluble protein and 
first responder in wound healing, can encapsulate retinol, a popular active ingredient commonly 
found in cosmetics skincare. Fibrin can also be degraded using bromelain, a natural enzyme also 
found in cosmetics, to control the release of retinol. This demonstrates the opportunity for 
fibrin’s use as a novel delivery carrier for cosmetic product ingredients. Utilizing an automated 
manufacturing process, fibrin microthreads may be infused with popular active ingredients in the 
cosmetic industry, and ground into smaller particles to be incorporated into a topical cream. The 
team developed a prototype of a fibrin-based skin cream and a mechanism to automate the 
process of producing infused fibrin microthreads.  
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Chapter 1: Introduction 
Fibrin is a protein developed at Worcester Polytechnic Institute (WPI) that have the 
potential to affect the field of biomedical research and tissue engineering through a variety of 
applications. Fibrin, which is composed of fibrinogen and thrombin, is produced within the body 
when a person suffers an injury that results in bleeding. The protein compound plays an integral 
role in blood clotting by initiating the regenerative process of wound healing [1]. Fibrin has 
already been reproduced in a laboratory setting where it has been manufactured into 
microthread-like structures. A number of experiments, ranging from human mesenchymal stem 
cell (HMSC) engraftment to closing heart defects, have explored the potential use of these 
microthreads in cell therapy applications and in wound closing [2]. The expansion of the 
microthreads’ studies in research has presented new opportunities for future medical device 
products and other industries. The current process to develop the microthreads in research 
laboratories, however, only enables manual production of fibrin microthreads in small quantities 
per batch. In order to ease the production of fibrin microthreads for research, and to further 
enhance market opportunities for the invention, a manufacturing machine that can mass produce 
fibrin microthreads in large, consistent quantities is required. 
The team, consisting of three WPI students recognized that due to Food and Drug 
Administration (FDA) regulations, certain applications of fibrin microthreads, such as human 
mesenchymal stem cell (HMSC) engraftment to enclose heart defects, are not currently 
commercially plausible. Although such applications are desirable by stakeholders in the future of 
fibrin microthreads, the team determined that current commercial promise exists in the cosmetics 
field.  
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Although background and cosmetic market research provided substantial information on 
fibrin and its potential value in the cosmetics realm, it was decided that more could be done with 
regards to customer discovery. The team opted for a consumer-driven design approach to 
producing Fibrina. Over 30 interviews were conducted with professionals in the cosmetics 
industry. These professionals included dermatologists, manufacturers, distributors, retailers, and 
cosmetics marketers. Every-day consumers were also interviewed within low, middle, and high-
end stores. The resulting takeaways provided enough information to identify a customer segment 
and value proposition which drove much of the experimentation work for this project. 
Using background literature on cosmetic dermatology and the insights taken from 
customer discovery, a series of experiments were created to validate Fibrina’s as a valuable 
cosmetic ingredient. The first experiment involved identifying a cream composition which could 
work as a baseline for current and future testing with fibrin-based particles. The second 
experiment was broken down into two parts: part one identified a way to degrade fibrin and 
subsequently release retinol introduced to it; part two quantified the release of retinol from 
degraded fibrin particles using UV spectroscopy. An additional sub-experiment was performed 
to try and identify any potential losses in retinol during the extrusion process. Finally, an 
experiment utilizing atomic force microscopy was performed in an attempt to discover other 
properties of fibrin which could enhance active delivery to the skin. Through the customer 
discovery process, two more experiments were identified, but ultimately not undertaken by the 
team. These two experiments were designed to identify fibrin’s skin diffusion and UV 
absorbance properties. 
Results from the Fibrina experiments highlighted fibrin’s capabilities to exist and be 
tested within a baseline cream composition. Using a natural fibrinolytic such as bromelain, fibrin 
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can be degraded. This degradation allows for the release of actives encapsulated within fibrin, 
and with different concentrations of bromelain, fibrin’s degradation rate can be controlled. 
However, UV spectroscopy analysis performed in conjunction with the degradation experiments 
was unable to match degradation with the release of retinol. Atomic force microscopy imaging 
was able to show nanoscale surface roughness properties of fibrin particles. 
 In order to implement fibrin particles within our Fibrina product, the team realized that 
fibrin microthreads, due to their extrusion process, high surface area to volume ratio, and 
advantageous mechanical structure, could be utilized in this production process. The team set out 
to design and prototype an automatic fibrin microthread extrusion device that fulfilled the need 
for mass production of fibrin microthreads to be implemented into our novel skin cream. The 
benefits of a fibrin microthread extrusion device include minimizing production time for threads, 
eliminating human error in the formation of consistent, customizable threads, and creating a 
method of mass production for future commercial applications of the invention. Using a precise 
engineering design process and computer-aided-design, the team aimed to create a device that 
replicates the current, manual fibrin microthread extrusion process into an automated system 
with greater accuracy and consistency. The ability to manipulate the ingredients of the 
microthreads, their properties, and to form a desired end product opens greater opportunity to 
have an efficient supply of additive infused fibrin for our product.  
 The final design of the team’s fibrin microthread manufacturing device incorporated a 
stepper-motor driven chain mechanism that completely automated the extrusion process for the 
production of fibrin microthreads. The mechanism can be attached to a syringe pump, which is 
commonly found in laboratories, via tubing, to deliver a fibrinogen, thrombin, and additive 
solution to the extrusion phase of the production process. The design incorporated magnetic 
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clamps that guide a drawn fibrin microthread through its production process. The fibrin 
microthreads were drawn into a tub of HEPES solution, a buffering solution used to polymerize 
the fibrin microthreads, across the surface of two open magnetic clamps and a submerged 
conveyor belt. The magnetic clamps were attached to chain links that moved in tandem with the 
submerged conveyor belt. Once the threads reached the end of the conveyor belt, the clamps 
were guided shut and lifted out of the HEPES tub via sprockets. From there, two chain guiding 
platforms guided the clamps away from one another, stretching the fibrin microthreads to double 
their original length. A dryer was placed within the frame of the mechanism to dry the threads 
during this process. At the end, the threads could be removed manually by a user. Utilizing this 
mechanism, additive infused fibrin microthreads could be mass produced. From here, the fibrin 
microthreads needed to be converted into fibrin-based particles. 
Next, the team designed a process of converting the produced fibrin microthreads into 
particle form within a range of 0.1 – 1 mm. In order to do this, the team explored four methods 
of conversion. The four methods were grinding and kneading, rotational flat disks, manual 
trimming, and dual-action automated blades. After conducting initial testing and doing image 
analysis, the team identified three methods: grinding, manual and automated trimming, which 
successfully converted the fibrin microthreads to a particle form. The second part of this 
objective included creating a mechanism that utilized successful methods in order to create a 
space for a more equal and cleaner conversion. The team performed a design analysis and came 
up with a final design that included two clamps with PVC coated prongs that were attached to a 
ring stand. The first clamp has bundled fibrin microthreads mounted to them with tape to 
stabilize them, while the second clamp is holding a 50 mm circular piece with mesh to filter out 
debris and particles larger than 1 mm. A 60 x 15 mm petri dish collects the desired particles. The 
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first clamp can also hold a small funnel that can bundle and group the fibrin microthreads as 
well. Utilizing this method, fibrin-based particles were able to be introduced as an ingredient in 
Fibrina. 
In regard to the entrepreneurial pursuit, customer discovery was essential to defining the 
scientific metrics needed to validate fibrin as a valuable cosmetic ingredient. Given the lack of 
any research into fibrin’s use as a functional cosmetic ingredient, much of the approach to this 
project existed as trial and error. Background literature, insights from industry professionals, and 
continuous learning helped to guide the team throughout its scientific endeavors. Modeling fibrin 
particles as carriers for actives proved to be difficult, and more testing is required to better 
validate its use within cosmetics. 
  Recommendations towards furthering the customer discovery process of Fibrina, 
repeating and expanding upon Fibrina experiments, and upscaling and refinement of the 
automated machine can be made. The team is hopeful with more research that Fibrina can see 
itself in the cosmetics market relatively soon. Milestones for entrepreneurial success need to be 
established to help guide future work in adding value to fibrin as a skincare ingredient. 
In the report herein, the team conveyed the research, methodology, findings, and results 
for the validity of fibrin in the cosmetics market, the design of the fibrin microthread production 
process, and the conversion of fibrin microthreads into particles used for implementation into 
Fibrina. 
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Chapter 2: Literature Review 
2.1 What is Fibrin? 
When the body suffers an injury such as a cut or wound, the first major protein to act as 
the blood clotting agent is fibrin. Fibrin is composed of a chain of fibrinogen monomers. These 
monomers exist solubilized within the blood until they are activated by a protein called 
thrombin. Fibrinogen is produced in by both the liver and blood plasma. When the fibrinogen 
monomers bind together, they form a mesh-like structure which traps surrounding blood cells at 
a wound site to form a clot and prevent further bleeding [1]. 
Fibrin formation begins at a wound site in which the interaction between the two proteins 
(fibrinogen and thrombin) commences. When the body recognizes an injury, prothrombin, which 
is produced in the liver, becomes proteolytically cleaved into its active version known as 
thrombin. Thrombin then catalyzes the hydrolytic removal of two fibrinopeptides (Type A and 
B) on fibrinogen molecules [2]. The removal of fibrinopeptides A and B reveal binding sites, 
which interact with complementary sites at the ends of other fibrinogen molecules. Soluble 
fibrinogen molecules can then bind to each other freely to form fibrin. Fibrin monomers will 
continue to assemble as long as thrombin activates more fibrinogen molecules. A clot then forms 
when a large amount of fibrinogen monomers are bound together into a fibrous branch structure 
[3,4]. 
 
2.2 Current Applications of Fibrin 
Fibrin has been utilized in a variety of ways within the biomedical field. It has been used 
to create scaffolds for tissue engineering applications and as a sealant material in a plethora of 
surgeries. Together, along with other existing applications, these uses reveal the broad range of 
benefits of which Fibrin is being used for today. 
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Fibrin’s use as a scaffold for tissue engineering has taken multiple forms including: gels, 
glues, and microbeads, which are used for engineered bone and skin tissues [5]. These scaffold 
choices can be modified to incorporate several biologically active peptides to increase the local 
concentrations of growth factors and mimic the natural milieu surrounding the cells [5]. Fibrin is 
used extensively to support three-dimensional scaffolds in tissue engineering. Such examples 
include its use for adipose, bone, cardiac, cartilage, liver, nervous, ocular, skin, tendon, and 
ligament tissues [5].  
Fibrin sealant or "glue", is a unique hemostatic/adhesive material used in a number of 
surgical applications [6]. Fibrin sealant devices work much like a two-for-one syringe, where 
fibrinogen and thrombin are at separate in the device, but once injected, are injected 
simultaneously. The amount of fibrinogen and thrombin within these devices is in high 
concentrations; thus promoting immediate clotting [6].  The first fibrin sealant that was approved 
for use by the Food & Drug Administration (FDA) was in 1998. However, in countries such as 
Europe, fibrin sealants have been around for much longer. Fibrin sealants have predominately 
made a beneficial impact in surgical procedures that require site-specific blood clotting [6]. 
Fibrin gels have also taken stride in the biomedical industry, providing the same positive 
benefits of blood clotting and natural wound healing. Their nonlinear elastic properties, in 
conjunction with their soft compliance at small strains and stiffening to resist large deformations, 
make them useful for their function as hemostatic plugs and matrices for cell migration and 
wound healing [7]. Their current clinical uses stem from general surgical wound repair to also 
drug/cell delivery [7]. 
These applications demonstrate the extent to which fibrin can be altered to improve the 
medical field, and further advance the biomedical sciences. A number of commercial fibrin 
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sealants and glues have already been FDA approved, while others are awaiting FDA approval [6] 
[8]. While these applications have shown the extent at which fibrin has taken certain forms to 
enter the commercial market, one application that has not been mentioned is the application of 
fibrin in the form of microthreads.  
 
2.3 What are Fibrin Microthreads? 
Fibrin microthreads are a recent invention in the biomedical field of research. These 
laboratory-developed threads are used in a variety of experiments relating to wound healing and 
cell therapy engraftment. Currently, biomedical researchers are investigating the use of these 
microthreads on the medical market. However, the time and resources required to push fibrin 
microthreads into the market make this invention less profitable. It is still vital to learn and 
understand the process by which fibrin microthreads are made in order to understand the 
promising applications for fibrin microthreads.  
2.3.1 How are Fibrin Microthreads made? 
 The general process of making these threads involves the extrusion of fibrinogen and 
thrombin into a specially crafted extruder device (see Appendix I). Once the fibrin microthreads 
are extruded from the device, the threads sit in a 10mM HEPES solution. This particular HEPES 
solution also contains 10mM CaCl2, which helps activate thrombin, allowing it to hydrolyze the 
removal of the fibrinogen peptides A and B. The threads are then left in the HEPES for 10 
minutes before removal from the bath for drying. Once the threads are dried completely, they are 
stored in an aluminum foil wrapping, or used immediately for other experiments. 
2.3.2 What are the Applications of Fibrin Microthreads? 
Fibrin microthreads have been used in a number of laboratory experiments, mainly 
focusing on experiments surrounded cellular therapy and delivery. In one experiment, the threads 
were engrafted with human mesenchymal stem cells (HMSCs) to determine whether they were 
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an effective cell delivery method [9]. The purpose of this experiment was to determine if this 
method effectively localized cell delivery [9, 10]. The threads were woven into grafts and 
implanted into diseased animal hearts as a means of treating myocardial infarctions [2]. Other 
scaffolding design strategies were explored. Threads were woven into a braid, or aligned 
together in a sheet. The purpose of these various weave structures was to mimic the alignment of 
certain tissue structures within the body [9, 10]. The results of these experiments identify 
potential for use of fibrin microthreads as suitable cell delivery carriers as well as scaffolds for 
aiding in tissue recovery.  
 
2.4 VitaThreads 
VitaThreads is a limited liability company that was founded in 2012. Vitathreads focuses 
on the potential for fibrin microthreads to be used as medical-grade sutures. Thus far, 
VitaThreads has aligned its marketing of fibrin threads toward facial reconstructive surgery [11]. 
Due to fibrin’s naturally decomposing properties, fibrin-based sutures would be ideal in closing 
facial skin. With ownership of the intellectual property on fibrin microthreads, VitaThreads has 
pushed to get the threads out into the medical market [12]. 
 
2.5 Current IP status of Fibrin Microthreads 
The research and development of fibrin microthreads has broken ground in the field of 
tissue regeneration. The realm of this discovery includes its use in wound and cardiovascular 
tissue development. Due to the extent of these discoveries, the team’s institution, Worcester 
Polytechnic Institute (WPI), and professors who have developed the threads, including Professor 
George Pins, and the team’s advisor, Professors Glenn Gaudette, have claimed the rights to their 
discoveries through filed patents with the World Intellectual Property Organization (WIPO) and 
the United States Patent and Trademark Office (USPTO). 
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            These filed patents, which are all assigned to WPI, claim several developmental methods 
and applications for fibrin microthreads that is optimal for future commercialization efforts. For 
example, a WIPO published patent, WO 2007109137A1, claims a method for producing fibrin 
microthreads along with its composition. Specifically, it claims using fibrinogen and another 
molecule, which for research purposes refers to thrombin, to create a mixture that is extruded 
into a medium to produce a thread [13]. Since WPI is assigned the patent, this enables the team 
to use this method for consideration of a large scale manufacturing method for these threads.   
Several patents that have been filed on fibrin microthreads enables the team to explore 
different opportunities for application of the threads. United States patent application 
20130096610A1, “Biopolymer microthreads with microscale surface topographies,” discloses a 
method for creating textured threads [14]. The development and change of texture on these 
threads allows its application to different kinds of damaged tissues. Additionally, a filed patent 
application, 20150005739A1, discloses the use of a fibrin microthread coupled with a needle in 
order to suture a region of damaged tissue. By removing the needle from the thread, the fibrin 
thread is retained in the body, which allows it to treat damaged tissue. This includes, but is not 
limited to, cardiovascular tissue [15]. Finally, a WO patent publication, 2015148993A1, 
discloses the use of fibrin microthreads to suture a damaged tissue, which can be absorbed by the 
tissue rapidly for treatment. This patent has been assigned to Vita Threads, LLC [16]. Although 
these published patents and filed applications provide exclusive rights to the development of 
fibrin microthreads, certain limitations to the use of these threads still exist. 
2.6 Food and Drug Administration 
Although the intellectual property assigned to VitaThreads contains novel claims in the 
field of tissue engineering, the commercialization of fibrin microthreads presents several 
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obstacles. Since fibrin microthreads present ample opportunity in the field of sutures, wound 
healing, and potentially, in the future, cardiovascular procedures. Since the Food and Drug 
Administration (FDA) regulates the commercialization process of inventions of this nature, 
VitaThreads is required, under the Food, Drug, and Cosmetic Act (FDCA), to disclose the device 
to the FDA for approval. The financial implications and timeliness of this process proves 
unfavorable for VitaThreads. 
            The FDA defines products that are regulated either as a device, drug, or biologic. For 
purposes fully understanding the scope of potential regulation of fibrin microthreads, it is 
important to be knowledgeable of the regulatory processes of both biologics and devices. In one 
definition, the FDCA defines a medical “device” as an implant “intended to affect the structure 
or any function of the body [17].” However, depending on the risk the medical device presents, 
the degree of FDA regulation may differ. Three different classes exist, (Class I, Class II, and 
Class III), for identifying the degree of necessary regulation in order to receive FDA approval for 
commercialization. Specifically, a Class III medical device, the classification that requires the 
most taxing approval process, claims that “insufficient information exists [on the disclosure] to 
assure that general controls and special controls will provide reasonable assurance of safety and 
effectiveness” [17]. Further, a Class III medical device claims that the disclosure may be 
“represented to be life threatening or life supporting, those implanted in the body, or those 
presenting potential unreasonable risk of illness or injury” [17]. Considering these parameters, 
the potential commercial applications of fibrin microthreads, the risk these procedures could 
have on a human subject, and fibrin’s origin in the blood classifies the invention as a biologic 
under the FDCA.  
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            In order to obtain FDA approval on a Class III medical device, an approved Premarket 
Approval Application (PMA) is required. The fee of a PMA application alone, reported on the 
FDA website under 21 CFR part 814 for fiscal year 2003 was $154,000 [18]. The PMA, 
however, is not merely an application preceded by a user fee; rather, an in depth process that 
involves experimentation and overwhelming proof of intended effectiveness of the device. 
Expanding upon this process, an Investigational Device Exemption (IDE) is required to receive 
PMA approval. The IDE involves sponsored human subject research that is approved by the 
FDA and the Institutional Review Board (IRB). In the case of fibrin microthreads, where studies 
comprise obvious risk to the subjects, the difficulty of FDA and IRB approval increases. PMA 
approval exists on the terms that the sponsored research assured safety as defined in the FDCA, 
and that experts in the field of research can “reasonably conclude” that the disclosure presents 
effectiveness in achieving its purpose [17]. Finally, prior to commercialization of a Class III 
medical device, a Quality System Regulation (QS)/Good Manufacturing Practices (GMP) 
examination, as defined in 21 CFR part 820, must occur in regard to the process and standards of 
mass production of the medical device [18]. 
 Fibrin is a blood product. If the fibrin microthreads were applied without the use of 
another implantable device, it would be classified as a biologic. A product classified as a 
biologic engages in premarket approval through regulations outlined in the Public Health 
Services (PHS) Act. Specifically, regulations for biologics based upon guidelines stated in 
section 351(a) of the PHS Act are enforced by the FDA’s Center for Biologics and Research 
(CBER). Under section 351(a), a Biologics License Application (BLA), which cost itself exceeds 
$250,000, may be issued by the FDA if the product, “meets standards designed to ensure the 
continued safety, purity, and potency of such products” [19,20]. In order for this determination to 
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be reached, the licensure must disclose convincing data show through preclinical and clinical 
research. 
 Finally, a product may be defined as a combination product, that is, a product composed 
of a combination of a drug, device, or biological product [21]. In the case of fibrin microthreads, 
the FDA may define an application for the invention as a biologic/device under a combination 
product categorization. In the case of a combination product, the product is assigned to an 
agency center after it is determined what the primary jurisdiction is based on which constituent, 
(device, biologic, or drug), has a primary role in delivery the performance of the product [18]. 
Therefore, a biological/device may have the biologic constituent determined to attribute 
primarily to the end-result of the product, and therefore would be assigned to a biologic agency 
for regulation. 
 
2.7 Cosmetic Industry 
When dealing with a new potential product, it is important to define the scope and use of 
the product’s final form. In order to determine the best way to utilize the product, the team 
researched its current regulatory guidelines and understands the products on the market in the 
industry of interest. 
Cosmetic products and cosmeceuticals are not regulated by the FDA. The Food, Drug, 
and Cosmetic Act was passed in 1938 and became the official regulation document for cosmetic 
products [21]. An independent panel known as the Cosmetic Ingredient Review (CIR) also 
assesses the safety of cosmetic products through medical and scientific expertise. Their feedback 
is considered by the FDA when determining the safety of cosmetic products. Even though the 
majority of cosmetic products (aside from color additives) do not require FDA approval in order 
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to be sold and marketed to buyers, the FDA still monitors the safety and effects of the products 
[22]. 
One way the FDA monitors cosmetics products on the current market is through their 
level of transparency with buyers: the product labeling. According to Section 602 of the Food, 
Drug, and Cosmetic Act, a cosmetic is considered a misbranded item if it contains one of the 
following: the label contains false information and/or is misleading, the label does not include 
information such as the origin of manufacturer, packer, and distributor and the amount of 
contents of the product that was produced, the label does not clearly state the information in a 
way consumers can understand, and the container or bottle is filled with a product different from 
what is labeled [23].  Product labelling is important for the consumers’ safety as well as the 
product’s legitimacy. 
Some ways the FDA encourages cosmetic manufacturers to confirm the validity of their 
products is through the Voluntary Cosmetic Registration Program [20]. This program gives 
manufacturers the opportunity to release information regarding their products to a public 
database. Based on the feedback from the CIR and industry data, the FDA often performs 
manufacturer inspections (factory and products), while specifically examining products that have 
been reported to cause consumer problems. Even though the FDA cannot prevent cosmetic 
products from being marketed globally, they still inquire levels of transparency and honesty to 
ensure the products are safe for usage. 
 
2.8 Current Cosmetic Products on the Market 
Current cosmetic products offered on the market include facial cleansers, skin creams and 
moisturizers, and scar treatments. According to the Cosmetic, Toiletry, and Perfumery 
Association (CPTA), the purpose of these products are to replenish and protect the skin, alter the 
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external appearance (i.e. face) to give the user a rejuvenated and cleaner look, and remove the 
excess oils from the external surfaces of the body [23]. Skin care products in particular have 
been the source of interest for many buyers because they are cheaper than medical alternatives 
and can be easily accessed. In 2015, it was shown that the anti-aging creams in the cosmetic 
industry held the biggest market share of global skin care products due to their varied uses [24].  
According to an article written in September 2016 [25], it is predicted that the sales of cosmetic 
products will rise globally due to their diversified uses. The appealing effects of these skin care 
products such as the minimization of wrinkles, minimization of acne scars, and dark spot 
correction motivate major brand name companies to constantly reevaluate the contents and 
ingredients of their skin care products. 
The major ingredients included in skin care products vary from product to product and 
from company to company. The ingredients that are frequently used in skin care products are 
Alpha-hydroxy acids (AHAs), retinol, hyaluronic acid, copper peptide, alpha-lipoic acid, and 
dimethylaminoethanol (DMAE) [26]. These ingredients are utilized in skin care products that 
produce anti-aging effects. In Table 1, a summary of these ingredients can be found: 
Table 1: Common Ingredients Used in Skin Care Products [26] 
Product Description 
Alpha-hydroxyacids (AHA) AHAs are used in lotions and creams to help correct the discolored pigmentation on 
the skin as well as remove the appearance of age spots. It is found in many over-the-
counter products. Glycolic Acid is a type of AHA 
Retinol Retinol is an ingredient that is a derivative of vitamin A and is used to produce anti-
aging effects. Skin responds better to retinol than other ingredients due to the 
molecular structure of Vitamin A. It is small enough to penetrate deep within the skin 
where it combines with the collagen and elastin to initiate the rejuvenation process by 
correcting skin pigmentation, texture, and tone. 
Hyaluronic Acid Hyaluronic acid is often an ingredient mixed with vitamin C to increase the amount 
of skin permeation. This ingredient is found in the body naturally in young skin. The 
natural aging process lowers the amounts of hyaluronic acid in the body. Reapplying 
hyaluronic acid into the skin helps to maintain a youthful appearance. 
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Copper Peptide Copper peptide is a relatively newer ingredient used in skin care products as it has 
been on the market since 1997. This ingredient promotes the growth of collagen and 
elastin in the body while encouraging the effectiveness of the body’s tissue 
regeneration process. It also has the ability to smoothen, soften, and toughen up the 
skin in a shorter amount of time than other anti-aging skin care ingredients. 
Alpha-lipoic Acid Alpha-lipoic acid has been called the universal antioxidant because it can dissolve in 
oil and water. It has the ability to repair past damage to the skin and prevent future 
damage. It has the ability to protect the skin from harmful agents and reduce the lines 
in the skin. 
Dimethylaminoethanol (DMAE) DMAE is in foods such as salmon, sardines, and anchovies. It is produced in the brain 
and important for mental health. In skin care, it is found to be effective in reducing 
lines and wrinkles on the skin when applied as a topical agent. 
  
Many of these ingredients found in skin cream have alternative purposes aside from the 
anti-aging and rejuvenating effects when used in skin care products. Fibrin, as mentioned earlier 
in this chapter, can help to repair damaged tissues as a blood clotting factor and is a naturally 
occurring protein in the body. Due to its small molecular size, it can potentially be utilized as a 
skin care agent to help promote rejuvenation and replenishment. 
2.9 IP Coverage on Powder and Cosmetics  
The application for fibrin microthreads in which the team pursued commercialization is 
in the field of cosmetics. Specifically, the team's method involves a composition containing 
fibrin microthreads infused with another agent, such as retinol, to improve the performance 
capabilities of the infused agent. The infused fibrin microthreads are converted into particle form 
for use as an active ingredient in skin cream. Therefore, it was important to explore the prior art 
within these embodiments to determine what limitations the art presents. This helped the team 
determine what factors to improve upon. 
            Methods and compositions used for cosmetic purposes are well known in the art. For 
example, US patent application 11761893, “Skin care compositions and treatments,” teaches of a 
composition containing growth agents to be used in pharmaceutical or cosmetic applications. In 
this disclosure, the method of caring for skin cells is utilizing cultured skin agents synthesized 
from cultured skin. A cell medium is utilized to capture these skin agents, and are incorporated 
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into a product to be applied to the skin of a patient [27, 28]. Skin care compositions of this nature 
may be commercialized and marketed within the cosmetics industry. 
            Further, fibrin powder is well known in the art. For example, US patent 9119897B2, “Dry 
powder fibrin sealant” teaches of a powder sealant composed of fibrinogen, thrombin, and an 
additional biocompatible material. Although relevant to the team’s desire to create fibrin powder, 
strict limitation exists in the claims in the powder’s application to open wounds to serve as a 
sealant. Recognizing this limitation to the patent proved important in ensuring our future 
concepts would not infringe on a previously claimed fibrin powder [29].       
   
2.10 Cosmeceuticals and the Consumer 
A crucial part of the cosmetics industry is the sub-group named “cosmeceuticals.” 
Cosmeceuticals, coined by Dr. Albert Kligman, claims that cosmetics products under this label 
contain pharmaceutical like properties. In particular, Dr. Kligman recognized that “some 
cosmetic products” had impact on the structure of skin. Since cosmeceutical products must have 
sufficient scientific evidence to back these claims, consumers contain high expectations. Due to 
an increase in consumer expectations of scientific claims in cosmeceutical products, the FDA has 
contained authority over these claims. The FDA acts against cosmeceutical companies that claim 
false principles, as defined by the scientific reasoning behind claims, and false labeling. 
Additionally, the Federal Trade Commission (FTC) presides over marketing and advertisements 
that cosmeceutical companies in the industry claim in order to protect consumers from deceptive 
advertising regarding products in the field [30]. The team recognizes that sufficient scientific 
research exists as a necessity in order to efficiently pursue the commercialization of a product 
cosmeceutical market. However, it is important to first understand cosmetic dermatology. 
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2.11 Cosmetic Dermatology 
Existing knowledge on the field of cosmetic dermatology can greatly benefit the team’s 
approach of scientific experiments, which will ultimately lead to the final product of a novel skin 
cream. This section focuses on the subfields of cosmetic dermatology that pertain to this project. 
These subfields include some of the basic concepts of skin physiology, the delivery of cosmetic 
skin actives, the science of moisturizers, and finally, developments related to anti-aging and the 
world of cosmeceuticals. 
2.11.1 Skin Physiology Pertinent to Cosmetic Dermatology 
Four main concepts play a primary role cosmetic dermatology as it relates to skin creams. 
The first concept discusses the epidermal barrier and the corresponding layers of the skin which 
contribute to its general function and permeability. The next topic covers information related to 
the skin’s somatosensory system. Next, the team addresses topical agents and their effect on 
skin. Finally, different techniques for evaluating cosmetic products is introduced and discussed. 
2.11.1a The Epidermal Barrier 
The skin acts as the physical barrier between the body and the external environment. 
There are three main components of the skin: the epidermis, the dermis, and the hypodermis [31, 
32]. The epidermis is the outermost layer of the skin, and is comprised of several layers of 
epithelial tissue. The stratum corneum (SC) is the outermost layer of the epidermis [33]. The SC 
acts as a barrier which retains water and electrolytes [34]. 
The epidermal barrier is responsible for protection against other factors such as UV rays 
and disease immunity [35]. The epidermal barrier changes with age. The external environment 
also plays a role in this change. Along with other factors related to health and lifestyle, the 
barrier will either sustain or lose elastic, retentive, and otherwise youthful properties [35]. The 
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team’s objective in creating a novel skin cream primarily interacts with the biological properties 
of the epidermal barrier. These properties include water evaporation, skin hydration and 
moisturization, desquamation, and potentially other barrier properties and protein functions. 
Properties such as water evaporation, skin hydration and moisturization, and 
desquamation are vital to the epidermis. The SC takes part in providing hydration and 
moisturization to skin via natural moisturizing factors (NMFs). NMFs are a collection of water-
soluble compounds which are vital to maintaining hydration, barrier homeostasis, desquamation, 
and plasticity [36]. The SC acts as the lipid barrier to the NMF, thus preventing its loss. The 
NMF provides hydration to the skin, even in harsh external environments [35, 37]. 
Desquamation is the shedding of the outermost layer of the skin. This process is vital for skin 
homeostasis [37]. Another sub process of the SC involves the regulation of proteases, which 
cause desquamation [38]. 
There exists a number of cosmetics ingredients that help restore skin barrier properties. 
Products labelled as moisturizers have shown to contribute positively towards restoring the SC 
[38]. The main ingredients used within these moisturizers are labelled as humectants, emollients, 
barrier compatible lipids, and antioxidant/anti-inflammatory agents. Humectants consist of a 
range of amino acids and their metabolites. Humectants aid to relieve dry skin conditions. 
Emollients prevent excessive moisture loss from the skin surface.  Barrier compatible lipids 
replace the loss of lipids naturally synthesized in the skin that are responsible for barrier 
recovery. Finally, antioxidants and anti-inflammatories protect skin from UV and decrease skin 
redness [39]. 
While modifying the properties of the epidermal barrier can be beneficial to the health of 
one’s skin, one must caution from applying substances which penetrate deeply into the skin. Said 
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substances can disrupt cellular processes existing in the lower layers [40]. Interrupting 
maturation of these cells or production of barrier lipids can result in undesired changes to the 
skin’s desquamation process and ultimately the thickness of the SC [41]. 
2.11.1b The Somatosensory System and Skin Sensitivity 
The somatosensory system of the skin covers the nerve impulses, which result in the 
brain responding to feelings of touch, temperature, pleasure, pain, and itch. Applications of 
topical products produce nerve responses that tell a person how an application is affecting their 
skin. Understanding skin sensitivity is essential to creating a good product that induces a positive 
feeling for the consumer. 
The skin recognizes its surrounding environment by means of multiple receptors that 
respond to different stimuli. The perception of pressure, vibration, and texture, all rely on a 
group of four different receptors, known as low threshold mechanoreceptors (LTMs). Together, 
these receptors are effectively responsible for the perception of touch [41]. 
Pain is a response to irritation, stinging, burning, soreness, or painful sensations arising 
from the skin. The perception of pain is not solely dependent upon receptor input; it is also a 
result from other processes and pathways that provide information about emotional or contextual 
components [42]. Itch was thought to be a response of weakly activated pain nerves. Recent 
findings show the feeling of itch has a set of primary afferent neurons [42]. Pain and itch are 
both useful skin responses that indicate a product is having a negative response to the skin. These 
receptors can be signaled off by agents within a skin cream, or are a response to how the product 
was put on. 
Pleasure is felt in response to low force, slowly moving mechanical stimuli affecting 
particular afferent neurons in the skin [43]. These afferents, alongside key myelinated and 
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unmyelinated fibers found in the skin, respond to parts of the nervous system which signal for 
pleasant touch [44, 45]. This is a highly sought after response for a skin cream product.  
The somatosensory system plays a key role in the development of a quality cosmetic 
product. Interactions between different stimuli create the sensation for positive, neutral, and 
negative responses to the skin. This can result in a favorable or unfavorable experience to the 
user of a skin product. 
2.11.1c Contact Dermatitis and Topical Agents 
Within the application of topical agents onto the skin, there exists the possibility of 
having adverse reactions. Contact dermatitis is among the most predominant type of adverse 
reactions that have occurred as a result of cosmetics products [46]. Various forms of contact 
dermatitis exist. Irritants, allergens, phototoxic exposure, and foreign body reactions all have 
potential in causing contact dermatitis. Common irritants include everything from environmental 
elements to various chemical compounds. Notable allergen groups include fragrances, 
preservatives, and botanicals, all of which can be found in nearly all cosmetic products, 
especially creams [47]. 
Contact dermatitis is a negative response from the skin due to contact with undesired 
substances. The reaction with the undesired substances typically produces an inflammatory 
response to the skin. This reaction couples with disruption of the stratum corneum, and 
epidermal cellular changes [48]. Allergic contact dermatitis works much like regular allergenic 
responses in that a person needs to be pre-sensitized to the causative agent in order for there to be 
an allergic reaction [47]. Phototoxic dermatitis is a particular type of dermatitis resulting from 
using plant-derived photosensitizing compounds followed by exposure to UV light. 
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Fragrances are a common cause of contact dermatitis [48]. Preservatives are a common 
skin care product allergy inducer [49]. With respect to moisturizers, the most common irritants 
and allergens include fragrances, preservatives, vitamin E, essential oils, benzyl alcohol, 
propylene glycol, and lanolin [50]. In short, a certain population of consumers will run into 
difficulty in trying to use products with fragrances and preservatives. While there are products 
that don’t use fragrances, nearly every skin cream product uses some form of preservative, as it 
is necessary for good shelf life. 
Treatment of contact dermatitis primarily relies on discovering the agent which is 
affecting an individual. From there, the objective is future avoidance of the allergenic agent. 
While not every consumer might be able to apply a skin cream product due to the adverse effects 
resulting from its ingredients, it may be important to have variations of product which allow for a 
larger consumer pool. 
2.11.1d Evaluation of Cosmetic Products 
Any kind of skin care product needs to be tested for its safety and efficacy. Non-invasive, 
cheap, and accurate testing protocols are the most ideal. One of the most effective ways of 
measuring the change in someone’s appearance through the use of cosmetics products is digital 
photography, although other means of evaluating cosmetics products exist. 
There are two challenges for photography in a clinical setting. The first challenge is to 
choose the best photographic technique relative to the aims of the study. The second challenge is 
to maximize the consistency of the imaging at each clinic visit throughout the trial. In choosing 
the right photography technique, there exist a number of options. These options are visible light 
photography, raking light photography, polarized photography, UV reflectance, and finally UV 
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fluorescence. Each technique helps to focus on a particular area or aspect of the skin that is being 
aimed at for study purposes [51]. 
There has been demand for new technology in the field of photography as a result of the 
need for more objective, quantitative, and noninvasive tools for skin assessments. Some of these 
methods include new light spectrophotometric techniques in which light is penetrating the skin at 
up to 2 mm. Images taken of this light penetration are able to provide a better view into the 
changes happening under the skin as a result of product use. Improved 3D imaging systems are 
being used to better capture skin sagging conditions and wrinkle depth.  
Photography and other non-invasive techniques are useful when assessing the safety and 
efficacy of cosmetic products. As the subject of evaluating products drives forward the type of 
ingredients used in cosmetics skin products, there begins the discussion of the active ingredients 
being used in cosmetics skin products. 
2.11.2 Delivery of Cosmetic Skin Actives 
With recent developments in new technology, new advances in delivering substances 
through the skin have arisen. The delivering of cosmetic skin actives has been primarily done 
through delivery by penetration of the stratum corneum into the skin. With thorough 
understanding of skin physiology and structure, it is possible to create vehicles for passage by 
physical and/or chemical means. 
Thorough the understanding of skin physiology must accompany with knowledge of the 
active being delivered into the skin. Measurable characteristics that help in determining an active 
ingredient’s potential in entering the skin include molecular weight, dissociation constant, 
solubility, octanol/water partition coefficient, and net ionic charge [52]. 
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Permeation of an active across the stratum corneum (SC) can be approximated using an 
equation known as Fick’s Law, which defines steady state flux. Fick’s law can be seen here, in 
Equation 1: 
𝐽𝐽 = 𝐷𝐷𝐷𝐷
𝐿𝐿
(𝐶𝐶)  Equation 1: Fick’s Law 
D is noted as the diffusion coefficient of the SC. L is the diffusional path length or 
membrane thickness. K is the partition coefficient between the SC and the vehicle. C is the 
applied drug concentration, which acts as a constant in this equation. Through manipulations of 
K and C, scientists have been able to increase drug diffusion, increase drug solubility, and also 
increase the degree of saturation of drugs in formulations [53]. 
2.11.2a Vehicles 
One of the most commonly used vehicle types for topically delivered actives is either oil-
in-water, or water-in-oil based emulsion. There is a difference between oil-in-water and water-in-
oil based emulsions. These differences are more effective in certain formulation strategies. 
Theoretically, high solubility and affinity for the hydrophilic and lipophilic components of the 
SC allow for faster partitioning of the active into the skin. This can be done using chemical 
adjuncts, supersaturation, eutectic blends, skin occlusion, and penetration enhancers which come 
in chemical or physical forms [54]. 
Vectors for aiding in penetration enhancement include liposomes, niosomes, solid lipid 
nanoparticles, and nanocapsules. Liposomes are useful for encapsulating active ingredients for 
passage through the SC [55]. Liposome effectiveness varies by size, lipid composition, surface 
charge, mode of application, and total lipid concentration [55]. Niosomes have an infrastructure 
consisting of hydrophilic, amphiphilic, and lipophilic moieties. Together these properties allow 
for a wide range of actives to be encapsulated within them at various solubilities [56]. 
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Solid lipid nanoparticles require no solvents for production processing. They were 
originally developed as an alternative carrier system to emulsions, liposomes, and polymeric 
nanoparticles. Currently, they are being investigated as carriers for skin delivery of sunscreens, 
vitamins A and E, and other actives [57]. Nanocapsules are a type of submicron delivery system 
(SDS). Their small size allows for easy penetration into the skin. They have shown potential to 
be safe for the delivery of actives, and can also control the level of delivery to the skin [58]. 
2.11.2b Devices for penetration enhancement 
In terms of devices used for skin penetration enhancement, moderately invasive to 
slightly invasive systems exist. Among these systems are ultrasound waves, patches, 
microneedles, and iontophoresis. Ultrasound waves have shown to change the skin barrier 
properties through mechanical and thermal energy [59]. Patches have been in existence and are 
useful for localized delivery [60]. Microneedles are a more invasive route. Various micron sized 
needles composed of different materials penetrate the skin for direct active delivery. 
Iontophoresis is the process of using current to manipulate charge properties on the skin, 
allowing for better passage of actives [61]. 
2.11.2c Assessment of Cosmetic Active Delivery 
Assessment of cosmetic active delivery in vivo and in vitro can be done through different 
forms of testing. These tests include Franz cell, tape stripping, microdialysis, and confocal 
Raman microspectroscopy. A key evaluation metric with particular respect to skin creams and 
moisturizers is the rate of diffusion at which active ingredients are passing through the stratum 
corneum and into the deeper layers of the skin. This kind of evaluation is important for 
understanding whether an active added to a formulation is able to enter the skin at all, and if so, 
at what rate, due to the carriers which exist as part of the formulation. One particular method of 
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measuring the rate of diffusion through skin that will be discussed more in detail is known as 
Franz Diffusion Cell [62]. 
A Franz Diffusion Cell permeation assay functions by taking a membrane (in many cases 
a skin sample), and placing it between two chambers. The top chamber is known as the donor 
chamber. In this chamber, the donor compound (typically a formulation) is introduced above the 
skin sample. The bottom chamber is known as the receptor chamber. Here, fluid (typically PBS) 
is added and sampled through a sampling port. A stir bar sits at the bottom of the chamber to 
create circulation. A heater and circulation section surrounding receptor chamber is filled with 
fluid that is maintained at 37 degrees Celsius. The donor compound, or test product, is applied to 
the membrane via the donor chamber. Fluid within the bottom chamber collects ingredients 
which permeate through the membrane. Using the sampling port, samples can be taken at 
different time intervals.  
Some of the drawbacks of this kind of assay include not being able to determine how 
much of an active ingredient is needed to provide a beneficial effect. Advantages of the test 
include its low cost and replicability. For most test products, this assay is used to evaluate the 
ideal formulations to be tested in vivo. 
While the manner in which actives are delivered into the layers beyond the stratum 
corneum, it’s important to show precaution towards penetrating actives deep enough into the skin 
that they begin to interrupt corneocyte functions which affect the properties of all the above 
layers in the epidermis. Testing can demonstrate the effect of active delivery. Delivery of actives 
is a balancing act of localization, penetration, and the cost of laboratory techniques. 
27 
 
2.11.3 Creams 
Creams are emulsions. An emulsion is a colloidal dispersion comprising of two 
immiscible liquids (for example, oil and water), one of which is dispersed as droplets within the 
other [63]. An emulsion also contains emulsifiers or dispersing agents that are responsible for 
keeping the two different phases together for a long time. There are two subcategories of 
emulsions which separate the oil-in-water and the water-in-oil type of emulsions. Only the oil-in-
water based emulsions will be discussed, as they are the preferred emulsion type for making 
creams. 
2.11.3a Composition of a Cream 
Oil-in-water (O/W) creams are the most popular type of emulsions used in skincare 
products. O/W emulsions are composed of a mixture of ingredients which make up the water 
phase, and a mixture of ingredients which make up the oil phase. Along with the ingredients 
which comprise of these phases, there are additional fragrances or essential oils which can be 
added, additional preservatives, color, and pH adjustments. Together these ingredients create a 
complete O/W cream. 
There are five general components that have an individual effect on the aesthetic of an 
O/W cream. These components are the emulsifiers, emollients, active ingredients, humectants, 
and thickeners. Emulsifiers play a role in determining the pH of the emulsion. They affect the 
application and stability of the emulsion, as well as the delivery of materials into the skin. There 
exists a popular group of emulsifiers to use which are “cationic”: said emulsifiers have a net 
positive charge, which attaches more readily to the net negatively charged skin. [64] 
Emollients play a major role in the feel, application, and delivery of the active ingredients 
to the skin. There has been an increased use in silicone and natural emollients as of recent. These 
have given rise to much more possible emollients to choose from. The most difficult part of 
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choosing an emollient is in picking the one which delivers the right initial, middle and end feel 
for a user. 
Humectants can be a part of the solvent system for the active ingredients in an emulsion. 
They also play a role on “skin cushion”, and may function to help with freeze/thaw stability. 
Thickeners control the viscosity and rheology of an emulsion. They also help in maintaining the 
stability of the emulsion. The choice of thickener is very dependent on the compatibility of the 
thickener with the rest of the ingredients, as well as the pH of the formulation. For O/W 
emulsions, the most common types of thickeners are acrylic based polymers. 
Together, these ingredients form an emulsion, alongside any fragrances, essential oils, 
additional color, preservative, and pH adjustment (used as required for emulsion formation). It is 
essential to know the roles existing ingredients within skin creams play. In addition to the main 
ingredients that formulate a baseline skin cream, there is one final type of added ingredient: 
cosmeceuticals. 
2.11.4 Cosmeceuticals 
The term cosmeceutical describes any cosmetics product which contains biologically 
active ingredients claiming to have medical or drug-like properties. There exists a large variety 
of cosmeceutical ingredients. Each will be discussed for their value brought to the cosmetics 
realm, as it possible for some of these ingredients to eventually become incorporated into the 
product of which this project is focused. Listing the types of cosmeceuticals currently in 
existence, there are botanicals, antioxidants and anti-inflammatories, peptides and proteins (of 
which fibrin can fall under as a new ingredient), cellular growth factors, retinoids, topical 
vitamins, and hydroxyacids. 
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2.11.4a Botanicals 
Botanicals refer to any of the herbal-based products which exist in today’s market. 
Botanicals have been shown to have beneficial effects on photoaging. They have been shown to 
target aging pathogenesis occurring from a disrupted/impaired stratum corneum barrier, and 
chronic inflammation [65]. There are also botanicals which have active ingredients to brighten or 
lighten skin, tighten skin, modulate nucleic acids, and protect from light exposure [66]. 
Botanicals research is still developing, with more herbal ingredients being tested through clinical 
trials. The botanical realm is extremely vast, and advantageous to understand for potential 
opportunities in emulsion formulations. 
2.11.4b Antioxidants and Anti-Inflammatories 
The role of antioxidants for use in both oral and topical applications is in part to reduce 
the number of free radicals and reactive oxygen species which exist in the body and cause 
damage to proteins, DNA, and lipids [67]. Anti-inflammatories bind to DNA regulatory elements 
which in part inhibit specific pro-inflammatory genes that set off the inflammation cascade [68]. 
The important aspect of both antioxidants and anti-inflammatories is their potential role in 
minimizing the damage caused by aging. Unfortunately, many anti-inflammatory products 
currently out on the market have shown negative side effects when applied to the skin. These 
side effects range from the lowering of collagen production which reduces fibroblast 
proliferation, to causing immunosuppressive effects which can lead to cancer. Overall, new, safer 
anti-inflammatory technologies need to be discovered in order for them to become viable for use 
[69]. 
2.11.4c Peptides and Proteins 
Peptides play a major part in many biological signal functions. Peptide hormones already 
control important biological activities such as the regulation of blood sugar concentration, blood 
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pressure regulation, and much more [70]. With the right carriers, it is possible to introduce 
peptides topically into the epidermis, where biological signals can be activated (or inactivated) 
within keratinocyte cells [71]. With the right peptides, certain biological signals can alert cells to 
produce desirable actions, such as faster repair, reduction of skin sensitivity to a variety of 
stresses, or an increase in elastin synthesis [72].  
Proteins offer much less capability in the cosmeceutical realm. They are much larger and 
more difficult to carry through to the deeper layers of the skin. Proteins are the vital 3-
dimensional structures which form muscles as well as the skin. Enzyme proteins in particular 
speed up biochemical reactions that would otherwise occur too slowly for the body to function. 
Within the realm of cosmeceuticals, there are particular protein enzymes which have been used 
for chemical peelings, photoprotection, and in some newer cases infrared protection. As a protein 
compound, fibrin faces the same difficulty of diffusion through the skin. Despite this, it is 
advantageous to show fibrin’s inability to diffuse through the skin. Fibrin can act as a reservoir 
for other drugs or actives to pass through the skin as fibrin degrades over time, without 
penetrating the SC. 
2.11.4d Cellular Growth Factors 
Cellular growth factors have some of the greatest potential in anti-aging. Studies have 
shown their major advantages of accelerating wound healing. Studies have also shown 
disadvantages in potentially promoting cancerous cell formations [73]. Other disadvantages and 
obstacles include difficulty in maintaining activity of growth factors through product shelf-life. 
Cellular growth factors also have an issue with successfully passing any large proteins through 
the skin [73]. While there are some alternative methods of getting large molecules into the skin 
(mainly in the form of physical skin penetration techniques), it would be more ideal if simple 
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topical application was the only requirement. From there, control over the acceleration of 
biological activity would aid in preventing issues associated with carcinogenic activity. 
2.11.4e Retinoids  
Topical cosmeceutical retinoids are a class of substances composed of vitamin A and its 
natural and synthetic derivatives. Retinoids are lipophilic molecules that can pass through the 
stratum corneum, where they then bind to nuclear receptors. This binding results in the 
modulation of gene expression involved in cellular differentiation and proliferation [74, 75]. The 
different classes of retinoids provide certain advantages and disadvantages. Retinoids have been 
used in cancer treatment and prevention due to their role in increasing tumor-preventive 
transcription factors while also decreasing factors linked to proliferation and inflammation [74].  
Hyaluronan has been shown to be a valid partner for cosmeceutical retinoids [76]. 
Hyaluronan (HA) is the major component of the extracellular matrix (ECM) and is found in high 
quantities in the skin. HA can accommodate many water molecules due its negatively charged 
areas. This helps to maintain hydration and viscoelasticity of the skin [77]. Studies have shown 
that topical retinoids, particularly retinaldehyde, can restore epidermal functions by stimulating 
HA synthesis and biological functions [78].  
One of the major issues resulting from the use of retinol and retinyl esters (such as retinyl 
palmitate) in topical use is the induced irritant dermatitis that occurs at the same concentrations 
required to induce any measurable biological action similar to that of retinoic acid [79]. To 
counteract this, combination with other topical agents can be used to mitigate irritant response 
from skin. Overall, cosmeceutical retinoids can be seen as an excellent potential additive to be 
mixed in with fibrin as a cosmeceutical. Retinol’s ability to pass through the membrane while 
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subsequently delivering positive effects to the skin is highly promising, given a low threshold to 
avoid irritation. 
2.11.4f Topical Vitamins 
Based on form and concentration, many vitamins can be applied topically to the skin to 
improve skin appearance. Aside from Vitamin A (retinoic acid), there is vitamin B3, B5, C, E, as 
well as several forms of vitamin D, K, and P. Each type of vitamin poses its own set of 
formulation challenges. For vitamin B3, the main issue is hydrolysis of niacinamide into 
nicotinic acid, which causes intense skin reddening [88]. Panthenol (B5) can produce 
sticky/greasy feeling formulations which may be undesirable to users. While the antioxidant 
benefits among most of these vitamins are attractive, there remains the problem of getting a 
measurable amount through the skin in a form that is both aesthetically pleasing and 
cosmeceutically beneficial. 
2.11.4g Hydroxyacids 
Hydroxyacids (HAs) are low pH substances that exfoliate the SC and modulate the 
process of keratinization [81]. Hydroxyacids can be categorized into five groups. The most 
widely studied and commercialized group is the alpha-hydroxyacids (AHAs). The simplest of 
AHAs, glycolic acid, can be derived from sugar cane. AHAs are great for targeting oily and 
acne-prone skin. Certain HAs, such as malic and tartaric acid, double as antioxidants.  
Other benefits from HAs include antiglycation, zero change in sun sensitivity. Certain 
HA groups such as PHAs and bionic acids are non-stinging and non-burning [82]. For clinical 
uses, HAs aid dry skin and hyperkeratinization, keratoses and dyspigmentation, wrinkles, and 
photoaging. As mentioned before with retinoids, HAs have already been shown to possess 
synergistic qualities with topical drugs. 
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2.11.5 Cosmetic Dermatology and Fibrin-Based Skin Cream 
The purpose of detailing some of the many possible formulation ingredients, as well 
explaining the science of cream formulation down to the individual ingredients, was to better 
understand the complexity and science behind producing a skin cream. The role which fibrin can 
play as an additional ingredient of choice within the skin cream realm is a top priority for this 
project. Formulations using the various ingredients mentioned above alongside fibrin can be 
designed so as to have a complete cream.  
As a protein, fibrin faces the challenge of passing through the stratum corneum and into 
the epidermis of the skin. This is because of its relatively large size. However, this may not be 
the desired intent for fibrin within a skin cream. Due to the nature of the extrusion process in 
which fibrin micro threads are created, it is more likely that fibrin can be beneficial as a natural 
vehicle for other cosmetic actives. The results of this could mean a longer-lasting release of 
actives into the skin. 
The process of using an anti-aging regimen follows this order: Cleanse, exfoliate, protect, 
and treat. Cleansing involves the removal of dirt and other debris on the skin. Exfoliation by 
definition is the removal of dead skin cells on the outermost surface of the SC. Protection is the 
use of photoprotective ingredients to help avoid damage caused by sun exposure. Treatment 
involves the use of ingredients which aid in the skin’s look and health. 
It is possible for fibrin to aid in more than one of these anti-aging regimen steps. With 
regards to exfoliation, it is possible for fibrin particles to have a positive mechanical abrasion 
effect on dead skin. As a potential photoprotective, fibrin absorbs a set amount of UV radiation 
before crosslinking. There are endless possibilities for fibrin to be used an effective skin cream. 
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2.12 Previous Designed Mechanisms to Manufacture Fibrin Microthreads 
In order to develop a feasible design that will successfully extrude fibrin microthreads, an 
analysis of previous Major Qualifying Projects (MQP) related to automated manufacturing 
machines is important to comprehend because it will help the team eliminate non-viable design 
options and specify the important objectives and components needed. This will also help the 
team decide upon what specific design mechanisms to include in the final design. The team 
evaluated two MQPs from 2010 and 2012 that worked to design automated manufacturing 
machines of collagen microthreads and fibrin microthreads respectively. The team focused on 
the groups’ approaches to their design process as well as their final design outcome and results. 
        In general, both teams had similar obstacles when deciding on important design objectives 
for their machine. The manual extrusion process of collagen and fibrin microthreads is extremely 
time consuming and does not always produce threads that are uniform and of similar diameters 
[83]. It also requires additional labor to manually extrude the threads and due to inconsistencies 
in the microthreads’ properties, not all the threads are viable following the extrusion process 
[84]. The 2010 MQP team’s objectives was to design an automatic manufacturing machine that 
would yield precise and reproducible collagen microthreads, produce threads that can withstand 
uniaxial loads and can be applied towards therapeutic effects, and allow for thread modifications 
following the extrusion process [84]. The 2010 team approached their design by focusing on 
automating the entire thread extrusion and drying process. The final design was comprised of a 
motorized bi-directional extrusion system, an extrusion bath, the removable anchor system, and 
drain system [83]. They modified the machine to allow for a variation in the output of the 
collagen threads. One aspect of the final design that the 2010 MQP team focused on was the 
anchoring system. This system allowed them to dry and stretch the threads, while creating a 
35 
 
smooth transition platform from the extrusion phase to the post-production phase of the machine 
[83]. The removal and drying process, however, was not automated and did require manual 
labor. Despite this drawback, the team did achieve success in automating the main extrusion 
process, which saved collagen thread production time and money. 
While many of the design challenges for both teams were similar, the project team from 
the 2010 MQP required additional design parameters because they dealt with collagen threads. 
For example, the team had to add an additional heating element set at 37 degrees Celsius (body 
temperature) because that temperature is required for the collagen to remain viable following the 
extrusion process [84]. On the other hand, the 2012 MQP team dealt with different constraints 
because they were working with fibrin, which is a smaller thread and required different extrusion 
parameters (i.e. the extrusion process did not require a heated water bath since Fibrin can thrive 
at room temperature) [84]. The 2012 team also referenced the 2010 MQP and aimed to try to 
automate both the extrusion and removal/drying process. The 2012 team had many design ideas 
including ways to secure the threads and remove them without breaking them. One of the ideas 
involved the use of a Velcro material to hold the threads in place [84]. They performed 
experiments to test the reliability and durability of the Velcro’s ability to stabilize the threads 
without breaking them. Even though many of the 2012 team’s ideas were worth trying, 
constraints such as budget and accessibility to design materials led to a final design of only a 
semi-automated machine for fibrin microthreads [84].  
Understanding the design processes of previous MQPs can help future projects increase 
their chances of success in the final design. Understanding manufacturing processes can also 
help the team design products that adhere by FDA and safety regulations and to ensure success in 
the manufacturing gold standards. 
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2.13 Good Manufacturing Standards 
Putting a product on the market requires specific standards, both manufacturing and 
safety related, in order to be viable and safe. In terms of the automated manufacturing machine 
and the cosmetic applications of the fibrin microthreads, the manufacturing process itself and the 
marketing of the cosmetic cream requires a level of strict regulation and consumer transparency. 
According to the United States Food and Drug Administration, the regulation system used to 
monitor different manufacturing facilities and practices is the current good manufacturing 
practice (CGMPs) regulations [85]. Based on the product, different standards and regulations 
apply to ensure that the product is abiding to the correct design and manufacturing procedures. 
Products range from biological devices to pharmaceuticals to a mix of biological specimens and 
biological devices.  
The team desired to design a mechanism to automate and mass produce fibrin 
microthreads. In order to efficiently develop a design, it was important to consider devices that 
previously exist in the relevant art made for the purpose of the creation of other biopolymer 
threads. For example, US 5378469 discloses an apparatus and method of creating threads 
composed of collagen for certain manufacturing applications, including knitted and woven 
particles, to implantable prostheses. Kemp et al. teaches that the collagen solution can be 
extruded into a “dehydrating agent” that is under conditions to allow the extruded solution to 
form into a collagen thread [86]. The design includes an extrusion mechanism, a syringe, the 
dehydrating agent bath, and a series of pulleys that lead the thread through a drying device to be 
stored in a spool. In order to create a viable fibrin microthreads automated manufacturing 
machine and use them towards greater applications, abiding by safety and regulatory factors was 
important in making the product legitimate and recognizable by overarching bodies such as the 
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FDA. When moving forward with the design process, the team focused on adhering to good 
manufacturing principles while accomplishing the tasks of the fibrin microthread production 
mechanism. 
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Chapter 3: Project Strategy 
This project consists of three distinct parts: validating fibrin’s value in the cosmetics 
industry, assembling the automated manufacturing machine, and converting the fibrin 
microthreads into a powder form for the application of fibrin microthreads in a new cosmetic 
cream. Each part contains its own set of objectives and goals. The team decided to accomplish 
each part by separating the design objectives into three separate analyses: a breakdown of the 
requirements for the fibrin mixed cosmetic care skin cream, a breakdown of the requirements for 
the automated manufacturing machine, and a discussion of the ways the fibrin microthreads can 
be converted into an applicable form for the cosmetic skin cream. The team first analyzed the 
initial client statement with the aim to gain a sense of what direction the project was headed and 
what further information was needed in order to move the project forward. A qualitative and 
quantitative analysis was then performed to identify and rank the objectives according to 
importance. 
 
3.1 Initial Client Statement 
The team was tasked with an initial objective statement that established the foundation of 
the project. Per Professor Glenn Gaudette, the team was given the following client statement: 
 
“The main objectives for this Major Qualifying Project is to create an automated manufacturing 
device that can extrude fibrin microthreads and minimize the need for continuous manual labor, 
while subsequently altering fibrin into a form useful for cosmetic cream applications.” 
 
 In order to address these tasks, the team explored and analyzed extensive background 
information, discussed in detail in Chapter 2, to further develop the initial client statement and 
generate a revised client statement and more detailed list of objectives. The team also utilized 
research from past MQP projects and regulation standards in order to understand what type of 
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regulations each part of the project must adhere by to ensure a successful outcome for the client 
and the potential user(s). 
 
3.2 Design Requirements of Validating Fibrin’s Value for a Cosmetic Cream 
When validating fibrin microthreads for cosmetic skin creams, the design requirements 
included several property-identification experiments. The main objectives of these experiments 
focused on demonstrating fibrin’s potential as a demandable skin cream product ingredient. 
Constraints, such as time and supplies, were considered when planning the timeline of 
experiments. Validation of the experiments are explained via the protocols for the experiments 
(See Appendix III for more detail), as well as the decision behind running each experiment. 
Standards and regulations of cosmetics products will be readdressed to validate the team’s 
pursuit towards the final product of fibrin-based skin cream. Figure 1 below lists the major 
objectives for our Fibrina skin cream product. 
Figure 1: Objective Tree for Fibrina 
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3.2.1 Objectives 
The overarching goal for validating fibrin’s value as a cosmetic skin cream ingredient 
was to identify and scientifically support all benefits of fibrin for use in cosmetics. The team ran 
several experiments on the various properties that helped to identify the outcomes of applying 
fibrin along with other common skin cream additives. The following breakdown of objectives 
details all aspects of the overarching goal and how the team evaluated their achievements as part 
of the overall objective. 
3.2.1a Showing Ingredient Compatibility 
Since the team is introducing a new ingredient to the cosmetic industry, it is important to 
provide data that qualifies fibrin as a compatible ingredient. For this project, the objective of 
ingredient compatibility was to show that fibrin was compatible with retinol, a highly 
popularized active skincare ingredient. Success or failure in achieving basic compatibility with 
retinol creates an opportunity to create better protocols for testing fibrin’s synergistic properties 
with other ingredients.  
Basic compatibility corresponds to introducing retinol into fibrin while maintaining 
fibrin’s compositional form as a microthread upon production. This objective breaks down 
further when looking at the process of attaching retinol to fibrin. Synergies among combinations 
of ingredients used in the cosmetics industry exist. Discovering synergies of actives alongside 
fibrin would further promote the use of fibrin in cosmetics. 
3.2.1b Fibrin Vehicle Capabilities 
Larger proteins such as fibrin are especially difficult in penetrating through to the skin, it 
is important to find use for fibrin in cosmetics, primarily as a carrier for other actives. The 
purpose of assessing fibrin’s vehicle capabilities was to demonstrate that active ingredients 
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carried by fibrin can be delivered to the skin more optimally than it would on its own. In order to 
achieve this, fibrin must release any active over time, after it has been applied to the skin. With 
regards to the release profile of fibrin, there should also be customization. Depending on 
determining factors of fibrin-active release, the team wanted to control those factors in order to 
offer various options in time-release capabilities. 
3.2.1c Cream Composition Formula  
 Since there are existing FDA regulations on the active percentage allowed within 
cosmetics products, the team wanted to understand the relative quantities of fibrin-to-active that 
would be required for a baseline cream. For that, there was the objective of determining how 
much active can be successfully carried by fibrin. Knowing the maximum carrying capacity for 
additives within fibrin would showcase how well the team’s final product would be able to 
perform as a novel carrier. The resulting quantity of fibrin particles required to be used in a 
cream will affect overall costs, as well as the texture and appeal of the cream. 
3.2.1d Fibrin’s Property-Driven Benefits 
 The last three objectives looked to identify fibrin’s capabilities as a carrier for actives. 
Success in achieving these objectives would be great, but perhaps not great enough in terms of 
differentiating fibrin from other ingredient-encapsulating products on the market. One positive 
product outcome identified through cosmetology research was the existence of exfoliates. Given 
that the team sought to ground up fibrin microthreads into particles, there was incentive to 
objectivize finding results on whether the surface roughness of those particles would aid in skin 
exfoliation. Other existing research highlights fibrin’s UV absorption properties. Since UV 
absorbance is a sought after property for sunscreens, the team wanted to understand how fibrin’s 
UV absorption properties could benefit a skin cream. Overall, the proposed objectives lean to 
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various lab experiments. With a budget shared for both laboratory work as well as mechanical 
work, the team had to identify constraints. 
3.2.2 Constraints 
 Constraints included limitations on time and money. The team was tasked with focusing 
on three major sections of the project (validating fibrin’s value through cosmetology experiments 
and customer discovery, mechanical engineering through automation design, and fibrin’s 
conversion capabilities). Since the team had three major project focuses, there was little room for 
errors that could lead to extending certain deadlines, thus pushing the project’s deadline behind 
schedule. Money was also a major factor. The team was given $750 for the MQP. Fortunately, 
through the team’s participation in the WPI Accelerate Program, more funds were secured for 
this project ($1728.67). However, splitting the total amount of funds among experiments and 
machine parts would be straining for both project sections.  
3.2.3 Functions of Additive-Infused Fibrin Threads 
Functions for additive-infused threads were created to focus the team on what outcomes 
were desired for the experiments being conducted.  The team focused primarily on one 
ingredient: Retinol (also known as vitamin A). Through a set protocol of experimenting fibrin 
threads with retinol, the team desired for three functional outcomes: 
1. Additive-infused threads should be able to hold at least 10% of actives with respect to 
their overall weight. 
2. Additive-infused threads should be capable of being ground into particles. 
3. Additive-infused threads should be capable of releasing actives within it. 
The identified outcomes cover the basic necessary functions for additive-infused fibrin 
threads to be commercially valuable within a skin cream. 
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3.2.4 Standards and Regulations 
Standards and regulations for developing skin cream are covered under the background 
research on the FDA and its jurisdiction over cosmetic products. The FDA does not require the 
need for approval of a cosmetic product prior to its entry to the cosmetic market. However, the 
FDA monitors products for their safety and its effects on consumers. The team chose to be 
transparent with the ingredients it uses to develop the cream. These standards help to maintain 
the safety of the product by making it the job of the FDA to hold the commercialization of a 
product such as fibrin skin cream accountable for its effects on consumers. 
 
3.3 Design Requirements of the Automated Manufacturing Machine 
Developing an automated manufacturing machine required a detailed design plan in order 
to produce successful results. The team’s overarching focus for the automated manufacturing 
machine for the extrusion of fibrin microthreads was to automate the entire extrusion process. 
The team generated and compiled a list of objectives, constraints, functions, and specifications of 
the machine, taking into consideration the feedback and suggestions of the team’s client, 
Professor Glenn Gaudette.   
3.3.1 Objectives 
 In order to efficiently organize the objectives and requirements of the machine, the team 
generated an objective tree (Figure 2) to organize and identify the tasks in each of the major 
objective categories (next page):  
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Figure 2: Objective Tree for the Automated Manufacturing Extrusion Device 
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the amount of manual labor needed for the extrusion process. This ensured more consistent 
threads of equal thickness, which is hard to achieve during the manual extrusion process. 
3.3.1b Method of Mass Production 
The second objective of this device was to produce fibrin threads in mass quantities. This 
means two things: the first is that the threads being produced by the machine are consistently 
identical (within a given tolerance). The second meaning is that the machine can reliably produce 
threads over and over again, in large batches. Fibrin microhreads should become a surplus 
resource material because of this device. 
3.3.1c Machine User-Friendliness 
The third objective of this device was to have a user friendly machine interface. A user 
should have minimal difficulty with controlling the device. A user should also be able to 
understand how the device works, ideally through a user manual, but also by looking at the 
device and understanding its basic actions. Overall, one should be able to recognize what the 
device does, and how to go about using it without difficulty. 
3.3.2 Constraints 
The constraints of the automated extrusion device are based on how the device runs and 
the setting of the device. Constraint factors such as complexity, software resources, powering 
resources, and safety affects how the device runs. Constraint factors pertaining to where the 
machine is placed (i.e. a laboratory setting) involves the machine’s size. Cost was the ultimate 
limit for the design of the machine. 
 Powering and software resources were a major constraint for any automated. Based on 
the scope of the design, it was important to choose the correct motor or actuator. The control of 
these motors were dependent on the software decided upon by the team.  
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 Safety was the constraint that takes priority for an automated system. The device must be 
safely operable under any conditions. These conditions can include, but are not limited to, 
starting the device, stopping the device, repairing the device, replacing any parts to the device, 
and cleaning the device. In summary, the device could not be a threat to the safety of a user. 
 The constraint of size affects the dimensions that the machine can be designed around. 
The machine prototype had to fit on a lab bench to allow the machine to be efficiently tested in a 
laboratory setting. 
Considering the budget allocated for the project, the team also had to determine the type 
of materials and moving parts which will be used to develop this device. The team kept in mind 
that this budget was also used for any preliminary device testing is crucial. Reusing parts from 
preliminary and being smart about material purchases will help to maintain the cost constraint 
from devaluing the end result of this project. In thinking about the kinds of materials to use and 
their respective costs, the team must consider the machine’s functions and specifications. 
3.3.3 Functions and Specifications  
The functions and specifications of the automated fibrin microthread extruder machine 
related to the machine’s ability to output quality microthreads, as well as the machine’s 
capabilities. The machine needed to perform the following actions as they pertained to the 
current manual process of making threads: 1. The machine had to extrude fibrin microthreads; 2. 
The machine needed to dry the fibrin microthreads. 
The first main function for this machine was to extrude threads. Threads must be 
extruded into a HEPES bath in order for the threads to form properly. From there, either the 
HEPES bath or the threads themselves must be moved in order for the drying of the threads to 
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occur. Finally, threads produced by the machine must move to a stage where they can be stored 
for future use, or placed into a grinder or other form-changing machine. 
Other minor existing functions included the need for the device to be cleaned prior to the 
next extrusion batch. This was important for removing excess fibrin that may be lying around the 
surface part of the machine where new threads would be formed via extrusion. The machine 
itself also needed to run at a set pace: given the multiple stages of extruding, drying, removing, 
and cleaning of the threads, if the device was to run in sync, then for efficiency’s sake, each 
stage had to run in coordination with the others. 
3.3.4 Standards and Regulations 
The automated extrusion device consisted of programmed mechanisms that perform a 
general task without human intervention. To account for the standards and regulation for this 
manufacturing machine, ISO standards must be abided by. Under ISO 8373:2012, a manipulator 
is defined as, “machine in which the mechanism usually consists of a series of segments, jointed 
or sliding relative to one another, for the purpose of grasping and/or moving objects (pieces or 
tools) usually in several degrees of freedom” [87]. As this pertains particularly to the intended 
design of the mechanism, further consideration must be put into ISO 9283:1998, which outline 
testing and performance standards for manipulating industrial robots. Under this standard, 
methods for regulating pose accuracy and repeatability, distance accuracy and repeatability, path 
accuracy and repeatability, and static compliance is included, along with other regulations [88]. 
Finally, under ISO 3952-1:1981, in order to provide proficient description of the mechanism 
through technical writing, reports must contain kinematic diagrams. These diagrams are required 
to include motion of links, kinematic pairs, links and connections of components, and N-Bar 
linkages and components [89]. 
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3.4 Conversion of Fibrin Microthreads into a Usable Form 
 An important aspect of the project was to tie Objectives 1 and 2 together. To accomplish 
this task, the team had to determine a method to convert fibrin from microthreads to a particle 
form.  
3.4.1 Objectives 
 There was one major objectives for this part of the project: find a method to equally 
convert the fibrin microthreads. Within the two sub categories, the team identified potential 
conversion methods for transforming the fibrin from microthreads to particle form and the 
specifications for mechanism to allow for more equal conversion of the microthreads. In Figure 3 
below, a breakdown for this objective is shown. 
Figure 3: Objective Tree for the Conversion Method of 
Fibrin Microthreads 
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3.4.2 Constraints 
 Constraints of this objective included the type of conversion mechanism and materials 
used for producing fibrin microthreads within a certain particle size range. When considering the 
conversion mechanism and the materials/components used, the team looked into options that 
allowed the user to have good control over the conversion process and reduced static cling. 
 Producing fibrin particles that fall within a certain particle size range is important 
because the fibrin used for delivering actives in the skin cream must both be successful in its 
delivery and its ‘feel’ when mixed with the final skin cream composition. The integration of 
fibrin with the skin cream is important because in order to be a favorable product with 
consumers, the cream must ‘feel good’ when applied to the skin. Therefore, the conversion 
mechanism must convert the fibrin microthreads to particle sizes suited for delivering actives, 
while feeling good when applied topically.   
Static cling is a phenomenon that occurs between dry materials and is caused by static 
electricity. An exchange of electrons causes the two surfaces to stick together [90]. An example 
of this is dry hair strands attaching to combs or brushes or dust particles on the floor. Dry fibrin 
microthreads or particles experience this phenomenon. A way to reduce static cling is by wetting 
the threads [90]. When looking into potential materials for the mechanism to allow for more 
equal fibrin microthread conversion, the team must consider materials that can be compatible 
with wet microthreads and reduce the potential of static cling. This limits the team’s component 
options to items that are smaller and more compact to allow for more control over the fibrin 
particles’ collection process.  
3.4.3 Functions and Specifications  
 Based on previous research performed for agents used in active delivery, the size of the 
agents were around the range of 100 microns or less [91]. The active particle sizes delivered 
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usually range from 1 – 10 microns [92]. In order to maximize delivery, the team decided a range 
of 0.1 – 1mm for the fibrin particles appropriate for the use in skin cream. Even though this size 
range is larger than typical ranges, it allows for maximum active delivery to the skin. 
 The team formulated a list of functions and specifications based on the background 
knowledge and objectives formulated above: 
1. The fibrin particles produced must be between 0.1 – 1 mm in length. 
2. The method for conversion must be consistent and produce particles within the range 
stated in specification 1. 
3. The mechanism for conversion must be safe to use. 
4. The mechanism must convert and collect the fibrin particles. 
 
3.4.4 Standards and Regulations 
Similar to the machine standards explained in section 3.3.4, the ISO 9283:1998 and ISO 
3952-1:1981 protocols were followed, allowing for correct execution of mechanism conversion 
decisions and designs.  
 
3.5 Revised Client Statement 
After the team analyzed the necessary quantitative and qualitative parameters of the 
project, a revised client statement was generated with the necessary detailed updates: 
“The first main objective of this Major Qualifying Project is to validate fibrin’s value in 
cosmetic skin cream applications through experiments with active ingredients found in 
cosmetic cream, and customer discovery on product value. The second main objective is to 
create an automated, reliable, and user-friendly manufacturing device designed for the mass 
production of fibrin microthreads that can extrude fibrinogen and thrombin solutions, and 
consistently create fibrin microthreads. The third main objective is to convert the fibrin 
microthreads into equal particle sizes that range between 0.1 – 1 millimeter” 
 
 The team’s plan to separate the cosmetic application objectives and goals, the machine 
objectives and goals, and the conversion objective and goals into three parts helped to produce 
organized and coherent results.   
51 
 
Chapter 4: Design Process and Approach 
 The team performed separate analyses on the application of fibrin in a novel cosmetic 
skin cream termed Fibrina, the fibrin microthread extrusion device and, the conversion of fibrin 
microthreads to particles. In order to determine the ideal components for the preliminary design, 
the team formulated three different full-scale machine designs and performed a design analysis 
on each individual component. This design approach also will help the team formulate a final 
design essential to the process. The team also took part in a Worcester Polytechnic Institute 
program that pivoted the scope and application of Fibrina in the cosmetics market. 
 
4.1 Fibrina 
The team wanted to explore the development of a fibrin-based skin cream product. This 
involved the creation of an initial value proposition. This decision led the team to take part in a 
program hosted at WPI, known as the Accelerate Program. 
 During the Accelerate Program, the team connected with various industry peoples and 
consumers of interest. Within the duration of this program, the team conducted over 30 
interviews. Every ten interviews, the team revised its value proposition while making critical 
insights on steps for the team to take in the future. 
During the process of conducting interviews, the team made a few substantial pivots 
which led to different concepts of a fibrin-based skin cream. By the end of the interviews, one 
path towards commercialization was established for the time being. Suggestions and 
requirements on how to prove the value of the cream were documented and subsequently 
planned out for experimentation. 
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4.1.1 Interviews 
The interviews are broken down into separate categories. Each category is based on the 
type of individuals interviewed. The team conducted interviews with dermatologists, 
cosmetic/plastic surgeons, one cosmetics industry marketing specialist, several consumers and 
salespeople at low, middle, and high-end stores, and lastly two wholesale 
manufacturers/distributors. The chronology of the interviews discussed in the upcoming sections 
does not align with the order in which the team conducted the interviews.  
4.1.1a Dermatologists 
The team conducted several interviews with several dermatologists throughout the time 
of the program. The first interview ever conducted by the team centered on questions about 
treatment options for cleaning and healing wounds after skin surgery. The team also asked about 
the importance of minimal scarring for patients, post-operation. In order to remain concise of the 
interview insights and takeaways, all of the major questions/insights are organized in a table. 
Summaries of the takeaways from the interviews are shown in Tables 30-35 in Appendix II.  
This first interview answered questions that were important in understanding the project’s 
objective of creating a novel fibrin-based skin cream. Two main takeaways became apparent 
from the first interview: A substantial amount of time can be spent concocting various formulas 
or recipes for an ideal fibrin-based skin cream and the market ultimately sells the product. 
The team’s second interview was with a dermatologist with their own cosmetic line. The 
team looked to address three main questions from this interview: 
1. What kind of treatment options would you recommend to patients after a dermatology 
procedure or appointment? 
2. What do you look for in product labeling?  
3. What key ingredients do you look for in a product? 
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The second dermatology interview revealed the truth behind skin cream products on the 
market today as well as highlighted the general practice behind producing and selling a skin 
cream. The interview introduced the notion of claims and described the process of making 
cosmetic claims using careful terminology.  
4.1.1b Cosmetic/Plastic Surgeons 
 Cosmetic and plastic surgeons were interviewed within this program as the team sought 
benefit from learning more about their view of post-op products. As with some dermatologists, 
there are cosmetic and plastic surgeons who have their own cosmetic product lines. Interviews 
with surgeons were typically very brief, and many of the insights taken from surgeons were 
nearly identical.  
Prior to the first interview with a cosmetic surgeon, it was assumed that cosmetic/plastic 
surgeons commonly recommended topical products to their patients for better post-surgery 
recovery. This was found to be mainly true for those surgeons which had their own cosmetic 
lines. Other than pointing out products to research and compare with, most surgeons followed 
one main principle: a good product that is recommendable has to work, and has to have scientific 
backing to prove it works.  
 
4.1.1c Cosmetics Industry Marketers and Branders 
The team interviewed one executive with major success in marketing/positioning and 
branding. Due to the nature of this interview, the main questions asked pertained to:  
• What are the key considerations that go into marketing of a product?  
• Where does one begin to market a product? How does that process evolve over time? 
• How do we compete against existing competition? (Target Audience) 
• What resources/techniques can we use to target initial key consumers? 
The major takeaways received for the marketing aspect of cosmetics were substantially 
helpful. While the knowledge gathered from this interview applied more so to the pricing of a 
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product based on a number of costs made to ensure product success, the information itself proved 
vital for better product creation. Understanding the competitive market and establishing a unique 
answer to consumer problem(s) very much affects the final product. The advice/push to get out 
of the building and interview salespeople and consumers at different stores was also a major 
breakthrough and motivator for the team.  
4.1.1d Salespeople from Low, Middle, High-End Stores 
As a means of dividing and conquering research and customer discovery on various 
stores, the team split off to take the low, middle, and high-end stores. The resulting interviews 
with both salespeople and general consumers provided major insights into consumer behavior 
during shopping, as well as key insights into marketing of products via packaging and shelf 
placement. To concisely address each of the stores visited in an organized fashion, the following 
tables are being categorized by the type of store (low, middle, or high-end) which best describes 
them.  
1: Low-End Stores 
The low-end store interviews gave a varied glimpse into the consumer habits of skincare 
shoppers. A special note should be taken to look into the online market, which was noted during 
the team’s interview with the cosmetics marketer/brander. With regards to product placement, it 
is obvious that certain brands are constantly paying a little more to be at eye-level in multiple 
stores. In the end, there is still a ton of products out there, and choosing just one seems 
overwhelming at first glance. Shoppers in these stores are variably picky with ingredients. Cost 
can be a major factor in some cases, and in others, a willing sacrifice.  
2: Middle and High End Stores 
 For the middle and high end interviews, the team interviewed sales representatives at 
major department stores and high end stores. The Department Stores visited included 
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Bloomingdales, Neiman Marcus, and Nordstrom. Some of the counters visited in the department 
stores included Estee Lauder, Chanel, Lacome, Tris McEvoy, Space.NK, and Philosophy. In 
general, the major takeaways from these interviews surrounded branding and marketing through 
the representatives’ sales pitches. For example, the branding and display for the products were 
marketed in such a way that had bold adjectives associated with each product (“dramatically 
different skin cream”, “All natural, fresh feel skin cream”). The representatives would take these 
adjectives and, based on each customer’s need, explain why the product is different and works 
the best for his or specific condition. Since many of the counters in the department stores were 
part of a high-end brand company, similar marketing tactics were used at the high-end stores 
visited (Sephora, Mac, Chanel, and Clinique). 
4.1.1e Wholesale Manufacturers and Distributors 
 The team met with two wholesale marketers and distributors. One individual was the 
president of a group of companies, while the other owned a smaller business which focused on 
producing batches for sample development. Both interviews offered unique perspectives on 
manufacturing and distribution, and will be discussed separately. 
The first wholesale manufacturer/distributor interview the team held was with the CEO of 
a conglomerate of companies, one of which was a major manufacturer and distributor of what 
appeared to be high-quality cosmetics products. Said high-quality cosmetics products openly 
claimed use of cellular growth factors, retinoids, and stem cells.  
 
4.1.1f Arizona Conference 
 Two members of the team flew to Scottsdale, Arizona to attend a conference where many 
cosmetics-based companies were in attendance. Due to the scheduling nature of the conference, 
it was difficult to make time with anyone for an interview. In fact, the two team members were 
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only able to have one interview with the president and VP of a wholesale 
manufacturer/distributor company.  
However, while in Scottsdale, it was noticed by the two team members that the Scottsdale 
area was riddled with salons, spas, and most notably, dermatology offices. Given the spare time 
the team members had while in Scottsdale, a number of interviews were conducted with salon 
owners, cosmetics specialists, and a number of dermatologists. 
One interview conducted in Arizona was with a wholesale manufacturer and distributor 
who offered to educate the team further about the complexities of manufacturing cosmetic 
products. The main takeaways gathered from the interview were that the manufacturing of 
cosmetic products itself has its own set of regulations. If a group such as ourselves wants to 
begin mass producing, then the process by which our skin cream is developed must follow 
regulated manufacturing guidelines. Failure to do so prevents us from getting product out into 
the market. 
Aside from the wholesale manufacturer and distributor interviews, the team’s main 
takeaways from the salons, spas, and dermatology offices are as follows: 
• The retail market is highly saturated with products. There’s essentially a product for 
nearly every skincare problem out there. 
• The retail market is becoming much more educated. Scientific backing is essential. 
Education of a product’s efficacy to salon and spa specialists are extremely effective. 
• Dermatologists are always on the look for better products, as their improved results with 
patients benefit their business. Again, scientific backing is a must. Marketing is also very 
important to any product sitting on a dermatologist’s shelves. 
 
4.1.1g Summary of Takeaways 
Consumers today are trying to understand the ingredients used within their products. All-
natural based products are on the rise. Dermatologists are in need of better products which can 
meet consumer demands (such as ingredient originations) while still addressing consumer 
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problems (healthier, better looking skin). It is easier to determine the types of experiments to 
conduct on a cream to prove its efficacy by asking those who readily perform such experiments. 
Finally, regardless of how good our product may become, marketing is what ultimately sells. 
 
4.1.2 The Accelerate Program 
In the beginning, the team created both a value proposition and customer segment based 
on underlying assumptions learned from a superficial view of the cosmetics skin cream industry. 
Table 2 below shows the team’s first take on a value proposition and customer segment. 
Table 2: Initial Value Proposition and Customer Segment 
1st Value Proposition 1st Customer Segment 
No new development in skin creams over the last 25 years. Problem: Customers want whatever it is that 
they’re buying to work. 
We have a new all-natural ingredient (fibrin). We can 
integrate our new ingredient with other natural ingredients. 
Consumer Target: Women in their 40s and 
50s  
Combining fibrin with other natural ingredients produces 
synergistic effects. 
Distribution Channel: Sell through surgeons, 
physicians, and cosmetic companies. 
Fibrin has a lot of potential to be the next big brand in 
today’s cosmetics industry. 
 
 
This value proposition and customer segment was crafted before any interviews were conducted. 
Table 3 shows our final value proposition and customer segment, which was created after the 31 
interviews conducted. 
Table 3: Current Value Proposition and Customer Segment 
Current Value Proposition Current Customer Segment 
There has been no new “special ingredient” 
introduced into skin creams in over two decades. 
Problem: Customers want all-natural, scientifically 
backed products with proven results. 
The team has fibrin: a novel ingredient found 
naturally in the body during wound healing. 
Archetypes: The team is pitching to cosmetics 
companies looking for a competitive edge in the market. 
The team has a process that allows us to combine 
fibrin with other ingredients that is unique 
Channel: The team wants to license the technology to 
cosmetics skin cream manufacturers: The suppliers 
The team can show synergistic properties between 
fibrin and other natural ingredients resulting from 
our processing and experimentation. 
Relationships: The team wants to build awareness 
toward scientifically backed products in the cosmetics 
industry. The plan is to educate both the customer 
companies and general cosmetics consumers on the 
product. 
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The conclusions for what the team needs to do in order to prove fibrin-based skin cream as a 
valuable product in the cosmetics market all point toward one objective: show data on fibrin’s 
usefulness within a skin cream. There is currently no known scientific research that has been 
done on fibrin-based skin cream. Through both literature and discussion with dermatologists, the 
team created a list of experiments to perform that would show fibrin’s value as a cosmetic 
ingredient. 
Aside from experimentation, the team needs to conduct more interviews with both 
dermatologists and manufacturers and distributors in order to build a larger network of 
dermatologists to contact, as they are currently the target distributors/marketers of our product. 
The team was only able to conduct two interviews with wholesale manufacturers/distributors of 
cosmetics products. In order to better understand the benefits and costs of mass producing 
product through these individuals and companies, the team needs to learn more about them.  
A comparison of scientific data and testing on competing skincare products on the 
professional market is necessary. Determining the market value of these products and comparing 
their claims with ours will help to configure a price point for fibrin-based skin cream. With that, 
a more in-depth cost analysis of our product must be done. Considering larger scale production, 
the team must discover the various suppliers needed to mass produce.  
4.2 Fibrin Microthread Extrusion Device 
 Utilizing the feedback from our advisor and reevaluation of our initial client statement, 
the team performed different analyses that helped to determine the necessary components of the 
final preliminary design. The team took the main three objectives and performed a needs analysis 
of the main and sub objectives to develop quality design ideas. 
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4.2.1 Machine Components and Needs Analysis 
 The team broke the major stages of the machine into different phases: Pumping Phase, 
Extrusion Phase, Stretching Phase, Drying Phase, and Removal Phase.  Below in Table 4 is a 
summary and description of each phase. 
Table 4: Definition of the Different Phases of the Machine 
Phase Definition 
Phase 1: Pumping The stage in which fibrinogen and thrombin are 
combined to form a fibrin-infused mixed  
Phase 2: Extrusion The stage in which the threads are extruded from an 
automated extrusion head onto the chain system, which is 
incorporated in our final design 
Phase 3: Stretching The stage in which the threads are moved and stretched 
uniaxially in opposite directions to increase the threads 
end-product viability 
Phase 4: Drying The stage in which the threads are dried with an external 
dryer source to speed up the drying process 
Phase 5: Removal The stage in which the threads are removed  
 
Along with our machine objectives defined in Chapter 3, the phase approach helped the 
team determine the essential features needed for a successful preliminary and final design. The 
team also put together a chart of the important wants and needs of the system to determine the 
necessary components of the machine’s final and preliminary design. The system needs are 
defined as the systematic components of the machine design that are essential to success. The 
system wants are defined as the components of the system that the team would like to include to 
the machine’s preliminary design, but are not required for success. Below in Table 5 is an outline 
of the Needs and Wants of the machine design: 
Table 5: Summary of the Needs and Wants of the Machine Design 
Needs Wants 
Automated Extrusion and Stretching Process Durable  
Safe for Users Simple, Modifiable User Interface 
Option for Input of Additional Ingredients Fits on a Lab Bench  
Minimize Thread Failure Precision 
Mass Production of Threads Reliable 
Conversion of Threads into an Applicable Form Sterilization 
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 4.2.1a: System Needs 
The needs of the machine were chosen based on objectives highlighted in Chapter 3 of 
the Report and the phases broken down in the previous section. A major objective of the machine 
was to create a safe and fully automated machine. Therefore, it was important to include an 
automated extrusion and stretching process to achieve this design objective. Two major 
objectives include the option for customization, which include the option for additional 
ingredient input, and the conversion of the threads into an applicable form. These need 
components are essential to the final design because the combination of other ingredients with 
fibrin is vital to our final project because it aids the success of the team’s second main objective, 
which is the infusion of fibrin microthreads in a cosmetic skin care application.  
In order to create these infused threads, it is also necessary to minimize thread failure in 
order to gain a mass production bulk of the threads. This need is essential to the machine’s 
ability to mass produce fibrin microthreads, which is an important factor in ultimately creating a 
successful skin care product. 
4.2.1b: System Wants 
Similar to the system’s needs, the system’s wants were generated based on the objectives 
highlighted in Chapter 3 of the report and the phases broken down in the previous section. While 
not essential to the final success of the machine, formulating the wants of the machine was 
important in determining the essential components of the preliminary and final design since it 
directed the team toward a better and well defined design. The team formulated these wants 
based on the features that would enhance the machine’s ability to produce fibrin microthreads. 
Even though a main objective of the machine was its user friendliness, the team decided it was 
essential that the machine was completely automated, meaning sub-objectives such as its simple 
user interface was not crucial to the final design.  
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 Other components such as its durability, reliability, precision, size, and sterility are great 
components to have for the machine design, but are not essential to the ultimate goal of the 
machine, which surrounds the mass production of infused fibrin microthreads that can be 
converted for cosmetic applications. Therefore, the precision of the fibrin microthreads are not 
necessary because the threads will be converted into an alternative form used in the powder. The 
reliability, sterility and durability of the machine would be ideal, but the system can be altered, 
cleaned, and repaired in time (if needed) without the constraint of using expensive materials to 
ensure a longer lasting machine. While it is also important for the machine to be of a reasonable 
size that can fit on a lab bench and be safe for users, a bigger machine that has an intricate design 
and still outputs the necessary product is more desirable. 
4.2.1c: Design Needs and Wants Decision Matrix 
 After defining the needs and wants of the machine, the team put together two separate 
design matrices to connect the needs and wants objectives to specific components in the machine 
design. These components are ones the team generated when discussing options for the 
alternatives and final preliminary design. Tables 6 and 7 below show these comparisons. 
 
Table 6: Design Matrix for the System Needs 
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Pumping System X  X X X X 
Syringe Head System X   X X  
Channel System  X     
Chain System  X  X   
Oval Conveyer system      X 
Clamping system  X  X   
Magnetic tracks  X  X   
Dryer    X   
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Air Dry    X   
Collection Bin      X 
Robotic Removal    X  X 
 
Table 7: Design Matrix for the System Wants 
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Syringe Head System    X X X 
Channel System X  X  X  
Chain System X    X X 
Oval Conveyer system X X   X X 
Clamping system     X X 
Magnetic tracks X    X  
Dryer  X X    
Air Dry     X  
Collection Bin   X    
Robotic Removal X X X  X X 
 
 This analysis helps the team make decisions on important components to include in the 
final preliminary design based on the wants and needs. For example, in Table 4, the Clamping 
system component can affect the automated stretching process and the minimization of thread 
failure, while, as seen in Table 5, it can affect the reliability of the machine. The purpose of this 
analysis is to draw conclusions based on the comparison between the potential components of the 
design and the needs and wants of the system. 
4.2.2 Concept Maps/Conceptual Designs and Alternative Designs 
 In order to develop a novel, efficient method to automate the production of fibrin 
microthreads, the team developed several preliminary and alternative designs. The designs herein 
incorporate concepts for both the production of fibrin microthreads in an experimental, 
laboratory environment, and the large-scale manufacturing process of fibrin microthread infused 
skin cream. The team seriously considered three preliminary designs, and further considered 
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alterations to certain processes of these designs, and ultimately made a decision on a final 
preliminary design. 
4.2.2a Concept Design 1 
 The team’s first preliminary design can be seen in Figure 4 below. The design involves a 
single conveyor system that starts from extrusion of the fibrin microthreads and delivers the 
microthreads through different phases required for the microthreads to successfully form. It is 
important to note that aspects of this design may be adjusted based on the intended use of the 
production for microthreads. For example, the phase of removing threads from the conveyor may 
involve the eventual storage of the Fibrin microthreads for future experimental use, or may 
include an adaption of a grinder to create a powder. 
Figure 4: Design Concept 1 
 
The first aspect of the design involves storing fibrinogen and thrombin with an 
incorporated pumping systems to deliver the protein solutions to the device. In an industrial 
application of producing fibrin microthread infused skin cream, there would be an extra storage 
unit depicted for the storage of an antioxidant ingredient, such as retinol or hyaluronic acid. An 
existing pumping system (Figure 5) would be incorporated. 
64 
 
 
Figure 5: Piston Rod Syringe Pump 
  
This pumping system is designed to be used with syringes that store the protein. A piston 
rod is controlled to extrude the protein out of the syringes at a specified extrusion rate. In an 
industrial application, this concept would involve larger tanks for storing the protein that would 
have individual pumps that direct the fluid from the tanks to an extruder head, as depicted in the 
schematic of the design. For the sake of our preliminary design for a prototype, the piston 
controlled pump system would be used and be adapted with the rest of the conveyor system. 
 When the piston rod compresses the syringes located on a syringe holder, the protein 
would be in fluid communication with an extruder head. The extruder head is a two to one port 
system, such that fibrinogen and thrombin would be extruded out a single port as a protein 
mixture. Further, in the production of fibrin microthread infused skin cream, the antioxidant 
ingredient would be pumped into the same port as thrombin, where it would mix; then, the 
antioxidant thrombin mixture would mix with fibrinogen as one mixture and be extruded. 
 The system itself consists of a conveyor belt, controlled by an external motor, which 
would run continuously through a tub filled with HEPES solution, and external the tub through a 
dryer. The conveyor would move at a speed to give threads a minimum of three minutes in the 
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HEPES tub to allow the threads to formulate. Further, the speed of the conveyor may be directly 
adjusted based on the desired diameter of the threads, as a faster conveyor would produce thinner 
threads, and a slower conveyor would produce thicker threads. 
 The thread would be extruded directly from the extruder head through a stationary tube 
directly to the surface of the conveyor. This design would allow for a single, continuous thread 
of fibrin to be produced through the system. The conveyor would extend out of the upper corner 
of the HEPES bath and level out to enter the dryer phase. The dryer that may be incorporated in 
this design can be found in Figure 6 below. 
Figure 6: SIMCO Aerostat XC Air Blower 
  
Once the continuous thread of fibrin leaves the tub of HEPES, the conveyor levels out 
and the threads enter a drying phase. To expedite the drying process, a dryer such as the SIMCO 
Aerostat XC Air Blower may be used. In this aspect, the dryer can be set to various settings, such 
as air blowing rate, to a standard that is tested to be most effective for successful production of 
fibrin threads. After this phase of the design, the threads must be removed from the system. 
 Removal of threads from the system in Design 1 may vary depending on the purpose of 
use of the machine. If the machine is being used for industrial application, or the production of 
fibrin microthread infused skin cream, the single thread may fall off the conveyor into a grinder 
in which the thread would be manipulated to a powder and collected. In a laboratory setting, the 
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thread may be cut by a user, once dried, and placed in a storage unit. In further embodiments, a 
robotic mechanism can be designed to cut the thread into piece and place them on a storage rack. 
However, for the preliminary design, it is intended to have a user control cutting the threads and 
removing them from the device. 
 Advantages of Design 1 include the ability to control the rate of extrusion and the 
movement of the conveyor to a custom rate in order to effectively create threads of a desired 
diameter. By incorporating the piston rod extrusion pump, there is an easy user-interface that 
allows the user to change the rate of the piston with a control module. Further, the system makes 
use of extruder heads that are currently used in the manual production of fibrin microthreads in a 
laboratory. Additionally, the conveyor system is completely linear, which is a design of 
minimum complexity. The simple chain that the conveyor would rely on in this linear system is 
mechanical in nature, and are readily available for reasonable prices by several manufacturers, 
making it a reliable design. 
 Disadvantages of Design 1 includes the limitations the linear design has on organization 
of the threads. Since the system is completely linear, and the extruder head is stationary, only 
one continuous thread can be produced. The production of threads by cutting one continuous 
thread into smaller pieced either requires a user that must be stationed after the drying stage of 
the machine, or an advanced system of robotic nature to cut the threads and place them to 
storage. In an industrial application, the single thread would be fed into a grinder; however, the 
end of the design is convenient for only this purpose. Finally, one aspect of fibrin microthread 
production that is not incorporated in design 1 is the stretching of threads. Stretching of fibrin 
microthreads have beneficial benefits for their formation and increase the amount of thread 
produced from a given amount of protein solution. Therefore, the lack of the stretching of 
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threads may drive the cost of production of microthreads up compared to other designs that 
stretch threads. 
4.2.2b Concept Design 2 
A schematic of a side view of the team’s second design can be seen below. The design 
incorporates a conveyor system that operates on both the upper surface of the conveyor belt, and 
the bottom surface of the conveyor belt. The design incorporates a channel system that can 
separate the extruded mixture into separate threads of a desired length. Design 2 involves an 
intricate design that includes 8 main components: pumping, extruding, stretching, flipping and 
dumping of HEPES solution, drying, collecting, cleaning, and replenishment of HEPES solution. 
These aspects of the design can be found in Figure 7 and are labeled 1-8, respectfully. 
 The first aspect of the design includes pumping. 
Similar to design 1, the system may include storage tanks 
with a pump for each individual tank that would lead a 2-
to-1 tube extruder head. Like the first design, another 
tank may me incorporated with an antioxidant solution 
with a separate pump that may be mixed with thrombin 
in one entry tube of the 2-to-1 tube extruder head. In another embodiment, the piston rod 
controlled syringe pump may be used with the system. 
However, with extrusion, unlike Design 2, the extruder 
head has one degree of freedom across the extruder. 
Specifically, the extruder head would move back and 
forth along the axis of movement along a grooved 
channel within the surface of the conveyor. This channel Figure 7: Design 2 channel system for 
organizing and stretching threads 
Figure 8: Design 2 
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system would allow for the system to extrude separate threads. The length of the channels would 
correspond to the desired length of the threads. Additionally, each individual channel would be 
filled with HEPES buffering solution to allow the threads to form. A top-view schematic of the 
channel system may be seen in Figure 8. 
The channel system of Design 2 serves two purposes. The first purpose is to separate the 
extruded mixture into separate threads; and, the second purpose is to create individual systems to 
stretch the threads. As seen in the above schematic, each channel system includes two blocks that 
are stationed across from one another. In the schematic above, each block is in a “closed” 
position, in which a thread is clamped within the block and is able to be stretched. The block has 
two plates that are connected by a hinge. Once the extruder head moves across the channel and 
extrude the thread on the lower plate, the block closes. This movement of the block may either 
be controlled by a timed motor system, or by magnetic forces that exist between the block and a 
surface below the conveyor. 
 Once the blocks are in a closed position, they are able to move along the bottom surface 
of the conveyor. In the design, the bottom of the conveyor may include a track set-up in which a 
motor would allow the blocks to move away from one another on the track. This track can be a 
roller system, or a separate chain system within the channel may allow pull the blocks away from 
one another to allow the thread to stretch. In other embodiments, a magnetic system may be used 
to separate the blocks. By the end of section 3 of the design, the threads should be in a 
completely stretched position. 
 At section 4 of the design, the conveyor begins to turn over. At this point, the blocks still 
remain in the closed position, so the threads do not move despite the channel beginning to flip. 
As the conveyor begins to fall over, the HEPES solution is dumped out into a collection bin (not 
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depicted in the schematic). This HEPES can either be disposed of, or it can be collected and 
pumped back into a storage tank for re-use. Once the conveyor is almost upside down, one clamp 
may open through a step-motor or other means to allow the first plate to open with movement by 
the hinge joint. At this point, the thread may hang. In other embodiments, both clamps may 
remain shut to ensure the stability of the thread. 
 At section 5 of the design, the threads go through the dryer. Like design 1, an 
incorporated dryer may be the SIMCO Aerostat XC Air Blower. An aspect of this dryer is that it 
is on a swivel, and the angle of air flow may be adjusted to accommodate for the threads being 
above the dryer. Additionally, the rate of airflow may be adjusted to whatever desirable 
specification that will be most effective for the production of the fibrin microthreads.  
 After drying, the threads must be removed from the system. This can be accomplished in 
a few embodiments. In a first embodiment, the threads are already hanging by one clamp when 
approaching section 6 of the design. At this point, the clamp holding the thread may open and 
allow the thread to drop into either a collection bin, where a user must take the thread out, or a 
grinder, where the thread is grinded into a powder and collected. In another embodiment, both 
clamps are closed as the threads approach section 6 of the design. If this is the case, a first block 
will become open through a step-motor, and a second clamp will open after the first block is 
opened to allow the hanging thread to fall into the collecting bin or the grinder. In a third 
embodiment, similar to Design 1, a user may be stationed at section 6 of the machine and cut the 
threads off and place them in a storing unit. 
 At section 7 of the design, the channels must be cleaned. Since threads formulated on the 
surface of the conveyor and on the inner surface of each plate of the blocks that clamped the 
threads, residue of fibrin may still exist within the channels. Before HEPES is replenished in 
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each channel, the channels are cleaned with water. At section 7, a tank of water and hose system 
is stationary and sprays down each channel as the conveyor moves (not depicted in the 
schematic). 
 Finally, at section 8, HEPES solution is replenished in each channel from a HEPES 
storage tank (not depicted in the schematic) and a stationary extruder head. Each channel, that 
had just been cleaned, is replenished with HEPES solution before a new thread is extruded into 
the channel. The HEPES may be recycled HEPES, or may be a limited supply of HEPES 
solution if the HEPES is not recycled or continually replenished in the storage tank. 
 There are several advantages to preliminary Design 2. Like Design 1, the pumping 
system enables to flow rate of the protein mixture to be controlled to a desired value. If the 
piston rod syringe pump is used, there is an easy user-interface. The only true difference between 
this extrusion processes of the first preliminary design to the second preliminary design is that 
the extruder has a degree of freedom to move along each channel of the conveyor, so the piston 
rod syringe pump would be adapted with a tube to the extruder head from the 2-to-1 syringe 
head. This degree of freedom allows for separate threads to be formulated within each channel, 
which is a great advantage and less work for the user. Additionally, the channel system with 
incorporate blocks allow the threads to be stretched, which is more efficient use of the protein 
solutions. Further, the compactness of the system is an advantage of this design. Since the system 
is not completely linear, the specifications of the length of the device would not be as long. 
Finally, this design enables adaptability of its use as either an industrial machine or laboratory 
machine used for the production of the threads. 
 Although the design incorporates many aspects for efficient fibrin microthread 
production, some of its complexities have disadvantages. For example, the channel system with 
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moveable blocks is a costly design. Each individual channel may essentially need a motor or a 
driver to move the blocks, which is inefficient and costly. Further, the material in which the 
channels and block plates are made of is important. The material must not rust in the HEPES 
solution. Additionally, the fibrin threads must be easily removed from the surfaces, and there is 
risk that the threads may adhere too well to the plates when they are clamped, which would not 
enable them to fall when unclamped effectively. Further, the force in which the threads are 
clamped must be perfect that the threads are not torn, and timed well enough that the threads are 
formed enough to be clamped effectively when the blocks closed. This process includes very 
tedious complication, and excessive timing, as if one aspect of the stretching of threads is not 
timed correctly, the whole process can be thrown off time. Also, although cost may be saved 
through stretching the threads, more cost is lost through individual HEPES channels that are 
dumped. With this, especially if HEPES is tested to be unsanitary to be re-used from one thread 
to the next, a lot of HEPES solution will be wasted in this design. Finally, in this design, many 
different tanks would need to be used, which in the manufacturing of fibrin microthread infused 
skin cream could be five tanks (water, HEPES, fibrinogen, thrombin, antioxidant). Maintenance 
of all the tanks, and the efficiency of all individual pumps may be complicated. 
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4.2.2c Concept Design 3 
The team’s third design concept can be seen in Figure 9 below. The design incorporates a 
chain system in which chain links are coupled to small clamps. Threads are able to be extruded 
across the clamps within a HEPES buffering solution tub. From the tub, the clamps may close to 
allow the chain to pick up the threads and stretch them. Like the previous designs, a dryer is 
incorporated to expedite drying, and threads can be collected or grinded. 
Figure 9: Design Concept 3 
  
Design concept 3 consists of seven main components, including pumping, extruding, 
polymerization, stretching, drying, collecting or grinder, and cleaning. The design itself 
incorporates a chain link system that leads threads from extrusion to all these processes. The 
main chain of the design is run by a motor, such as a stepper motor. Sprockets are used to control 
movement of the chain throughout the system, such as the rising of the chain out of the HEPES 
tub (see label 3 in drawing), and to the stretching platform. 
 The first aspect of the design involves the pumping of the protein fluids to the extrusion 
portion of the design. Like previous designs, the syringe pump can be used to control the flow 
rate of fluid going to the extruder head. In this design, a larger needle apparatus is in fluid 
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communication, through tubes, with the 2-to-1 extruder head. The needle apparatus may move 
linearly to draw individual threads across a conveyor. Once a piston compresses the syringe and 
forces fluid through the tubing, the mixture will continue through the needle into the extrusion 
portion of the device. Additionally, similar to previous designs, in an industrial setting, large 
tanks can be used to store the protein fluid and any additive, such as antioxidants, that can be 
mixed with thrombin prior to mixture with fibrinogen.  
  The next aspect of the design is the polymerization of the threads. At this point, the 
threads are extruded onto a conveyor that is submerged within the HEPES tub. The conveyor is 
coupled to a hex shaft that is driven by the motor. A drawing of this concept can be seen in 
Figure 10 below. 
Figure 10: Conveyor submerged within HEPES solution concept 
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As seen in the drawing, the first sprocket that controls the direction of the chain is 
coupled through the hex shaft (not seen from side view in drawing), to the submerged conveyor. 
Considering this, the conveyor would move in uniform to the movement of the chain. Further, 
threads would be extruded directly onto the conveyor. Once threads are drawn, they can remain 
submerged in the HEPES solution to polymerize. The time in which the threads may be easily 
adjusted by a user by adjusting the location of the second set of sprockets along the frame of the 
device. The closer the second set of sprockets are to the first set of the sprockets, the shorter the 
threads will stay submerged within the HEPES solution. At the end of the conveyor, the threads 
are lifted by the chain that is controlled by the second set of sprockets, and the threads are 
brought to the stretching aspect of the device. However, in order to complete this transition, the 
threads must be clamped in place as they are lifted off of the conveyor. A top-view of Design 3 is 
shown in Figure 11 below. 
Figure 11: Top-view of design concept 3 
  
There are blocks that are coupled in increments along the chain. These blocks act as 
clamp mechanisms that hold extruded threads in place. In the HEPES tub where the threads are 
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extruded, the blocks run along-side the conveyor. When the mixture is extruded, it is extruded 
along a surface of parallel blocks and the conveyor, so that the original length of the thread is 
equal to the width of two blocks plus the width of the conveyor. Each block has a method of 
opening and closing in order to clamp polymerized threads before that are lifted by the chain out 
of the HEPES tub toward the stretching component of the device (Figure 12). 
 
Figure 12: Blocks coupled to chain for clamping threads 
  
Each block is coupled with a pin to the chain. The chain has small plates that extends 
toward the center of the device in between links. The blocks may simply be coupled to the plates 
on each chain, and follow the chain through its movement throughout the device. In the drawing 
above, a portion of thread is depicted to visualize that threads are extruded on these surfaces that 
extend from the chain. There is another identical block mirroring this block on the other side of 
the device. The second portion of the thread can be extruded to this second block. Once the 
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threads are polymerized and formed in the HEPES bath under a pre-set timeframe, the threads 
can be clamped by the blocks (Figure 13). 
Figure 13: Drawing of closed clamping mechanism 
  
The above drawing depicts a block that is in the clamped position. The clamp consists of 
two parts that are coupled with a hinge joint. The first part of the clamp is pinned to the chain at 
the top portion, while the second part of the clamp may move along the hinge joint to an open 
and closed position. A magnet is placed within the first part of the clamp where the thread is 
extruded on. Magnets are also placed within both surface of the second part of the clamp. In 
Figure 13, the top surface of the second part of the clamp is in contact with the surface of the 
block that the thread is extruded on due to magnetic force. In the actual machine, a servo may be 
used to provide force to separate the magnets, or force to the bottom surface magnet toward the 
magnet of the first part of the clamp to open the clamp (Figure 14).  
Figure 14: Drawing of opened clamp 
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The clamp is depicted to be in the open position. As previously described, an external 
force, such as from a servo or other means, may bump the bottom surface of the second part of 
the clamp to force the magnet from the top surface of the second part of the clamp away from the 
magnet in the first part of the clamp, and to force the magnet in the bottom surface of the second 
part of the clamp toward the magnet in the first part of the clamp. 
 Once magnetic forces close the clamp, the threads may be lifted out of the HEPES bath 
toward the stretching portion of the device. In this aspect of the device, a stretching platform is 
attached to the frame of the device to bend the chain to eventually double the distance between 
parallel clamps, allowing the threads to stretch. A depiction of this overall concept can be seen in 
the SolidWorks model below (Figure 15). 
Figure 15: CAD assembly of Design 3 concept 
 
The platform is coupled to the frame of the device and incrementally extends away from 
the center of the device in a parabolic like shape. On the device, and as can be seen in the top 
view drawing depicted in Figure 15, an identical platform is mirrored on the other side of the 
device coupled to the frame. The distance between the furthest points between the clamps is 
exactly double the distance of the clamps when the threads are first extruded in the HEPES tub
 The stretching platform (Figure 16) is designed in a way to allow the threads the 
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incrementally stretch apart. A platform that stretched the thread too dramatically would risk the 
threads breaking. This allows the threads to be stretched gently. Since the frame of the machine 
is stationary, the stretching platform must return its shape to allow the chain to return to the end 
sprockets. Further edits to this design may include adjusting the frame to allow for the threads to 
remain taut at its widest point throughout the duration of the device. 
Figure 16: CAD part of stretching platform 
 
 Next, threads remained clamped by the closed blocks and brought over a dryer. This can 
be seen at label 5 in Figure 9. This design, like the previous designs, allow the use of the SIMCO 
Aerostat XC Air Blower dryer. Like the second design, since the air blower can swivel, the dryer 
may direct air flow up toward the threads that would move above the dryer. 
 After the drying stage, threads may be released from the clamps to fall into a collecting 
unit or a grinder to allow for the creation of powder. Further, a pair of clippers may be 
implemented in the design to cut the threads. However, for cost efficiency, an ideal aspect of this 
design would be to allow the threads to simply fall when opening the clamps above the collector 
or grinder. Finally, at stage 7 of Figure 9, the blocks can be cleaned off. This can be done by 
placing a brush stationary with a small water hose to wash down individual blocks as the chain 
moves by this portion of the device. 
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 Design three has several key advantages that fit the team’s needs/want analysis. Several 
advantages of Design 3 include its complete automation of both the extrusion process and the 
stretching process. The design allows for minimum complexity to achieve complete automation. 
Like other designs, design 3 can add antioxidants to the threads, which is important to produce 
fibrin infused skin cream. Unlike previous designs, since the sprockets are adjustable along the 
frame, the timing of threads to be emerged in the HEPES solution may be easily adjusted. This is 
important, as when different ingredients are added to the fibrin microthreads, polymerization 
may take different times. Design 3 may accommodate for this variance in polymerization 
characteristics of different kinds of threads. 
 Disadvantages of this design include the cost of the customization of the clamps. These 
clamps need to either by produced/manufactured by the team, or printed three dimensionally. At 
least 100 of the parts would need to be created for the design, which may be costly. Also, the 
length of the device may be larger than what is convenient in a laboratory setting. Since the 
HEPES tub needs to be able to accommodate threads for as high as ten minutes, and the 
extrusion of fibrin needs to be continuous to avoid clotting the pump or tubing of the device, the 
device needs to be long to accommodate these threads. Further, some material may be lost if the 
surface areas of the clamps are not large enough, and if the surface areas of the clamps are made 
larger, it is more expensive for the team to produce them. Finally, the chain itself, given its 
unique plate design and ability to flex into the necessary flexing positions during stretching, may 
be rather costly. 
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4.2.3 Final Preliminary Design Selection 
 After generating the three design concepts in detail, the team put together two decision 
matrices: one for the design components used in the three designs and one for the overall designs 
themselves. The team formulated eight total design conditions, in which were each given a 
weight on a scale from 0-1 based on their importance in making the final and preliminary designs 
a success.  
A score of 1 was viewed as being extremely important while a score of 0 indicated the 
condition was not as vital to the machine ultimate success. Specific Design Components (First 
described in the Design Matrices in Tables 4 and 5) were ranked on a scale from 0-10. A score of 
0 indicated the component would have a large-scale effect on the specific condition of the 
machine, while a score of 10 indicated the component would not be affected by a specific design 
condition. The team performed this analysis to gain a quantitative ranking of the important 
design components and overall designs to consider for the final and final preliminary design. The 
design conditions (shown in the top row of Tables 8 and 9 below) were used to produce 
quantifying measurements of the design components, which were qualified in the wants and 
needs analysis described earlier in this chapter (Section 4.1.1). The tables below show the 
weights of the design conditions for the components and overall designs respectively.  
The first four design conditions dealt with the major objective for the overall machine. 
The team decided to rank these objectives only for the overall final machine because certain 
components did not align with specific objectives (ex. Automation of the machine does not affect 
the function of the dryer).  
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Table 8: Decision Matrix for the Individual Machine Components 
 
Table 9: Decision Matrix for the Overall Machine Designs 
Design 
Component 
Automation 
of the 
Machine 
Mass 
Production of 
the 
Microthreads 
User-
Friendly 
Customization Cost Size of 
the 
Machine 
Complexity Durability Total 
Weight 1 0.8 0.5 0.2 0.7 0.6 0.6 0.7 
 
Design 1 7.5 6 6 6 6 2 7 7 31 
Design 2 9 8 4 5 2 9 1 3 27.9 
Design 3 9 8 5 5 4 7 6 5 33 
 
The results from the decision matrices indicated that Design 3 was the most optimal 
design to choose for the final preliminary design. As shown in Table 8, many of the components 
utilized in Design 3 (Pump system, chain system, dryer, collection bin, etc.) rank high as well, 
validating Design 3 is the best option for the team to choose for the Final Preliminary Design. 
Moving forward, the team separated the machine into the five different phases and determined 
Design 
Component 
Automation 
of the 
Machine 
Mass Production 
of the 
Microthreads 
User-
Friendly 
Customiz
ation 
Cost Size of 
the 
Machine 
Complexity Durability Total 
Weight 1 0.8 0.5 0.2 0.7 0.6 0.6 0.7 
 
Pumping 
System 
N/A N/A N/A N/A 6.5 6 9 9 19.85 
Syringe 
Head 
System 
N/A N/A N/A N/A 9 9 8 3 18.6 
Channel 
System 
N/A N/A N/A N/A 6.5 7 8 5 17.05 
Chain 
System 
N/A N/A N/A N/A 8.5 6 8 4 17.15 
Oval 
Conveyer 
system 
N/A N/A N/A N/A 6.5 8 5 6 16.55 
Clamping 
system 
N/A N/A N/A N/A 6 6 6 6.5 15.95 
Magnetic 
tracks 
N/A N/A N/A N/A 6 7 7 5 16.1 
Dryer N/A N/A N/A N/A 7 8 8 8 20.1 
Air Dry N/A N/A N/A N/A 2 0 10 10 14.4 
Collection 
Bin 
N/A N/A N/A N/A 8 8 4 8 18.4 
Robotic 
Removal 
N/A N/A N/A N/A 4 5 5 5 12.3 
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what types of tests were required to fully verify and create a functioning preliminary design 
concept and prototype. 
 
4.3 Conversion of Fibrin Microthreads 
The team utilized two types of analyses when determining the best conversion approach. 
The team split the conversion objective into a biomedical engineering analysis and a design 
analysis. Biomedical engineering analysis was used to determine the best method for converting 
the fibrin microthreads to particle form. Based on the preliminary results from the image 
analysis, preliminary designs were fabricated and design analysis was used to determine the best 
design mechanism for ensuring equally converted particles within the 0.1 – 1 mm range.  
4.3.1 Conversion Method Approach 
Before designing a mechanism to allow for more even and equal conversion of the fibrin 
microthreads, the team wanted to demonstrate fibrin’s potential as a novel skin care ingredient 
by separating and exploring the methods of conversion into two different categories: grinding 
and trimming. Based on the specifications described in section 3.4.3, the team looked at 
commercial methods that convert bigger items (strands, threads, etc.) into a particle or powder 
size and specifically analyze their mechanisms of conversion. In Figure 17, the team describes 
specific conversion methods tested for this objective.  
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The team first looked at a mortar and pestle and an herb grinder and analyze their 
groinding or kneading and dual-action rotational flat blade disks methods respectively. The 
action of the mortar and pestle included groinding and mixing the microthreads until they were 
in particle form. The herb grinder uses stacked blades rotating in opposite directions to convert 
the threads into particle form. For the trimming methods, the team looked at commercial scissors 
and an automated trimmer in which an analysis of the manual trimming and dual automated 
blade trimmer actions, respectively, were analyzed. When analyzing these methods, the team 
created a list of advantages and disadvantages for each mechanism. Tables 10 to 13 below 
display the results.  
Table 10: Advantages and Disadvantages of the Grinding or Kneading Method 
Advantages Disadvantages 
Easy to execute the groinding and kneading method Groinding and kneading method is tedious and time 
consuming 
Low cost method  The microthreads must be cut beforehand, leading to 
more tedious manual labor 
 
 
 
 
 
Figure 17: Objective Tree for the Specific Methods 
of Converting the Fibrin Microthreads 
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Table 11: Advantages and Disadvantages of the Dual-Action Flat Blade Disks Method 
Advantages Disadvantages 
Easy to execute the dual-action flat blade disk method The microthreads must be cut beforehand in order to fit 
within the mechanisms dimensions, causing more 
tedious manual labor 
Commercially available in a range of sizes Range of size needed for ideal effectiveness is not 
commercially available, so team would need to 
replicate design to fit our standards. 
 
Table 12: Advantages and Disadvantages of the Manual Trimming Method 
Advantages Disadvantages 
Easy to execute the trimming method Uneven particle sizes (human error) 
Manual trimming devices readily available Tedious manual labor 
 
Table 13: Advantages and Disadvantages of the Dual-Action Automated Trimmer Blades Method 
Advantages Disadvantages 
Requires little manual labor  Automated trimmer more expensive than other 
methods 
The threads do not need to be cut to smaller lengths  
  
4.3.2 Conversion Mechanism Design Approach 
 After conducting preliminary image testing from mechanisms described in section 4.3.1, 
the team designed mechanisms surrounding the conversion methods that produced the best 
results.  Ideally the team wanted to create a design that could incorporate different conversion 
mechanisms. However, based on the cost, time, and materials available, the team developed 
design options based on the results of initial method testing.  
 The team first developed a list of needs and wants of the machine to further understand 
what was needed for the final design option. Table 14 below displays a summary of the 
mechanisms needs and wants. 
Table 14: Needs and Wants of the Conversion Mechanism 
Needs Wants 
Filter unwanted particle sizes (>1mm) and debris Adaptable for different conversion methods 
Stabilize fibrin microthreads  Simple Interface 
Bundle fibrin microthreads Automated Process 
Collect the fibrin particles needed for Fibrina  
Safe for Users  
 (In 
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After determining the needs and wants, the team formulated the list of design 
requirements and objectives for the mechanism. In Table 15 below, a list of these 
recommendations is described. 
Table 15: Objective Descriptions 
Objectives Description 
Filter System  Filters out the debris and particles larger than 1 mm 
Stabilize Threads   Allows for equal conversion of the threads 
Bundle Threads  Automated process  
Collect Particles   Collects the desired converted fibrin particles 
Safe  Mechanism is safe use  
Simple Mechanism has a simple user interface 
Adaptable Mechanism is adaptable for different conversion methods 
Automated The mechanism’s process of bundling and conversion is automated  
 
The team will use these objectives to design a device that implements the successful 
conversion methods into the device based on the preliminary image analysis results.  
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Chapter 5: Preliminary Design Verification 
 In order to generate a successful final design, it was essential to verify the success of a 
preliminary design and its components. This verification helped the team identify the aspects of 
the design that worked and did not work. This chapter consists of three major sections: analysis 
needed to verify fibrin’s use in a cosmetic skin care product, machine testing for the final 
preliminary design and methods, and methodology for determining the best conversion 
mechanism. 
 
5.1 Fibrina Testing 
As a result of the insight gained during the interviews conducted with dermatologists, as 
well from the knowledge gathered in the literature review, the following experiments were 
created to test the value of a fibrin-based skin cream: cream composition testing, additive-
infusion testing, fibrin degradation assaying, and fibrin surface roughness measuring. Additional 
experiments for UV absorbance measuring and diffusion testing were established. However, 
given several constraints, they were not completed. 
5.1.1 Cream Composition Testing 
There are numerous base formulas for creating a skin cream. Different formulations are 
based on the percentages of ingredients used in an emulsion/cream, and the manner in which 
they are mixed together. Using a baseline formula found in literature, the team began to test 
variations in compositions. In Table 16 below, one can see the breakdown for a basic 
composition of an oil-in-water cream. 
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Table 16: Basic Composition of Oil-in-Water Cream [93]  
Ingredients % (weight/weight) 
Water Phase 
Deionized water 60.0 - 90.0 
Humectant 2.00 - 7.00 
Preservative 0.05 - 0.5 
Water soluble emulsifier 0.25 - 2.5 
Thickener(s) 0.1 - 1.0 
Water soluble emollient 0.5 - 2.0 
Chelating agent 0.05 - 0.20 
Oil Phase 
Emollient System – oils, esters, silicones, etc. 3.0 - 15.0 
Oil soluble emulsifiers 2.0 - 5.0 
“Active ingredients” As required by regulations of the actives being 
used 
Oil soluble antioxidants 0.05 - 0.5 
Fragrance/essential oil etc. 0.1 - 2.0 
Color As needed/required 
Preservative 0.05 - 1.0 
pH Adjustments As required for stabilization of emulsion 
 
The goal to test for the right composition was primarily to have the ability to make a 
cream which could be inexpensively used to test fibrin’s capabilities within a cream. Based on 
the composition table’s various ingredient options the team aimed to simplify down to a set of 
essential ingredients. The decided upon composition would contain grape seed oil, emulsifying 
wax, and water as the main ingredients. Smaller quantities of glycerin, essential oils, 
preservative, and vitamin E were added as well. This recipe is based upon a DIY website/blog 
for a basic moisturizer [94]. 
The team decided upon observational goals for the outcome of the cream composition 
which would deem the experiment a success. Said observations of the outcome of the cream 
included ideal texture properties, an appealing viscosity upon use, and an overall pleasant aroma 
(if any aroma was observable). The experiment was prepped to target the different weight 
percentages of the key ingredients within the base cream. The first batch, based on the online 
DIY site, had a water content of 50% in relation to the rest of the cream composition. The team 
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used this as a starting point, and created modifications for the water content to increase by 10% 
per batch attempt until optimal properties were found. 
5.1.2 Additive-Infused Fibrin Testing 
In attachment to the cream composition testing, there exists the incorporation of additive-
infused fibrin into the base composition. The additive-infused threads had to go through 
experimental procedures of their own. Said experiments highlighted the amount of additive 
mixed into each batch. They also produced a protocol for the whether the additive could be pre-
mixed with both the fibrinogen and thrombin solutions, or with just one.  
For the sake of the time and resources set for the project, the team only focused primarily 
on retinol. With respect to FDA regulatory limits of retinol use within a cream, standards were 
made on the number of additive infused fibrin batches required to contain enough retinol to 
match those FDA standards. Up to 1% of a cream can be comprised of retinol. 
 Results of the cream composition and the additive-infused fibrin experiments helped to 
design the rest of the experiments performed within this project. With particular respect to 
degradation, the additive-infused fibrin experiment results helped make the decision on how to 
explore releasing the additives from fibrin through degradative means. 
5.1.3 Fibrin Degradation Properties Testing 
In order to better qualify fibrin’s ability to act as a vehicle for actives within a skin cream, 
its degradation properties must be well understood. In natural wound healing, fibrin is typically 
broken down by plasmin via a process known as fibrinolysis. The resulting enzymatic 
degradation of fibrin produce fibrin degradation products (FDPs) which normally compete with 
thrombin during wound healing to prevent blood clots from growing and becoming problematic 
[95]. Because this process does not occur in a non in-vivo environment, the team had to find a 
way to replicate the process of fibrin degradation outside the body. Through literary research on 
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fibrinolysis, the team identified several proteases which could be purchased over-the-counter that 
have already been shown to break down fibrin. 
The team identified three possible proteases for use. These proteases were bromelain, 
serrapeptase, and nattokinase. Bromelain is derived from pineapples. Serrapeptase is produced 
by non-pathogenic bacteria found in silkworms. Nattokinase is extracted and purified from a 
popular Japanese food called Nattō. Each of the three proteases have shown to promote 
fibrinolysis when ingested [96] [97] [98]. The team wanted to observe whether the same 
degradation effects could be recreated within a neutral solution comprising only fibrin and 
protease. After looking into each of the acquisition means for each of the three identified 
proteases, the team chose to use bromelain. 
The bromelain used for experimentation was purchased over-the counter. Figure 18 
below shows an image of the purchased bottle. The bromelain existed as a lyophilized powder 
held within capsules composed of rice flour, gelatin, maltodextrin, and magnesium stearate. The 
capsules themselves were not used in any part of the experimentation process. 
Figure 18: Over-the-Counter Bromelain Capsules (500mg per Capsule) 
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To fully comprehend the manner of controlling fibrin’s degradation rate through the 
proteases, an exploratory experiment was created to see what quantities of protease were 
required to fully breakdown a specific quantity of fibrin. 1, 2.5, 5, and 10 milligrams of protease 
were placed into separate petri dishes, each containing 1 milligram of fibrin within 5 milliliters 
of phosphate buffered saline solution (PBS). Images were taken of the threads from under a 
microscope at 0, 1, 3, and 5 hours to see the degradation that occurred. The dishes were left in an 
orbital shaker throughout the time points. A final round of imaging was done after the dishes 
were left overnight to see if continued movement would eventually degrade the fibrin across 
each of the different quantities of protease. 
From the observations made in this exploratory experiment, another experiment would be 
conducted. This follow-up experiment would take advantage of UV spectroscopy. Retinol’s 
molecular structure reveals a pi bond that makes it a viable candidate for UV spectroscopy. Upon 
further literature research, retinol’s UV absorbance spectrum was confirmed at 325um [99].  
The team proposed degrading retinol-infused fibrin threads to assess fibrin’s infused-
active release capabilities. Said threads would be degraded over time using calculated amounts of 
protease. Samples from key time points would be collected for UV spec analysis. Comparing the 
data from the threads as they released retinol over time, the team would be more knowledgeable 
of fibrin’s release kinetics of additives. 
5.1.4 Fibrin Surface Topography Testing 
It may be required for the fibrin-based skin cream to stay on the skin for an extent period 
of time. During this time, it is important that the fibrin (and the actives it may carry) stay adhered 
to the skin long enough to perform their function. In addition to adherence, there is a possibility 
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for fibrin’s natural texture to be beneficial for fibrin to act as both a delivery method for actives, 
as well as an exfoliant. 
Atomic force spectroscopy can be used to determine the adhesive forces of fibrin cream 
against a skin sample. An experiment measuring the adhesion, friction, and wear characterization 
of skin and skin cream using atomic force microscopy can be mimicked to obtain the desired 
data collection from this experiment [100]. 
Upon learning of the required time it would take to reach a mastery of atomic force 
microscopy in order to perform adhesion tests, the team opted for more basic surface property 
imaging. As an aside to degradation, understanding microscale topography changes could 
potentially provide insight into characteristic surface properties of fibrin powder. 
The results of the degradation properties as well as the composition, additive-infused 
fibrin thread, and surface roughness experiments would become the main focus of this project. 
However, keeping in mind the objectives, the team identified two additional experiments that 
could be performed. One focus was on UV absorbance potential. Another focus was on fibrin’s 
diffusion into skin. 
5.1.5 Fibrin UV Absorbance Properties Testing 
There has already existed published work on the changes in fibrin microthread strength 
and stiffness as a result of crosslinking under UV light [100]. This study indicates that fibrin 
does have UV absorbing properties, to a degree. This could mean changes in degradation 
properties, as well other influential changes of the fibrin-based skin cream composition. On a 
related note, there exists an entire industry within the world of cosmetics that relies upon key 
ingredients which block UV light from causing skin damage: sunscreen. 
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The objective of measuring the absorbance properties of fibrin for this project is two-fold. 
The first part of the objective is to learn of any changes in composition or degradation which 
may occur as a result of fibrin absorbing UV light. The second part of the objective is to uncover 
any potential for fibrin to not only act as a vehicle for cosmetic actives, but also act an additional 
ingredient which can be used for UV absorbance. 
In order to determine whether fibrin that has absorbed enough UV light to start 
crosslinking will show degradative or other physical/chemical changes, a separate degradation 
assay can be performed alongside the degradation assay already proposed. The independent 
variable to be introduced is UV light. As a sample is observed for fibrin degradation under UV, 
the team will monitor differences in degradation rate, while also measuring promises  
In order to test for fibrin’s UV absorbance properties, a batch of fibrin powder can be 
created and dissolved in organic solvent. One possible organic solvent to use is isopropyl 
alcohol. Water, ethanol, hexane, and cyclohexane are also commonly used. Once fully dissolved, 
samples can be pipetted into a cuvette. The cuvette can then be placed in UV spectrophotometer. 
A UV spectrophotometer will diffract a beam of light into the sample cuvette and a reference 
cuvette (standard curve). The result will be a graph measuring the absorbance level of the fibrin 
at different wavelengths. Based upon whether fibrin absorbs any wavelengths within the UVA 
region (400-320 nm) or UVB region (320-290 nm) of the light spectrum, it can be determined 
whether fibrin has any significant absorption properties.  
5.1.6 Fibrin Diffusion Properties Testing 
There needs to be evidence of fibrin’s effectiveness in diffusing through skin. Both the 
literature and interviews conducted show a common practice done to test for diffusion with skin 
cream formulations: Franz Diffusion Cell Assays. Given monetary constraints to purchasing a 
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Franz Diffusion Cell chamber, the team proposed a simple alternative design for a Franz Cell 
apparatus, which can be seen in Figure 19. 
 The makeshift apparatus would be comprised of two media bottles (of different size) 
which would be cut to even the surface 
and allow for a skin membrane (porcine) 
to be placed over the smaller bottle. The 
larger media bottle would act as a water 
jacket, maintaining the inner chamber at 
37° C. If needed, to equalize the height of 
the smaller bottle, a supporting block 
would be placed at the bottom and 
glued. A donor chamber would be fashioned from any suitable non-readily absorbing material. A 
clamping mechanism would be applied through pressure of a heavy object pressing down on the 
donor chamber. The rest of the device follows in precisely the same manner as an actual Franz 
Cell apparatus. 
The objective of this experiment was to determine the concentration actives that pass 
through the skin membrane and dissolve into the PBS bath within the inner chamber. The team 
hypothesizes that due to fibrin’s large molecular size, it would not be found diffusing through the 
samples. This would be a positive result, considering that fibrin’s passage through a skin sample 
would no longer define it as a cosmetic. This would result in FDA requirements which the team 
has identified as a major barrier to entry for fibrin as commercial product. 
 Due to the small percentage of actives typically used in formulations (e.g. with retinol the 
percentage averages out to less than 1%) it was favorable to acquire or build a small diffusion 
Figure 19: A simple design of a Franz Diffusion Cell 
Apparatus. Produced by means of cutting two media 
bottles of different sizes and appropriately creating an 
inner chamber separately surrounded by a water jacket 
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chamber. Although this experiment was not defined as one of the main experiments to be 
accomplished by the team, an attempt was still made at creating a makeshift Franz Cell 
apparatus. 
 
5.2 Preliminary Design Machine Testing 
 Based on the phases described in Table 2, the team formulated what tests were required 
to verify the design components. The team discussed the aspects of each phase in conjunction 
with the Final Preliminary Design. In total, the team perform three tests to determine and verify 
the best conditions needs for successful extrusion of threads for the preliminary design prototype.  
5.2.1 Phase 1: Pumping  
 When discussing the first phase of the design, the team considered the budget and 
decided to spend a bigger portion of the funding towards the extrusion and stretching process, as 
these phases are important in delivering a complete automated machine. The team decided to 
utilize laboratory resources and determine the pumping speed of the machine based on previous 
extrusion logs. The team thought this was the best approach to take for the final preliminary 
design because it did not cost extra budget money and could perform the job needed to extrude 
threads successfully for the preliminary design. Below is the list of conditions, based on 
laboratory extrusion logs [101], for the pump system and its components: 
Flow Rate: 0.657 mL/min 
Inner Diameter of mix tubing: 1/16 cm 
Length of Mix Tubing: 15 cm 
18 Gauge Cannula for the tip velocity: 0.5 cm/s  
 
 Based on the values listed above, the team estimated the general size of the prototype that 
would allow use to produce consistent threads without the allowance for clogging or backup in 
the pump system, which were within 165 cm x 60 cm lab bench space.  
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5.2.2: Phase 2: Extrusion 
 In order to prevent clogging of the extruder head, the team needed to determine how 
many threads could be drawn and polymerized without interrupting the extrusion process and 
speed. To determine the amount of threads that could be made in conjunction with the movement 
of the machine, the team performed a test to figure out how long it would take for threads to be 
viably removed following extrusion into a water bath. The purpose of this test was to establish 
the required length of the HEPES bath used to hold the extruded threads. Threads that take a 
longer time to polymerize would require a longer bath size, while threads that take less time to 
polymerize would require a smaller bath size.  
Test 1: Thread Removal Time 
This experiment was performed to test if the threads could be removed successfully at 
different time points following the extrusion process. In order to determine if the extrusion phase 
could be shortened, which saves material and money for the final and preliminary design, the 
team wanted to verify if the threads were viable and strong enough to be removed earlier than the 
typical 10-minute sitting period following the extrusion process (See Appendix I for the normal 
extrusion processed used currently in the lab). After the threads are drawn, the team removed 
threads after one minute, three minutes, five minutes, seven minutes, and ten minutes (control). 
The team compared the threads removed at time points one, three, five, and seven minutes to the 
threads removed after the normal setting time of ten minutes or the control. The results of the test 
are shown in Table 17 below. 
Table 17: Results from Testing the Removal of Threads at Different Time Points 
Time (min) Were they viable after removal from the water bath? 
1  Yes, but the thread was not fully formed and weak in structure 
3 Yes 
5 Yes 
7 Yes 
10 (control) Yes 
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Based on the results of the test, the team concluded that the threads are viable after 
removal at earlier time points, therein reducing the size of the HEPES bath used in the final 
design. The team observed that the threads removed after one minute were a reach in terms of 
stretching viability since they were not completely polymerized. The threads at three minutes, 
however, were easy to remove and were fully polymerized and formed. Moving forward, the 
team decided to quantify the viability of the threads with mechanical tests of the threads removed 
at smaller, incremental time points.  
5.2.3: Phase 3: Stretching  
 Quantifying the threads’ mechanical properties at different time points helped the team 
determine the length to which the threads could stretch and remain in one piece and viable. This 
test aided the team in defining the length the threads would be stretched to on the machine. 
Test 2: Mechanical Testing of the Threads 
 This experiment was performed to determine the mechanical properties of threads at 
different time points following the extrusion process. The purpose of this experiment was to 
determine how long the threads could be stretched in order to determine the quantitative 
parameter of the machine dimensions. The team wanted to verify the strength of the threads 
following the extrusion process following the extrusion process (See Appendix I for the normal 
extrusion process used currently in the lab). Based on the results and conclusions of the 
“Removal of Threads at Different Time Points” experiment, the team decided to test the 
mechanical properties of threads at time increments closer to three minutes. The time points the 
threads were removed were at two minutes, three minutes, five minutes, and ten minutes 
(control). The team compared the mechanical properties of the threads removed at the specific 
time points.  
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Based on the results of the mechanical testing, the results were inconclusive in telling 
whether the threads formed at two minutes, three minutes, five minutes, and ten minutes had 
significantly different mechanical properties. There are a couple explanations as to why this was 
the case. As a primary explanation, human error is a major issue. Based on the performance of 
the individual drawing the threads, the threads may have had better or worse mechanical 
properties, regardless of how long they sat in the bath. As an example, both the two minute and 
the ten minute threads were drawn from the same batch of fibrinogen and thrombin. Looking at 
the results of the mechanical testing, there is insignificant data showing the two minute threads 
having less (or more) tensile strength and subsequent elastic modulus as compared to the ten 
minute threads. 
Other explanations include the relatively small sample size of threads tested, which was in part 
by the team’s choice to produce only 10 samples for measure. During the process of wetting the 
samples for measurement, two of the two-minute threads had broken from their test strips and 
became unusable. Based on what could be gathered from this experiment, it may be 
recommended to have threads being produced under the automated machine to sit for at least 
three minutes as a safety measure. 
5.2.4: Phase 4: Drying  
 The team defined a dry thread as one that does not have water droplets and extra residue 
hanging off. Utilizing the SIMCO Aerostat XC Air Blower in the laboratory, the team tested 
different settings and placement of the dryer to determine the best placement of the dryer in 
conjunction with the main stretch frame component of the machine. The team used threads that 
were manufactured following the normal protocol (See Appendix I). The team focused on 
distance of the dryer from the threads and the settings on the ionized blower/dryer in the lab. 
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Test 3 Drying Tests for the Threads 
 The team considered many different variables when designing the drying experiment. 
The team used threads drawn at regular dimensions used in the lab. The team used two 40cm 
long boxes (one for cold air and one for warm air from the blower) and each was marked with 
fifteen 2.7 cm length sections on the side of the boxes. The purpose of sectioning off the length 
of the boxes was to determine which distance was most ideal for drying the threads. The boxes 
were place five centimeters from the dryer while the dryer was placed at a 90-degree angle 
facing the box. The sections were then split into three different groups, with a total section length 
of 13.3cm. The variable groups are shown in Table 18. Figure 20 shows a set-up of Box 1 with 
the blower at medium fan speed. 
Table 18: Variables for the Drying Test 
Box 1 (Warm Air) Group 1: Low Fan 
Speed, close to the 
dryer (first 13.3 cm 
section) 
Group 2: Medium 
Fan Speed, 18.3 cm 
away from the dryer 
(second 13.3 cm 
section) 
Group 3: High Fan 
Speed, 31.6 cm away 
from the dryer (third 
13.3 cm section) 
Box 2 (Cold Air) Group 4: Low Fan 
Speed, close to the 
dryer (first 13.3 cm 
section) 
Group 5: Medium 
Fan Speed, 18.3 cm 
away from the dryer 
(second 13.3 cm 
section) 
Group 6: High Fan 
Speed, 31.6 cm away 
from the dryer (third 
13.3 cm section) 
  
Figure 20: Drying of the Microthreads with warm air at a medium fan speed 
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Based on the results of the test, it was determined that the blower did speed up drying 
time of the threads. However, the warm vs. cold air setting does not change the drying quality of 
the threads as the threads ended up drying at similar times for both boxes. The blowing speeds 
also did not impact the speed of the drying process. It did, however, show that the threads were 
strong enough to withstand high blowing speeds. The variable that did show changes between 
thread groups was distance. The distance of the threads from the blower displayed variable 
changes in drying speed. The threads that were placed closer to the blower dried quicker than 
ones placed at a further distance from the blower. The results from the tests helped the team 
determine that a closer distance of the dryer to the stretching frame (where the threads are 
stretch) is the most optimal position for faster drying. 
 
5.2.5: Phase 5: Removal 
 Since the final microthreads do not require exact uniformity and precision, the team 
decided the best way to remove the thread was to cut them and have them drop into a collection 
bin. This section of the machine will be replaced in the final design with a system that can 
convert the threads into an alternative form for use in the Fibrina skincare product. Figure 21 
below is an image of the final preliminary design prototype. 
Figure 21: Machine Prototype 
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5.3 Conversion of Fibrin Microthreads 
After performing initial image analysis on the converted fibrin using the four methods, 
the team determined which methods were suitable for the designs of the final conversion 
mechanism. 
5.3.1 Conversion Method Application Preliminary Imaging Results 
 Initial testing involved four experimental groups, one group for each of the methods. 
There were 28 fibrin microthreads total with average lengths of 16 cm. 7 threads were used per 
method group. After the fibrin was converted to its particle form, images were taken and 
analyzed in ImageJ. In Figures 22 to 25 below are some of the image results of the initial testing 
phase.  
  
Figure 22: Grinding or Kneading Results at 
10x Magnification, Scale bar = 0.1 mm 
Figure 23: Rotational Disks Image Results at 10x 
Magnification, Scale bar = 0.1 mm 
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Table 19 below summarizes the results of the average lengths of the threads taken for the 
four methods. 5 fibrin particles per method group were measured and the averages were 
calculated using Microsoft Excel (See Table 41, Appendix VI for the fibrin particle 
measurements). 
Table 19: Fibrin Particle Average Lengths for Each Thread 
Method Average Length (mm) 
Grinding and Kneading 0.42 
Dual-Action Rotational Disks 1.76 
Manual Trimming 0.32 
Dual Automated Trimmer Blades 0.24 
 
The initial results demonstrated that all methods were successful except the dual-action 
round rotational disks, as no threads were converted to particle form using this method. The 
kneading method was also not chosen as a desired final method because it required more tedious 
and manual labor than the trimming methods. 
5.3.2 Conversion Mechanism Preliminary Analysis 
The team aimed to create a mechanism that allowed for a more stable and cleaner 
conversion. Considering the needs and wants of the conversion mechanism, the team came up 
with 3 preliminary designs that are displayed on the next page. 
Figure 24: Manual Trimming Image Results 
at 10x Magnification, Scale bar = 0.1 mm 
Figure 25: Automated Dual-Blade Disks Image 
Results at 10x Magnification, Scale bar = 0.1 
mm 
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Design 1 
Design 1 (Figure 26) included the use of a 25 mm diameter tube around 80 mm long. 
Through this tube, the threads would be pushed manually, allowing the tube’s small diameter to 
bundle the threads together. At the end of the tube, represented by a cylinder in Figure 26, the 
conversion method would be placed and fastened by zip ties. A collection bin would be below to 
collect the particles. While this design is simple, organizes, and bundles the fibrin microthreads, 
it does not contain a filter system, so any particle size and debris would fall into the bin below. It 
also contains a collection mechanism. 
Design 2 
 
 Like Design 1, Design 2 (Figure 27) bundles the threads together, fastens the automated 
mechanism at the end of the track, and has a collection bin for the particles at the end of the 
track. However, using a servo motor and two motors, this design process automates the bundling 
Figure 27: Design 2 Conceptual Diagram 
Figure 26: Design 1 Conceptual Diagram 
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process. However, this method does not have a filter system as well, so even though it is easier to 
bundle the fibrin, it is harder to filter out the particles. 
Design 3 
  
Design 3 (Figure 28) is different from Designs 1 and 2 because it utilizes a filter system 
(a mesh that filters out particles larger than 1 mm) and gravity to collect the particles in a 60mm 
petri dish below the filter. A ring stand with two beaker clamps are used to hold the filter system 
and stabilize the fibrin microthreads. Figure 28above represents the system while the 
parallelogram represents the stabilized fibrin microthreads. The advantages of this method are 
that it can filter out unwanted particle sizes and more than one conversion method can be 
utilized. The disadvantages of this design include the difficulty of stabilizing and bundling the 
threads because the threads are not confined to a smaller diameter area. 
Design Analysis 
In order to determine the best design, the team performed a pairwise comparison based 
on the needs and wants formulated in Section 4.3.2. Using scores of 0, 0.5, and 1, the team 
determined the importance of each objective as they related to one another. A score of 0 was 
given if the objective in the row was less important than the objective in the respective column. 
Figure 28: Design 3 Conceptual Diagram 
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A score of 1 was given if the objective in the row was more important than the objective in the 
respective column. A score of 0.5 was given if the objectives in the row and column were of 
equal importance. These weights would determine the importance each objective would have in 
the design matrix. Table 20 shows the pairwise comparison chart from one of the team members 
while Table 21 shows the total weights of importance for each objective. 
Table 20: Example Pairwise Comparison Chart 
 
Table 21: Total Pairwise Comparison Results 
 
The team ranked safety, particle collection, a filter system, and the stabilization of threads 
as high importance. The team did not rank the automation objective of high important because 
for the purposes of this project and the time constraints the team was under, it was more 
important to stabilize and filter the fibrin.  
Pairwise 
Comparison 
Filter 
System 
Stabilize 
Threads 
Bundle 
Threads 
Collect 
Particles Safe Simple Adaptable Automated Total 
Filter System  0.5 1 1 0 1 1 1 5.5 
Stabilize Threads 0.5  0.5 0 0 1 1 1 4 
Bundle Threads 0 0.5  0.5 0 1 0 1 3 
Collect Particles 0 1 0.5  0 1 1 1 4.5 
Safe 1 1 1 1  1 1 1 7 
Simple 0 0 0 0 0  0 1 1 
Adaptable 0 0 1 0 0 1  1 3 
Automated 0 0 0 0 0 0 0  0 
Objective Pairwise Comparison Scores 
Filter System 12 
Stabilize Threads 12 
Bundle Threads 11.5 
Collect Particles 16 
Safe 21 
Simple 5 
Adaptable 6 
Automated 0 
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After determining the important objectives, a decision matrix was performed on the most 
feasible design. The team ranked each objective on a scale of 1-5. The numbered values are as 
follows: 
 
 
 
 
 
Table 22 and 23 are an example of a team member’s design matrix and the final results 
respectively. See Tables 42 and 43 in Appendix VI for the results of the pairwise comparison and 
design matrix analyses from each group member. 
Table 22: Example Design Matrix Used in Calculating the Total Design Matrix Score for each Design 
 
Filter 
System 
Stabilize 
Threads 
Bundle 
Threads 
Collect 
Particles Safe Simple Adaptable Automated Total 
Weight 12 12 11.5 16 21 5 6 0  
Design 1 1 3 4 3 5 4 2 2 279 
Design 2 1 4 5 4 4 2 2 4 287.5 
Design 3 5 4 4 5 5 4 4 2 383 
 
Table 23: Total Design Matrix Score 
Design Total Score 
Design 1 829.5 
Design 2 874 
Design 3 1107 
Based on the design matrix analysis, the team decided that Design 3 was the most 
feasible design. The team utilized the trimming methods when testing the design and performed 
further image analysis after the mechanism’s assembly.  
1 = Does not fulfill the objective 
2 = Somewhat fulfills the objective 
3 = Moderately fulfills the objective 
4 = Mostly fulfills the objective 
5 = Fulfills the objective 
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Chapter 6: Final Design Validation 
 This chapter describes how the team further validated Fibrin’s use in cosmetic skin 
cream, modified the preliminary machine design prototype, and tested the conversion mechanism 
that creates more equal and cleaner conversion. From the construction of the machine and the 
experiments conducted in the lab, the team could determine and formulate conclusions that will 
help the future development of Fibrina. This section is separated into two sections: The final 
machine design and the Fibrina testing results. 
6.1 Fibrina Testing 
 The results of the Fibrina testing were organized by each of the varying experiments. 
Again, the experimental approaches were based off of findings on validating fibrin’s value, 
which were highlighted in Chapter 4. Complete protocols, data, and images for each of the 
experiments can be found at the end of the report, within Appendix III and IV. 
6.1.1 Composition Results 
 The team formulated three creams based on the ingredients decided upon earlier in the 
project. The first cream made followed the quantities found in the DIY site, which corresponded 
to a cream comprising of about 50% water. The rest of the quantities for this first cream can be 
seen in Table 24 below. 
Table 24: Composition Experiment, 50% Water-Based Cream 
Ingredient Unit Original Measurement  Unit of Measure in mLs % to total 
Grape Seed Oil Cup 0.50 cup 118 31.50% 
Emulsifying Wax Cup 0.25 cup 59.1 15.75% 
Water Cup 0.75 cup 177 47.25% 
Glycerin Tbsp 1 tbsp 17.8 4.73% 
Vitamin E Tsp 0.25 tsp 1.48 0.39% 
Essential Oil Drops 12 -15 drops drop 0.700 0.19% 
Germall Plus tsp 0.13 tsp 0.740 0.20% 
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The resulting 50% water-based cream failed to meet physical requirements indicated by 
the team. The cream was found to be too viscous, and unpleasant to apply. However, it did prove 
to have a pleasant, non-overwhelming aroma. Recognizing that the viscosity could be lowered by 
increasing the amount of water within the cream, a 60% water-based cream was made. The 
quantities used for the second cream can be found in Table 25 below. 
Table 25: Composition Experiment, 60% Water-Based Cream 
Ingredient Unit Original Measurement  Unit of Measure in mls % to total 
Grape Seed Oil Cup 0.13 cup 29.6 23.08% 
Emulsifying Wax Cup 0.0625 cup 14.8 11.54% 
Water Cup 0.33 cup 78.1 60.93% 
Glycerin Tbsp 0.25 tbsp 4.44 3.46% 
Vitamin E Tsp 0.0625 tsp 0.370 0.29% 
Essential oil Drops 3.25 drop 0.700 0.55% 
Germall Plus tsp 0.03 tsp 0.185 0.14% 
 
The 60% water-based cream was ideal for a baseline cream. It had a smooth texture, 
without feeling entirely liquid. The aroma was pleasant, and the cream itself was physically 
appealing to put on skin. As a precaution, one 70% water-based cream was created. The third 
cream was found to be overly water-based. After a day of sitting a container, the oil and water 
mixtures had already separated out. Figure 29 below showcases the 70% water-base cream’s 
separating states. 
Figure 29: 70% Water-Based Cream, water separating from oil base at bottom of jar 
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With knowledge of FDA regulations on the maximum retinol concentrations, a ratio for 
fibrin-to-additive was determined which ultimately affected the final cream composition. Table 
26 seen below highlights the optimal percent compositions with additive-infused fibrin particles. 
An explanation of the particle-to-additive ratio is mentioned in the results of the additive-infused 
thread testing. 
Table 26: Weight % calculations for a baseline moisturizer with additive-infused fibrin particles 
6.1.2 Additive-Infused Fibrin Experiment 
 Before moving forward with mixing additive-infused fibrin into the baseline cream that 
was decided upon, tests on introducing additives into fibrin microthreads in the most optimal 
way possible were performed. By learning what the ideal concentrations of additive-to-thread 
were, the amount of fibrin required for a cream could be identified. 
 The team focused on retinol, in the form of retinoic acid. Retinoic acid comes in the form 
of a lyophilized yellow powder. This form of retinol was only dissolvable within ethanol. Two 
different ratios for dissolution were used. The first ratio was 25 mg of retinoic acid per ml of 
ethanol. The rate of dissolution for 25mg of retinoic acid in 1 ml of ethanol was rather slow. The 
25mg were not completely dissolved until a number of days passed. 
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 With a ratio of 25mg of retinoic acid per 2ml of ethanol, the retinoic acid dissolved in 
solution much more rapidly, although it still took a significant amount of time (several days) for 
complete dissolution. The team opted to use the 25mg/ml retinoic acid in ethanol for the 
remainder of the experiments despite its slower dissolution time. This was due to the objective to 
deliver as much active within a singular batch as possible. 
 When the retinol in ethanol solution is pre-mixed with the thrombin solution, the 
resulting mixture is a white, opaque solution. Figure 30 below is an image of that solution just 
described. The result of pre-mixing with fibrinogen was immediate clotting, and was thus 
impossible to use for extrusion. 
Figure 30: 100ul Retinol in Ethanol (25ug/ml) pre-mixed into 900ul Thrombin/CaCl2 Solution. 
  
With the retinol in ethanol solution only pre-mixing with the thrombin solution, 
experimentation with the ideal amount of retinol in ethanol solution that could be pre-mixed 
without causing difficulties with thread formation and extraction occurred. The first attempt at 
making retinol threads used 200ul of retinol in ethanol solution pre-mixed into thrombin 
solution. The observations that came from using the 200ul amount were as follows: 
1. Threads formed well on the bottom of the pan. 
2. Threads were difficult to remove from the pan if not drawn near perfectly. 
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3. Any threads drawn too thin were irretrievable. Threads drawn larger than average were a 
50/50 success. 
4. The consistency at which a thread was drawn well, taken off the plate, and successfully 
placed on a box for drying was low. 
 
Impediments with making these batches ultimately led to the use of 100ul for pre-mixing. 
The resulting batches were much easier to deal with, at the expense of having less retinol 
concentration per batch of threads. As a result of only being able to mix 10% of retinol into a 
single batch of fibrin threads, multiple batches are required to achieve the desired maximum 
allowable concentration of retinol for a cream, within fibrin-based particles. As an example, for a 
100ml cream, a maximum of 1ml of the cream is allowed to be retinol given FDA regulations. 
Given that only 100ul of retinol can be infused into a single batch of fibrin microthreads, ten 
batches would have to be produced in order to attain 1ml of retinol-infused fibrin particles. 
6.1.3 Fibrin Degradation Experiment Results 
 Two experiments were performed to better understand fibrin-based particle degradation 
properties. These experiments were the exploratory enzyme degradation experiment and the UV 
spectroscopy analysis experiment. The first experiment addressed the capabilities of a degrading 
fibrin using a natural fibrinolytic enzyme, bromelain. The second experiment addressed the need 
for quantitative data on active release performance.  
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 Five quantities of bromelain were used for this experiment: 1mg, 2.5mg, 5mg, 10mg, and 
a control (0mg). The entire protocol for this experiment can be found in Appendix III. Figure 31 
below shows the performance results of the 10mg bromelain sample in its ability to degrade 
fibrin particles over only two hours within a neutral buffer. 
Figure 31: Left: 1mg fibrin particle degradation via 10mg bromelain exposure after 1 hour.  
Right: 1mg fibrin particle degradation via 10mg bromelain exposure after 3 hours. 
 
Observations of the amount of fibrin left in each of the dishes were done with the naked 
eye, then through a microscope. Microscopic images for each of the time points and quantities 
can be found in Figures 54-84 in Appendix IVa. The 5mg and 10mg bromelain dishes were the 
only dishes to completely dissolve the fibrin completely. It can’t be determined through sole 
observations if the fibrin particles within each of the samples were degrading at different rates. 
However, with the results of the first experiment providing a baseline for the amount of enzyme 
to use on fibrin-based particles, a quantifiable UV spectroscopy experiment could be conducted. 
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Retinol-infused threads were drawn and weighed. Six batches of 1mg each were created. 
Five sample plates of 6, 7, 8, 9, and 10mg of bromelain were created alongside a control. These 
quantities were chosen based on the results of the exploratory degradation experiment, which 
highlighted the complete degradation of 1mg of fibrin particles using 5 and 10mg of bromelain. 
By looking at the differences in the release of retinol with the different quantities of bromelain, a 
release profile could theoretically be identified. Each of the plates were filled with 5ml of PBS. 
10mg of fibrin were then added to each of the sample plates. Supernatant sample from each dish 
was taken at the zero hour, and then again every other hour starting from the first hour. The full 
protocol for this experiment can be found in Appendix III. Figure 32 below shows graphed 
results of the UV spec values obtained from each of the samples. 
Figure 32 Results of UV Spec Analysis for Bromelain Enzyme. Significant Outlier for the 9mg dish at hour 5.  
 
No significant change in the readings from the first to third hour occurred. The most 
notable change occurred between hours three and five, with the exception of the 9mg reading at 
hour five, which was likely an outlier resulting from a mishap. The 6, 7, 8 and 9mg dishes all 
ended at fairly similar quantities of released retinol, while the 10mg dish showed an averaged 
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0.02 higher release of retinol. A two-way ANOVA test was calculated with MATLAB coding to 
determine if there was statistical significance between each of the samples. As shown by the 
results of the run MATLAB code (see Appendix IVc for the complete code), which can be seen 
in Figure 33 below, there was no statistical significance.  
Figure 33: Results from running the MATLAB code for the Two-way ANOVA. Circled is the calculation 
indicating no statistical significance 
 
Figure 34 Standard Curve of retinol in ethanol mixed with PBS. The retinol in ethanol amounts represent the 
amount of retinol in ethanol within a 500ml PBS solution 
 
The standard curve seen above in Figure 34 shows the expected readings from the UV 
Spec analysis in relation to the amount of retinol in solution. Based on the readings from the 
SpectraMax 250, not a single sample read showed a retinol concentration higher than 3ul of 
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retinol in ethanol solution. Due to the results of this experiment, it was speculated that some of 
the retinol might be escaping at some point during the experimental process. In an attempt to 
identify if this was the case, a sub-experiment was performed using a special 3D printed multi-
channel tub. Figure 35 below is an image of this tub prior to extrusion. 
Figure 35: 3D printed multi-channel tub. 5ml HEPES within each channel. 
 
Individual threads were drawn into each channel. Once a complete batch was produced, 
the 5ml HEPES from each of the channels were extracted and analyzed through UV 
spectroscopy to see if retinol would be found within the threads. This would indicate retinol loss 
in the thread, to the bath. No statistical significance could be identified to indicate or not indicate 
retinol loss. In-depth results from this sub-experiment can be found in Appendix IVd.  
6.1.4 Surface Roughness Results 
 Fibrin particles were created and transferred over to a sample plate, where they could be 
imaged under an atomic force microscopy machine. The type of AFM machine used was a 
NaioAFM. Figure 36 below shows images taken of a single fibrin particle. 
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Figure 36: Surface imaging of Fibrin Particle under AFM 
 
Surface roughness values of the particles varied heavily by the location along the particle. 
Due to the mechanical means by which the AFM cantilever travels across the particle, surface 
roughness values change more dramatically around the edges of the particle. 
Quantified data of the surface roughness at different points from within the above image 
were taken. Figures 37 and 38 below show two separate sections of the image being calculated 
for their area roughness values. 
Figure 37 Thread Surface image with Area Roughness Calculations 
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Figure 38 Thread Surface image with Area Roughness Calculations 2 
In-software analyses for the cross-sections seen in Figures 37 and 38 produce six 
different roughness values. The values are shown in Table 27 below.  
Table 27: Surface Roughness Values for the cross-sections in Figures 37 and 38 
 Surface Roughness Calculations (nm) 
 Sa (Average 
Roughness) 
Sq (Root 
Mean 
Square) 
Sp (Peak 
Height) 
Sv (Valley 
Depth) 
Sy (Peak-
Valley 
Height) 
Sm (Mean 
Roughness) 
Figure 37 238 270 539 -492 1030 70.6 
Figure 38 541 545 763 331 432 541 
 
Only imaging on the uncut surface of a fibrin particle could be conducted due to the 
difficulty in “standing” a particle on a cut face. Figures 97 and 98 found in Appendix IVc show 
AFM imaging of a “stood up” cut face image. The image was of unreadable quality, given issues 
with the movement caused by brushing the cantilever head against the unsupported particle.  
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6.2 Final Machine Design 
 Due to the structural quality of the preliminary prototype and time constraints of the 
project, the team decided to add components necessary for a complete final design (Figure 46) 
(See Appendix V: Figures 104 to 129 for specific SolidWorks models of individual components 
of the machine). The team took into consideration the results from the experiments conducted 
when designing the initial prototype and implemented the necessary changes to the final design. 
The major components that were added to the final design were the automated extruder head, the 
tub and the base it sits on, the conveyor, and the magnetic clamps. 
Figure 39: Final Machine Assembly 
 
6.2.1 The Extruder Head 
 As described in Chapter 5, the team used the syringe pump in the lab to combine the 
fibrinogen and thrombin. In order to begin the automated extrusion process, the team assembled 
an extruder head using a stepper motor to automate the extrusion process. 80/20 was used as the 
structural base for the motor, while an Arduino was programmed to automate the uniaxial 
movement of the extruder head. A long strip of 80/20 was cut to the width of the machine (13”) 
while two 80/20 stands were cut to 3” in length. The stands and the strip were then mounted to 
the base of the machine.  
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The team set a flow rate of the fibrinogen and thrombin mix at 0.5 cm/s and used this 
speed to extrude the fibrin microthreads onto the clamps. This speed was chosen based on 
previous manual microthread extrusion batches [94].  
 
6.2.2 The Tub 
The tub component of the design is comprised of 0.100 inch clear, rectangular. The tub 
was assembled and sealed with Kwik seal ultra-clear and Loctite fast cure marine sealant. The 
following dimensions were used for the tub: 
 Base: 23.5” x 8.125” 
 Short Side Panel (x 2): 8.125” x 3” 
 Long Side Panel (x 2): 23.5” x 3” 
 
 The team cut two base pieces with the laser cutter machine in Washburn Shops and used 
the sealant to glue the pieces together, forming a double layer. The long side panel pieces were 
then glued to the base and held in place overnight. The short side panel pieces were then glued 
into place. 
In order to keep the tub as steady as possible, a portable wooden base was constructed. A 
vertical band-saw was used to cut the pieces to their respective dimensions. The dimensions of 
the wooden stand are as follows: 
 Base: 24.5” x 10.5” 
 Short Side Panel (x 2): 9.5” x 6.5”  
 Long Side Panel (x 2): 24.5” x 9.5”  
 
Since the lab is a dynamic environment, components of the machine may be moved 
around the lab space often. The team considered this when designing the tub and its stand. While 
the two components are not attached to one another, they will be easy to handle by users because 
they can be moved around easily. Figures 40 and 41 show Top and Isometric views of the tub. 
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Testing 
 The team ensured the bath is tightly sealed through leakage tests. The team filled the 
assembled tub with 1.2 L of water. Water was poured into the bath using a 2000 mL beaker then 
the bath was placed on white paper towels and monitored for potential leakages. If there were 
spots of water on the paper towels, the team would pour the water in the tub back into the 2000 
mL beaker to check the amount of water that was left. If the team discovered a leakage, the 
source would be identified and sealed with more sealant. The team observed the bath at 30 
minutes, 60 minutes, 720 minutes (12 hours), and 1,440 minutes (24 hours). At each time 
interval, the team indicated if the tub passed or failed the leakage test, recording the values and 
results in Table 28 below.  
Table 28: First Test Tub Leakage Results 
Time (minutes) Amount Measured (L) Leakage Amount (L) Pass/Fail 
30 1.13 0.07 Fail 
60 N/A N/A Fail 
720 N/A N/A Fail 
1,440 N/A N/A Fail 
 
Figure 41: Isometric View of the Tub Figure 40: Top View of the Assembled Tub 
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 Since leakage was discovered during the first 30 minutes of the test, the team ceased the 
first tub test. The leak occurred at the side edges of the bath and went in between the double base 
layer and onto the paper towels. The team sealed the edges of the bath and retested it using the 
same protocol as used for the first leakage test. The results are shown in Table 29 below.  
Table 29: Second Test Tub Leakage Results 
Time (minutes) Amount Measured (L) Leakage Amount (L) Pass/Fail 
30 1.2 0 Pass 
60 1.2 0 Pass 
720 1.2 0 Pass 
1,440 1.2 0 Pass 
 
The team was successful in fixing the sources of the leaks in the tub system and the 
testing for this portion of the machine was complete.  
6.2.3 The Conveyor 
In addition to the extruder head, the conveyor was also automated by the same step motor 
using a string. In order to get the material at the dimensions needed for the conveyor, the team 
utilized the vertical band-saw and the plasma cutter in Washburn Shops to cut the pieces to the 
necessary shapes and sizes. The conveyor was assembled with the following materials and 
dimensions:  
Zinc Plated 1.5” 90 o Steel L-Bar with 3/8” holes and 5/16” slots (x 2): 20” 
3/8” Threaded Rod (x 1): 8” 
ABS Polvflex PVC Tube (x 6): 6” 
Acetyl Sleeve Bearing for the Conveyor Roller: 3/8”  
Acetyl Bearing for 5/16” Axle 
Washer, Nuts, Bolts: 3/8” and 5/16” 
 Rubber Bung 
Non-Slip Stick Tape and Orange Conveyor Tape 
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 The team is planning on automating the conveyor by attaching a thin, circular sleeve to 
the stepper motor used to extrude the fibrin, allowing it to move simultaneously with the extruder 
head. Figure 42 below is a picture of the structure of the conveyor. Additions will need to be 
implemented within the first two weeks of D term. 
Figure 42: Conveyor Base 
 
6.2.4 The Magnetic Clamps  
In addition to the test clamps used in preliminary design, the added a total of 44 clamps, 
making up 22 pairs of clamps. The magnets were 3/16” in diameter with a 1/16” thickness. Using 
screws and hex nuts, the clamps were attached to the machine’s chains and placed in their 
starting position above the tub. Figure 43 below shows the assembled clamps. 
Figure 43: Assembled Clamps and Conveyor Incorporated in Final Design 
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6.3 Conversion of the Fibrin Microthreads 
The final mechanism included the following materials: 
Two clamps with PVC coated prongs  
1 ring stand  
50 mm circular filter mesh  
60x15 mm petri dish 
 
The first clamp contained taped fibrin microthreads, while the second clamp is holding a 
50 mm circular piece with mesh to filter out debris and particles larger than 1 mm. A petri dish 
collects the desired particles. A funnel can also be used and placed in the first clamp to help with 
the grouping of the fibrin mcirothreads as well, making this mechanism adaptable for different 
method applications and bundling options. This mechanism can incorporate the two trimming 
methods. Figures 44 and 45 displays the set-up of the mechanism with the funnel bundle system 
in use and the bundled threads mounted respectively. 
 
Figure 45: Set-up of the Mechanism 
without the Funnel 
Figure 45: Final Mechanism with 
the Funnel to Bundle the Fibrin 
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Using image analysis, the team wanted to see if the particle mixes using the mechanism 
improved over initial image analysis. Figures 46 and 47 show the results of these experiments. 
The images include threads that are within the desired particle range, while the image itself is 
cleaner due to the removal of the extraneous debris and large particle sizes.   
Using the manual trimming method, the particle sizes in the picture shown above was 0.1 
and 0.8 mm in length respectively. Using the automated dual action blades method, the particle 
sizes were around 0.1 and 0.2 mm in length. The mechanism was successful in both removed 
extraneous debris and converted particle sizes within the desired range.  
6.4 Project Impact 
6.4.1 Economics 
When looking to market and promote Fibrina, the team targeted the high-end commercial 
market, which include store brand names, such as Philosophy, that contribute to the overall 
growth of the store brand market economy. Fibrina is a niche product being introduced to 
cosmetics and can have an impact in increasing economic growth if implemented. The protein 
itself does not cost much to manufacture and should not have a major effect on economy. 
Figure 47: Image Results Using the 
Manual Trimming Method with the 
Mechanism, Scale bar = 0.1 mm 
Figure 47: Image Results Using the 
Automated Dual-Action Trimmer Blades 
with the Mechanism, Scale bar = 0.1 mm 
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6.4.2 Environmental Impact 
The production process of Fibrina is an environmentally friendly process. The designed 
mechanism that will be used for the production of Fibrin-based particles for our product does not 
require any environmentally damaging components.   
To obtain solutions for our product, livestock may be used. If the process of obtaining 
materials for our product caused the killing of livestock, these are less wild-life animals that 
positively contribute to the environmental world. 
6.4.3 Societal Influence 
Through sales and marketing, our product has the potential to disrupt existing products 
and their performance on the market. These disruptions include causing consumers to be more 
alert in avidly fact checking their products. This knowledge will help customers understand if the 
ingredients used are safe, effective, and of an all-natural source. Within certain cultures and 
nations, bovine-sourced products are deemed immoral or unsafe. Therefore, Fibrina would have 
to switch over to human-sourced materials.  
6.4.4 Political Ramifications 
Due to the nature of this project, the only political ramifications could be in relation to 
adhering to FDA labeling standard regulations. As a governing body, the FDA does not have 
jurisdiction over the manufacturing of cosmetic products. However, it can regulate the labels and 
packaging of cosmetic products in order to ensure transparency for the customer.  
6.4.5 Ethical Concerns 
The ethical concerns behind using foreign body proteins as ingredients within topical 
creams seem minimal if at all existing. This product, however, is a problem for customers who 
are actively against the use of livestock as a resource for creating the product. Animal rights 
activists are very firm in their beliefs against the use of animals for cosmetic experiments. While 
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the team does not directly work with the animals, the team uses animals’ drained blood as a 
source of the fibrin, which could be deemed cruel by some consumers. 
6.4.6 Health and Safety Issues 
As a product made for cosmetic use, Fibrina is currently being testing to maintain the 
safety and healthiness of any users of the product is of the upmost importance. Given the nature 
of our product and where it comes from, guidelines must be followed to ensure 
contamination/disease free product. There have existed outbreaks of disease which originated 
from bovine sources. As long as safety precautions are followed, and quality inspections are 
performed, compromises in consumer health through the result of delivering unsafe product can 
be easily averted. Due to the history of incidences with contaminated biological materials finding 
their way to ordinary people, there are many regulations out there which now prevent such things 
from reoccurring. The team plans to follow those regulations accordingly to ensure good health 
and safety of future consumers.  
6.4.7 Manufacturability 
For designers and engineers with the knowledge of manufacturability and machining, 
assembling a machine that can extrude fibrin microthreads would not be a difficult task. In 
addition, proficient programmers can alter the machine’s automation capabilities, allowing it to 
extrude at different speeds. This will allow the machine to produce the desired amount of threads 
depending on the application and need of the user.  
6.4.8 Sustainability 
 The machine will save time and money through its use to produce fibrin microthreads in 
a faster amount of time. While the amount of resources utilized will still be the same, the 
reduction in time spent making threads will help speed up the time it takes to plan and execute 
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laboratory experiments and produce Fibrina itself. It will also reduce the need for continuous 
manual labor, eliminating the need for additional laboratory assistants. 
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Chapter 7: Discussion 
7.1 Fibrina 
 
7.1.1 The Fibrina Business Model 
The team gathered plenty of insight regarding the commercial prospect of Fibrina through 
the interviews conducted back toward the beginning of the year. The team also gathered insights 
through a number of presentations and contacts made later on in the second half of the year. 
Fibrina as a business stands to take two possible positions. One position would be as a licensor 
for the intellectual property that is fibrin-based particles being used in cosmetic compositions. 
The other position is as a main manufacturer/distributor of the product itself: additive-infused 
fibrin particles.  
 Regardless of what position is taken, marketing is going to be an incredibly large part of 
the success of Fibrina. Marketing can be approached in a number of ways. One recommendation 
that was brought up was the idea of partnering with tier-two cosmetics companies looking for an 
edge in the cosmetics market. By tier-two, the team means a company that is not one of the 
cosmetics giants (Olay, L’Oréal, etc.), but a company that does have some existing reputation 
with good brands and an ambition to grow. Teaming up with such a company could benefit 
Fibrina by allowing Fibrina to be labelled in concurrence with an already reputable name.  
 The concept of working with multiple companies becomes problematic as it would make 
sense that a single company would want to exclusively have access to Fibrina. That being said, 
fibrin within the cosmetics world would likely not last long without continuous innovation 
through the form of research and development. This is where the existence of a company around 
Fibrina would be beneficial, given that continued academic research through WPI cannot 
continue if its purposes are directed toward commercial prospect. 
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 More interviews can always be done, especially follow-up interviews with many of the 
subject matter experts in the marketing and wholesale manufacturer/distributor fields. At this 
point, interview objectives would likely lead more in the direction of understanding costs relating 
to marketing and distribution. 
It was fairly surprising to see the number of pivots made by the team on what Fibrina 
would exist as and how it would enter the cosmetics market. With the original intent of creating 
the entire cream, then jumping back and forth between dermatology and general consumer, the 
team had to consider many ideas and perspectives. This was done without having a complete 
base understanding of fibrin-based particles and their capabilities with containment and 
subsequent release of additives. Ultimately, the easy part of all these pivots was the change in 
perspective on how fibrin could be seen in cosmetics. The difficult part of making the pivots 
became understanding how to prove fibrin’s value with each pivot. 
The team quickly picked up on the importance of scientific validation and proven 
effectiveness. It was discussed at nearly every professional interview conducted. At more than 
one point, the team witnessed several general consumers searching product ingredients on their 
smart phones to learn more about what ingredients had positive backing. Those search results 
significantly affected their decision making. From the professional world, proven effectiveness 
came down to two major things: the objective finding, and the sample size of the conducted 
study. Without question, scientific validation and proven effectiveness remained a well 
understood need for the future of Fibrina. 
 Through all the interviews conducted, one understanding failed to make it to the team: 
how does one show the science behind a product. It would make sense that the answer to this 
question lies within the research and development of a cosmetics company. Such information 
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was not easy to come by, and even when trying to make it the primary objective to learn such 
information, the team was stumped. Literature provided some insight, but not a lot. The team 
was limited in its capabilities given the small budget for the project. Because of this difficulty, 
many improvisations were made. Such improvisations become more visibly clear in the 
discussion on experimentation and learning. 
7.1.2 Fibrina Experimentation and Learning 
As a team with zero prior experience or knowledge within the cosmetics realm, many if 
not all of the experiments and learnings gathered throughout this project were a result of trial and 
error. Assessing the experiments done for the validity was in itself a challenge. Information and 
knowledge which the team lacked could’ve significantly helped the process of experimentation 
overall. 
The core triumph made by the team was the success in devising concepts for experiments 
to show scientific validity. Each of the proposed experiment types, starting from cream 
composition testing all the way to diffusion, were designed to help the team learn something in 
benefit to Fibrina. Each experiment added value to Fibrina. Ultimately, much more was learned 
from failure on the way to accomplishing the experiments. 
7.1.3 Composition 
Beginning with the cream composition experimentation, a major success came in 
building a baseline skin cream that was both cheap and easily producible. From there, the next 
step was throwing fibrin particles within the cream. That’s where the team ran into trouble. 
There was no way of testing how fibrin reacted to the oil and/or water phases of the cream, if it 
was reacting at all. From an isolation standpoint, it appeared difficult to separate fibrin particles 
out of a cream for testing purposes. Outside of the testing obstacle that existed with this 
experiment, the process of tinkering with the base cream was simple.  
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7.1.4 Additive-Infused Threads 
Moving on with the additive-infused fibrin experiments, the many successes and setbacks 
came from mostly trial and error. When it came to using any kind of additive in any kind of 
form, the initial tests always go through the same two questions: 
1. Does this mix with fibrinogen and/or thrombin solution? 
2. Can threads form under the extrusion process and be extracted successfully? 
Through many of these attempts, a number of aliquots of fibrinogen and thrombin were 
used. Many drawn threads were not extractable. Syringe tips and tubing had to be thrown out 
when pre-clotting occurred during extrusion. In the worst case scenario, the pre-clotting could 
occur within the blending applicator. The team considered all these results a cost of figuring out 
what works. 
The team successfully managed to make threads using retinol, and is confident that more 
types can be extruded. With practice, and luck, the team was even able to produce some higher 
percent-concentration additive-infused threads. However, it is clear that the need for consistently 
well drawn threads should not be solely relied upon by skilled hands. 
 One seemingly unanswerable question that always came up: how much of the additive is 
actually getting trapped within the threads? After all, the extrusion process is not so much an 
encapsulating process in itself, where the additives are in the center of the “fibrin molecule 
mesh”. How much of the additive simply falls into the HEPES solution upon entering the tray? A 
sub-experiment was performed last-minute in an attempt to solve this. Unfortunately, the results 
of said experiment turned to be inconclusive. Above all this, there was the question of what 
interactions between additives and fibrinogen molecules were occurring. This was somewhat 
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being addressed by the results of the degradation experiment, however much was left 
unanswered. 
 Because of curiosity over the interaction between the fibrinogen molecules and the 
introduced additives, the team sought the opinion of an expert in the biochemistry field. Protein 
binding sites are nearly always hydrophobic in nature. This makes sense considering the largely 
aqueous environment that is the human body. Individual fibrinogen molecules, once cleaved by 
thrombin, will naturally look to bind with the hydrophobic sites of other fibrinogen molecules. 
With this knowledge, the team developed a yet untested theory: small hydrophobic molecules 
such as retinol may find themselves trapped between the hydrophobic binding sites of the 
fibrinogen molecules. This can result in poor binding between fibrinogen molecules, which leads 
to more difficulty in extracting/removing threads from the HEPES solution. The team spent, and 
sometimes wasted, hours trying to produce quality batches with high amounts of retinol (20% 
concentration), with much failure. Should this theory be correct, then any inability to extract 
those threads was not a result of their extracting approach, but of the more poorly bound threads. 
7.1.5 Degradation 
 The results of the exploratory degradation experiment positively highlighted the 
capabilities of degrading fibrin using natural enzymes. However, when it came to performing the 
UV spectroscopy analysis experiment, the results failed to explain whether it is possible to 
control the degradation and release of fibrin and its infused additives respectively. Looking at the 
data from the standard curve and comparing it to the values obtained from the degradation of the 
retinol-infused fibrin, the team goes back to the question presented in the previous section: where 
are the additives going? Throughout every step of the manufacturing process, as well as 
throughout the experiment, there was a chance for loss of additive. 
132 
 
 From the experimental process, the team noted a lot of difficulty in stabilizing and 
moving fibrin-based particles, mainly because of static cling. The team also with fairly small 
quantities of fibrin particles at a time, to avoid having to produce excessive amount of thread 
batches. The result was a constant struggle in handling small amounts of particles that needed to 
be transferred from one container to another. Within that struggle, there was chance for loss.  
7.1.6 Surface Topography 
 With regards to using atomic force microscopy for quantifying surface adhesion, the team 
was initially disappointed upon learning the time, practice, and education needed to use AFM to 
acquire such data. However, it was understood that reaching the capabilities to perform surface 
adhesion measurements would become future work. Meanwhile, there was much inclination to at 
least start with basic surface imaging for fibrin-based particles. The reason why goes back to the 
application of those particles. Within the skin cream industry, there exists a variety of products 
and treatments which use abrasion, by either mechanical or chemical means, to improve the 
absorption of active ingredients through the skin. Mechanically speaking, such methods of 
abrasion came in the form of brushes/abrasive tools, and microbeads, which became infamous 
for their impact on the environment. The team theorized that given the right method of grinding, 
it would be possible to create fibrin-based particles that would have beneficial abrasive 
properties. Such properties would aid in removing the top layer of skin, the stratum corneum, 
which would benefit a user via exfoliation and an increased penetration of actives through to the 
dermis. 
7.1.9 Assessing/Validating the Experimental Processes 
Seeing as the team had no major experience in the science behind validating a skin cream 
prior to this year, there was a lot of discussion on the validity of the experiments performed. 
Needless to say, many of the experiment proposed were adapted from background information 
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learned, alongside a simple willingness to test many of the team’s assumptions about what fibrin 
could do for skin cream. Ultimately, the team felt satisfied with the experimental processes that 
were decided upon, but it wouldn’t hurt to have an expert opinion on the choices. There was a lot 
of attempt at finding contacts both during the customer discovery phase of this project, as well as 
through personal relationships among the team members, to find knowledge about some of the 
testing that goes on in the cosmetics industry. With much digression, the team was not very 
successful in finding such a professional. 
7.1.10 Future Considerations 
A more extensive cosmetology background could have aided the team’s approach to the 
experiments for this project. Existing insight into biochemistry could have shed light on the 
complications that occurred during fibrin microthread production. This project, from the 
experimental perspective, turned out to be much less of a biomedical or mechanical engineering 
endeavor, and more of a biochemical one. Nevertheless, the team’s biomedical engineering 
background proved to be quite useful in solving the day-to-day complications and failures that 
came and went with experimentation.  
 With the commercial, mechanical, and biomedical/biochemical approaches all tackled 
together in succession by the same team, a lot was learned. With the multidisciplinary 
experiences propagating question after question within each of the approaches, the team was 
both satisfied yet eager to see the project come to close.  
7.2 The Machine Design 
 The team developed and assembled a machine that could automate the extrusion and 
stretching phases of the fibrin microthread extrusion process. However, due to time constraints, 
the final design requires the manual removal of the threads.  
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7.2.1 Design and Assembly of the Machine 
 When developing concepts for the machine, the team had many ideas. The team 
developed concepts such as a long, continuous conveyor that can extrude threads and a 
condensed conveyor that can extrude threads into a bath. The idea was to automate the entire 
extrusion process. However, due to time constraints, the team decided to focus on automating the 
first four phases of the extrusion process: mixing of the fibrinogen and thrombin, extrusion of the 
fibrin, stretching of the microthreads, and the drying of the threads during the automation 
process. The last phase, removal, will need to be furthered researched, but the team decided that 
utilizing a cutting mechanism to remove the threads as they are collected in a bin below the 
machine is the best way of going about this process.  
 Due to time constraints, the team could not design and build devices for all parts of the 
machine. For the pumping phase, the team utilized the pump in the lab instead of building a new 
device that could be integrated into our design. While the pump performed the task of mixing the 
fibrinogen and thrombin, the team could have designed a smaller device that would perform the 
same task and be better integrated into the design, saving lab bench space and laboratory 
resources.  
 When designing the components of the tub, conveyor, and clamps, the team ran into 
issues that slowed down production of the machine. As the team began to assemble the clamps, it 
was discovered that original measurements of the tub and conveyor design needed to be altered. 
Both the tub and conveyor were originally measured to a length of 13 inches. After assembling 
the 44 clamps, the team decided to extend the length of the bath to 24.5 inches to allow the 
clamps enough time to close and the threads to crosslink in the HEPES solution.  For the tub, the 
team decided to use strong glue and sealant to put the acrylic pieces together.  Another option 
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was cutting slots to fit the pieces of the bath together, but the team found the glue and sealant to 
be strong alternatives.  
The conveyor, however, required more alterations. The base of the conveyor was 
assembled and fit in the bath space, with the respective PVC tubs in place. However, finding a 
way to connect the drive shaft the stepper motor was an issue. One design that the team tried to 
alleviate this issue was to create pulleys to be placed on the chain drive shaft and the drive roller 
for the conveyor belt. A XL timing belt could then be placed within these pulleys, such that 
when a stepper motor drives the chain, the drive roller would move in tandem. Unfortunately, 
this design did not work due to a clearance issue with the tub. In the future, the tub would need to 
be redesigned to accommodate the timing belt, or there would need to be a deeper angle between 
the conveyor and the chain draft shaft to alleviate the clearance issue. 
 The current final design, due to the issue with coupling the conveyor and chain drive 
shaft, does not have a conveyor belt that is functional. In the future, the clearance issue would 
need to be alleviated, or a third stepper motor could be mounted on the mechanism to drive the 
conveyor separately from the stepper motor that drives the chain, and the stepper motor that 
drives the extruder head. 
 Altogether, despite the lack of functionality of the conveyor belt, the mechanics of the 
device operate as was designed. The Arduino for the stepper motor allows for the chain and 
extruder to move to the exact specifications that are needed for Fibrin Microthread production. In 
order to make the machine completely functional, a few steps moving forward would be to make 
the conveyor functional, improve the quality of the ABS plastic clamps, and to finalize a method 
of guiding the clamps closed upon lift from the tub. Once these further goals are met, the team 
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will be able to efficiently test the machine for its ability to produce Fibrin Microthreads to the 
specifications that are desirable for our Fibrina product. 
7.3 Conversion of Fibrin Microthreads 
The team found methods to convert the fibrin microthreads to particle form and created a 
mechanism to make the conversion process more accurate. The team ran into issues when 
finding materials to convert the fibrin microthreads because when converted to a particle form, 
the fibrin goes through the phenomenon of static cling. When coming up with methods for 
conversion, the team ran into problems because methods with large surface areas made it harder 
to collect the fibrin particles due to their tendency to attach to the surfaces of the object. Due to 
time constraints and budget, the team was limited in terms of the complexity and materials used 
to make the mechanism. Therefore, when coming up with designs and weighing the advantages 
and disadvantages of each, the team had to consider the weighed objectives when making a final 
decision in terms of which design was most feasible to manufacture in a short period of time. 
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Chapter 8: Conclusions and Recommendations 
8.1 Conclusion 
The purpose of the team’s project was to provide a means for incorporating fibrin as an 
ingredient into cosmetic cream, and to develop a unique manufacturing process to automate the 
production of fibrin-based particles. Through involvement in the WPI Accelerate Program, the 
team assessed the cosmetic industry to create a business model that would include delivering a 
cosmetic cream that incorporates fibrin as a time-release mechanism for already industry popular 
active ingredients, including retinol and glycolic acid. Customer discovery interviews and market 
research determined that the cosmetic industry has a continual need for new, scientifically tested 
cream compositions, and that a novel major ingredient has not been introduced into the market 
since the emergence of Collagen in the market over a decade ago. From these discoveries, the 
team developed a preliminary prototype of a fibrin-based skin cream which the team named 
Fibrina. 
Further, the team did extensive research into validating fibrin’s value as an ingredient in 
topical creams. Laboratory research conducted included diffusion, adhesion, and degradation 
assays of fibrin. Through these experiments, the percentages of ingredients in the cream may be 
determined, including the percentages of additive ingredients and fibrin, in order to enable the 
cream to formulate well, and have intended effect on its application surface. Further, the 
experiments educated the team about the properties of fibrin, which assisted in determining 
methods of incorporating active ingredients within fibrin. For instance, the degradation 
experiment proved that fibrin may degrade in bulk on a surface when activated with an enzyme. 
In order to create fibrin particles for skin cream composition, the team developed a novel 
manufacturing process that enabled incorporation additives within fibrin through an automated 
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process. By utilizing previous WPI and VitaThreads intellectual property protection on the 
production of fibrin microthreads, the team was able to develop an automated process of 
producing infused fibrin microthreads. From this production process, the threads may then be 
grinded and incorporated into the topical cream. The team had to test mechanical properties of 
fibrin microthreads to determine how to allow the threads to effectively polymerize, stretch, and 
be grinded into smaller particles. The design process was followed in determining different 
preliminary designs, a final preliminary design, and an operating prototype that utilizes a chain 
based system run by a programmed stepper motor. Effectively automating the manufacturing 
process of fibrin-based particles for the skin cream was essential in alleviating the timely burden 
of manually formulating threads and grinding them into small particles.  
 The team’s various experiments, Fibrina prototype, and extrusion mechanism prototype 
had promising results for the future of the product. Although the working prototypes and 
experiments met the team’s original project objectives, there are further considerations that need 
to be made in order to progress the development of Fibrina and its manufacturing process.  
 With respect to the manufacturing process, the mechanism needs to be further worked 
with to improve aspects of the process, such as clamping the threads and a novel means for 
collecting the threads from the mechanism. Further, the mechanism, if used for manufacturing 
and mass producing the fibrin-base particles for the cosmetic cream, will need to be designed 
with materials and pumps for large scale application. Finally, the process of grinding will need to 
be eventually completely automated, or incorporated within the design of the machine. 
In the realm of the cream composition, degradation and surface topography experiments 
were successful in their completion and acquirement of useful data. However, they have far more 
potential in data acquisition if they were to be explored further. The diffusion and UV 
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absorbance experiments present great opportunities for representing industry standard testing and 
added beneficial effects for Fibrina, respectively. 
There is a lot to gain in expanding the knowledge fields surrounding the Fibrina 
experiments. A more in-depth understanding of biochemistry, atomic force microscopy, and 
cosmetology are but examples of subjects that would be greatly suited to improve upon this 
project’s work. The resulting data from the Fibrina experiments presents a positive step in the 
future of Fibrina’s use in the cosmetics skin cream industry. However, such experiments need to 
be repeated for further validation. Future experiments and opportunities are organized in the 
following recommendations chapter. 
 
8.2 Recommendations 
 
8.1.1 Future of Fibrina  
 
8.1.1a Composition 
 As mentioned in the discussion of the composition experiment, the team would like to see 
future endeavors with the composition experiment as they pertain to studying the interactions 
between fibrin-based particles and the cream itself. Other potential future work is testing the 
effects of different types of skin cream ingredients with fibrin-based particles. Lastly, 
opportunities with introducing additive-infused fibrin-based particles within the composition 
differently should be explored. 
 Questions surrounding fibrin-based particles being used in an oil/water cream can be 
addressed better if the interactions between the two can be observed and understood. Both the oil 
and water phases of the cream are likely to have different types of interactions with the fibrin-
based particles. The team recommends looking into ways of conducting those observations. One 
idea that was proposed involves using chemical markers within the fibrin that can be seen with 
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the naked eye. Think dyes. With markers entrapped within the fibrin, one could create a batch of 
cream with the marked fibrin particles, and squish the cream between two plates. The “sample” 
should be thin enough to see the marked fibrin particles, which can then be observed over time to 
see what interactions are happening. Note that this proposal addresses the oil and water phases 
together, but not separately. 
 Another proposed experiment to see the interactions of the oil and water phase separately 
as they interact with fibrin simply involve creating the two phases separately and conducting an 
observation experiment using markers which clearly identify the fibrin particles within. For the 
oil phase alone, the team already proposed the marker experiment in the previous paragraph. For 
the water phase, the team recommends running a process similar to the exploratory degradation 
experiment.  
 There a plenty of skin creams available. Each cream has its own list of ingredients and 
manner in which it is produced. With regards to the different types of ingredients, it may be 
interesting to explore the types of interactions fibrin-based particles can have with say various 
oils, preservatives, emollient systems, and so on. There may be certain ingredients which fibrin 
works even better with, or not at all. When it comes down to working with a partner who 
expertizes in making skin cream, such information may be vital to having the cream and this 
technology combine successfully. 
  Advancements in the manufacturing of moisturizers and other creams have shown that 
there are various methods by which creams can be made. Such advancements go so far as to 
create oil-in-water-in-oil systems, vice-versa systems, and more. The process by which the team 
created a basic moisturizer made use of a lot of heat. It is well known that a high enough 
temperature will cause proteins to denature. Nevertheless, there may be ways to encapsulate 
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additive-infused fibrin in these phases within phases. The team acknowledges that this kind of 
experimenting would be far out of the comfort zone of those who aren’t experts in creating 
emollient systems of such complexity, but it may prove to be worthwhile in the far future. 
8.1.1b Additives in Fibrin-Based Particles 
 The team wants to see further experimentation of the various additives which can be 
introduced into fibrin threads. Said additives need to be experimented in all the various 
applicable forms. Experimentation with using multiple additives within a single fibrin batch is 
imperative. Finally, different ways of encapsulating or binding additives to fibrin-based threads 
or particles should be considered. 
 The team never experimented outside of using solutions/liquids which contained the 
additives that ideally needed to be incorporated into threads. Initial presumptions ran that 
lyophilized powder or other solid-like particles being pre-mixed into the fibrinogen and/or 
thrombin solutions would be in inactive states, and therefore useless to integrate fibrin-based 
particles in those forms. The team did not have the in-depth knowledge to say whether this was 
true or not. Nevertheless, it is being recommended to try. Oil-based additives are another 
opportunity outside of powders. With either approach, issues relating to pre-clotting and clotting 
mid-extrusion should be kept in mind. 
 Seeing as only a small concentration of a single additive has been successfully infused 
into a single fibrin batch, the team is curious to see how more additive, and how multiple 
additives, can be successfully infused. The team expects that well automated design can account 
for the imperfect manual drawings of threads, which is presumed to be a major cause of thread 
extraction issues. Outside of automation, other opportunities exist within redesigning the manner 
in which additives are introduced into threads.  
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 One such opportunity would be to incorporate the additives at a different time then during 
the pre-mixing. When fibrin threads were drawn particularly slow, it was consistently noted that 
threads would sink to the bottom of the pan and then spread out, forming these “flat threads”. 
When these threads are lifted from the pan, the outer edges of the flat threads would converge 
toward the center of the thread, forming that familiar cylindrical shape that ultimately becomes a 
dried thread. The team recommends looking into the possibility of introducing additives just 
before lifting those flat threads. If the outer edges of the thread are able to wrap over the 
additives, then it is likely that the additive will be encapsulated. 
 Such a process gets around issues with additives interfering with the fibrinogen 
monomers binding to each other, as most of the fibrinogen monomers will have already formed 
those bonds. From a negative outlook, this introduction of additives at a later step in the thread 
formation process becomes an additional step in manufacturing, resulting in another complexity 
added to automation. Pros and cons should be weighed on the capacity for each thread to hold 
more additives versus the addition of another manufacturing step. 
 
8.1.1c Degradation 
 The controlled degradation of fibrin particles needs to be understood further for the sake 
of commercial application. The experiments conducted by the team during this project should be 
repeated to determine accuracy in the team’s initial results. From there, improvements in 
degradation control should be explored. Finally, opportunities in releasing additives from fibrin 
particles outside of degradation should be considered. 
  Repeated results of the release outcomes of degraded fibrin-based particles are essential 
to validating the commercial capabilities for fibrin in the skin cream industry as the team 
currently sees it. Retinol and other additives which can be quantified through UV spectroscopy 
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due to their molecular structure should be quantified using UV spectroscopy so long as that 
works for the degradation experiments being conducted. However, for other additives which 
don’t work as easily with UV spectroscopy, the team recommends finding ways of tracking their 
release. 
 It could be argued that rather than tracking the release, one could track the degradation of 
fibrin within an experiment, and base the overall degradation of fibrin to the overall release of 
additives. This could theoretically work if the assumption of uniform distribution of additives 
across the fibrin particles can be proven as true. However, the tracking of degradative fibrin 
assumes that the only way for additives to be released is via degradation. 
 One theory that was discussed with the biochemistry expert was the concept of using 
polarity to egress additives from fibrin particles. This concept completely delineates from using 
degradation, although the team is unsure of how that would work for the commercial application 
of fibrin particles. The team was unable to explore this concept any farther than that short 
conversation. With that, a recommendation has been set to explore the capabilities of playing 
with polarity and the release of actives within fibrin. 
Going back to quantifying fibrin degradation, one way of measuring the degradation rate 
of fibrin itself within a skin cream would be to use antibodies. When fibrin is proteolytically 
degraded within the body by plasmin, it is cut up into smaller protein pieces that together are 
called fibrin degradation products (FDPs). FDP-specific antibodies exist and can be purchased. 
Over time, as fibrin-based particles are degraded through the application of an enzyme, samples 
can be taken. Said samples could be mixed with antibody receptors. The resulting antibody 
receptor attachment to the FDPs could be quantified to show the rate at which fibrin is degrading 
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within the cream. The team does want to note that such an approach with antibodies would be 
costly.  
8.1.1d Surface Adhesion using AFM 
With the results of the surface topography images done on the fibrin particles with AFM, 
the team wants to ultimately see the surface adhesion measurements that were originally sought 
after. Atomic Force Microscopy represents a unique dive into the properties of fibrin overall. 
Within the application of fibrin-based particles, there is definitely potential in tying adhesion 
properties with proving fibrin’s ability to stay on skin, and even exfoliate it. While it would take 
some considerable amount of effort to reach the level of proficiency with AFM required to 
perform such an experiment, the team places this recommendation with hope that it will be 
followed through. 
 
8.1.1e Diffusion 
 It is expected that with time, the core understandings of fibrin-based particles and their 
role in cosmetics skin cream can become prominent enough for there to be testing done that is 
equivalent to industry standards. Among those industry standards in testing is diffusion through a 
quality Franz Diffusion Chamber. Although such an experiment is costly, the team recommends 
performing a diffusion assay with the proper equipment and materials, as that would showcase 
fibrin’s capabilities of making a major impact in the skin cream industry.  
 Such an experiment would likely aim to show fibrin’s inability to pass through skin, but 
at the same time show that the actives previously trapped within the fibrin make their way 
through the skin sample. This would highlight the claims made by the team, that fibrin itself is 
acting solely as cosmetics agent that promptly carries actives to the skin in a controlled release 
manner. 
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8.1.1f Testing Fibrina on Human Subjects 
 All of the experiments and their future recommendations are likely to be excellent 
opportunities to showcase fibrin’s potential in skin care. However, the final hurdle for fibrin-
based particles is going to be actual testing on human subjects. This study is absolutely vital, 
according to nearly every dermatologist the team spoke with during the project’s customer 
discovery phase. A study such as this will prove to be difficult to conduct, given the intensive 
requirements of sample size, safety measures, a control over potential variable factors, and the 
overall time which the study would take. 
 Thankfully, a lot of the procedures on how to go about performing a study of this nature 
can be found in the book which was used by the team for background section on cosmetology. 
The focus of this study would primarily target the comparison between fibrin-based skin cream 
and a control group. The team recommends having the control group be applied to one of the 
subject’s arm, and the fibrin-based cream on the other, for each of the subjects. This would 
provide an ideal side-by-side comparison. The book provides testing procedures that can be used 
to quantify the deliverance of actives into the skin on a living subject. The most notable of these 
testing procedures is Raman Spectroscopy.  
 
8.1.1g Moving Forward with Fibrina 
 Looking at Fibrina as a future business, there are several action items which the team 
suggests be accomplished first. These actions are to gather more experimental data, find a key 
partner, learn more about Fibrina’s supplier and the supplier network, and finally raise capital 
through finding funds. 
1: Identifying Key Partners 
 It would take years for Fibrina to develop its own competitive line of skin cream. 
Everything from the manufacturing process to the lack of brand reputation becomes a barrier to 
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entry within the market. Rather than work through these barriers to entry, the team suggests 
finding a key partner, an up and coming skin cream company that would be interested in 
introducing additive infused fibrin-based particles into their existing products. This partnership 
benefits both parties very well. For Fibrina, the benefits of selling through an existing brand with 
a positive reputation helps get Fibrina out into the market much more quickly. For the partnering 
company, Fibrina presents itself as a new ingredient that can be mixed into existing products, 
and new products. The marketing potential with Fibrina is quite substantial. 
2: Understanding partner network 
 As of right now, fibrinogen and thrombin solutions are purchased through MP 
Biomedical. MP Biomedical produces their fibrinogen and thrombin solutions through blood 
collection from a closed herd that exists in New Zealand. Should Fibrina grow over time, their 
demand for fibrinogen and thrombin will likely grow. With that, close relationships with MP 
Biomedical will help ensure that supplier connection. Other supplier network possibilities should 
be explored as well to prevent issues resulting in a lack of supplier competition. 
3: Finding Funds 
 As a startup, Fibrina needs to find funds. There exists a number of opportunities within 
the area. These opportunities range from pitch competitions to local accelerator programs. The 
team was recommended to look into the I-Corp Program. The WPI accelerator program which 
the team participated in B term of 2016 was considered to be the miniature version of the I-Corp 
Program. Ultimately capital raising may end up coming from investors, which again would be 
found through programs, competitions, and overall networking. 
8.2.2 Machine Recommendations 
Based on the prototype of the final design, the team identified areas in which the machine 
must be further tested and adjusted. One aspect that will need to be tested is the extrusion rate of 
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the thread on a moving conveyor. Since the conveyor will be moving at an incremental speed, 
the rate of extrusion of the thread, and the location of extrusion may need to account for the 
movement of the conveyor to ensure threads are drawn completely linearly. The importance of 
drawing the threads completely linearly is to allow for the maximum amount of threads to fit on 
the conveyor. The clamping system was a big part in allowing for linear extrusion. Figures 48 
and 49 below show the prototype version of one clamp in an open and closed position. In order 
to maximize thread production, the surface of the clamps on the machine will need to be changed 
in future alterations and models of the machine.  
 
Figure 48: Clamp made through rapid prototyping in the open position 
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Figure 49: Clamp made through rapid prototyping in the closed position 
  
In order to maximize mass production of the threads, the clamps will need to hold 
multiple threads. Since only so many chain plates can fit within the length of the device 
(assuming we continue to have the device fit on a lab bench), the surface of the clamps will need 
to be maximized. It should be tested if the bottom surface of the first part of the clamps will be 
able to hold up to three threads when clamped. Further, a means will need to be developed to 
force the magnets toward and away from one another. A servo may be stationed in the device at 
a certain point in the HEPES tub to close the clamps before the threads are lifted out of the tub 
toward the stretching plate. Finally, the material of the clamps will need to be tested. The ABS 
plastic is a fragile material to drill and pin the parts together. The material selected will need to 
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be strong enough to not have the clamps break during assembly and offer a reliable material for 
threads to be extruded on. 
Figure 50: Stretching platform prototype made of birch plywood 
 
Future considerations for the stretching plate (Figure 50) will be to replace the wood with 
a material that will be both durable and smooth. Additionally, the concept of the stretching plate 
will need to be tested to ensure that threads are spread apart at an incremental rate that avoids 
breaking. Further, the current design leads the chain back to a sprocket mounted on the frame of 
the machine. As the threads dry, the threads are placed closer together to the original length. 
However, if the threads are too brittle after drying, there is a risk of the threads breaking instead 
of hanging. The design may need to be adjusted to allow the threads to stay at their stretched 
length throughout the remainder of the device. The final Sprockets at the end of the chain cycle 
near the head of the tub should also be replaced with larger sprockets, so the magnets from the 
clamps do not attract each other, breaking the automated cycle. 
 Finally, the means for collecting the threads after they are dried will need to be tested. 
The current options are to either cut the threads from the clamps, or open the clamps and allow 
them to fall into a collection bin or a grinder. We will need to test how the threads will fall, and 
need to make sure that threads do not adhere to the surface of the clamps in a way to prevent the 
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threads from falling. Additionally, options on how to automate grinding the threads would be a 
good addition to the machine. 
8.2.3 Recommendations for the Conversion of Fibrin Microthreads 
 To allow for better conversion of the fibrin particles, the team recommends to automate 
the conversion mechanism, while addressing the issues in relation to static cling of the fibrin 
microthreads to surface of the funnel before conversion via the automated dual action trimming 
blades. The team also recommends to add the fibrin microthread conversion process and 
mechanism to the automated machine, so there is continuous production of fibrin for its 
application in a skin cream. 
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Appendices 
Appendix I: Additive-Infused/Regular Fibrin Microthread Protocol 
How to Make Threads 
Materials: 
• Baking Pan 
• Syringe pump 
• 1 aliquot fibrinogen - 70mg/ml  
• 1 aliquot thrombin – 8U/200µl 
• 10mM HEPES solution 
• 2 - 1mL syringes 
• 1 – 3ml syringe 
• 1000mL graduated cylinder 
• Clear cup of room temperature water 
• 40mM CaCl2 
• 1000µl Micropipetter  
• 2 sets of forceps  
• Cardboard drying box 
• Kimwipes 
• Extruding tube 
• Blending connector 
• Polyethylene Tubing 
Preparation: 
1.     Rinse graduated cylinder with DI water 
2.     Fill Graduated cylinder with ~350mL of 10mM HEPES solution. Transfer HEPES into 
silver baking pan 
3.     Obtain 1 aliquot of Fibrinogen and 1 aliquot of Thrombin from -30C freezer 
4.     Obtain 40mM CaCl2 from fridge. 
5.     Defrost frozen aliquots by placing them into room temperature water 
6.     Once completely defrosted, add 850µL of 40mM CaCl2 into the thrombin, mix thoroughly 
7.     Label two 1ml syringes, one as T and one as F 
8.     For a 5% special thread solution: 
a.     Transfer 950ul of Thrombin and Fibrinogen into new microcentrifuge tubes 
b.     Add 50ul of additive solution (ECM, retinol etc.) into microcentrifuge tube 
(Total V=1000 ul) and mix thoroughly 
Percentage Volume of 
Thrombin 
Volume of 
Fibrinogen 
Volume of ECM in 
T and F 
5% 950 ul 950 ul 50 ul 
10% 900 ul 900 ul 100 ul 
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15% 850 ul 850 ul 150 ul 
20% 800 ul 800 ul 200 ul 
  
9.     Using 20 G syringe appropriate withdraw thrombin and fibrinogen into separate labeled 
syringes  
10.  Remove all air bubbles from syringe 
11.  Balance the two syringes so that they contain the same volume of solution 
 
Setting up Machine: 
1.     Plug in syringe pump and turn the power on (Power switch is in the back of the machine) 
2.     Make sure DIAMETER is set to 4.699mm and the RATE is set to 0.23 mL/min. 
3.     Plug the Fibrinogen and Thrombin syringes into the blending connector. The Fibrinogen 
syringe should ALWAYS be placed into the side with the small circle 
 
4. Place syringes into syringe pump. 
• Lift black knob and slide the ends of the syringes under black bar, splitting the two 
syringes with the knob. Make sure syringe body flanges are inserted in to clamp. Release 
black knob. 
• Tighten syringe clamp using the silver nuts. 
 
 
5.     Make syringe pump block flush with the syringe connector 
• Push down black button and pinch white piece   
6.     Attach polyethylene tubing to the free side of the blending connector 
 
Making Threads: 
1.     Press start on the machine. 
2.     Wait for ALL the air bubbles to pass through the PE tubing. Use a Kimwipe to collect 
anything that comes out while air bubbles are passing through. 
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3.     Once there is a constant flow, start making the threads.  
 
Hold extruding tube ≈ 4 inches from the end. Drag end of tube horizontally along the bottom 
of the silver pan filled with 10mM HEPES. Move the tube from the left side of the pan to 
right side at a constant rate. At the end of one thread move quickly bring the end of the tube 
back to the left side of the pan, move ≈ 1 inch down and begin a new thread. Repeat until you 
cannot make anymore. *Make sure the end of the tube is clean and free of fibrin debris, wipe 
clean if needed  
 
4.     Do Not Overlap Threads! 
5.     Turn off machine once you are done. 
 
Clean Up Part 1: 
1.     Immediately clean tube. Fill a 3ml syringes with water and flush extruding tube with water. 
Remove syringe from extruding tube, withdraw syringe with just air and blow air through 
extruding tube with syringe. Repeat with white co-extruder. 
2.     Throw away any used materials into the proper trash receptacle. 
 
Transferring Threads: 
1.     Use the two sets of forceps to take the threads out of the pan.  
• Grab each end of the thread with the forceps 
• Move right hand counterclockwise and left hand clockwise so you can pick up the thread. 
• Make sure not to pull too fast and to keep threads in the HEPES as long as possible. 
 
2.     Transfer the threads to the cardboard box. Secure one side to the box and stretch the thread. 
Secure the middle of the stretched out thread to the box. Cut the thread in half then stretch 
the remaining half over the box. One extruded thread should produce two threads.  
3.     Repeat this for all threads. Leave threads out to dry overnight. 
 
Clean Up Part 2: 
1.     Pour HEPES down the drain and rinse off pan. Dry the pan with paper towel. 
2.     Put all items away. 
3.     Dispose of any other used items in the appropriate receptacle.  
 
 
166 
 
Appendix II: Fibrina Interview Insights and Takeaways 
Table 30: First Dermatologist Interview Insights and Takeaways 
Major Questions/Insights Team Takeaways 
Many “Buzzword” ingredients 
labelled at the front of a product are 
typically just a minute percentage of 
the product itself (e.g. Glycolic Acid) 
Fibrin may likely be a very small percentage of our 
actual product, so what is the rest of our product going 
to be of? Also, if we are mixing ingredients with 
fibrin, what percentage of those ingredients will 
consist of our final product? Is that percentage 
effective in doing anything? 
Is our product cosmetically elegant? 
• Is it appealing to buyers 
aesthetically? 
• Does the product feel good 
Consumers won’t buy our product if it doesn’t feel 
good to them or look appealing. There are ingredients 
we can use which aid in both of those aspects, and 
they should be incorporated. 
The market is strict because of 
people’s personal preferences (e.g. 
some people like Vaseline because it 
is thick while others don’t.) 
Whomever we are appealing to, we can’t please 
everyone, unless we make different renditions of the 
same cream. Is that worthwhile? Maybe, maybe not.  
Are your ingredients safe? Is fibrin safe? We need to test for that. How do we go 
about doing that? Is sterilization enough? 
Be cautious about the claims you 
make on a product 
This is where the gray area where cosmetic meets 
pharmaceutical. Should our claims be pharmaceutical 
in nature, the FDA will want to ensure safety before 
commercialization (which means we can’t sell 
tomorrow). What do want to claim about our product? 
Cosmetics Companies (Branding and 
Marketing) 
• Choose consumer group and 
feed into their needs 
• Smart marketing ploys (feed 
into the masses demands) 
• Consumer Reports 
(price/ounce, minimize 
moisture loss, etc.) 
• Packaging of the product 
(ironically this can be more 
expensive than the actual 
product sometimes) 
 
Marketing is invaluable, especially in the retail end of 
the cosmetics world. Do we have to think of product 
packaging and cost right now? Perhaps not, but it 
would come up eventually.  
 
Who is our consumer group? What needs are we 
addressing for them? 
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Table 31: Second Dermatologist Interview Insights and Takeaways 
Major Questions/Insights/Comments Team Takeaways 
There are a lot of products out on the 
market. Few make money. 
This is in part the nature of marketing as well as 
the point that a good product speaks for itself by 
addressing the needs of its consumers. If 
consumers can address their needs by using a 
product, then that product will sell. 
In truth, some products work, and some 
don’t. 
There are a ton of products out there. Again, 
new products come out every month, claiming 
to be the next big. The hoax products actually 
make it more difficult to legitimize  
Sell without regulations The team took this as “don’t claim anything”. 
We were not exactly sure what this meant and 
want to follow up on it later. 
Don’t claim structural evidence. This is again what was mentioned from the first 
interview. However, this comment related more 
towards the idea of “don’t claim anything that 
the FDA will want data for”. 
Cosmeceutical: Relatively lax regulations - 
You don’t even need to show that a product 
works, only that it doesn’t have any toxic 
agents. 
FDA guidelines on cosmetics products only 
address regulation of products. This is 
something the team understood through research 
on the FDA. However, the extent at which  
Hyaluronic acid and glycolic acid are 
commonly used ingredients, because they 
work! Glycolic acid can be difficult to 
blend in emulsions. 
Our original expectation was to use these 
ingredients in our formulation. Our research on 
these ingredients already show the positive use 
of HA and Glycolic. There will definitely be 
more research needed into the challenge of 
creating formulations with all these ingredients. 
Cosmetics Companies bring marketing 
material: they don’t do science. 
Again, marketing is huge, but those who are in 
charge of marketing rely on the scientists to 
make product and explain the novelty to some 
degree. 
Look carefully at some of the claims you 
see on products. You’ll never read “Makes 
wrinkles go away” or “makes skin 
younger”. 
This goes back to the FDA claim gray area. Be 
careful with claims, but also be smart about 
claims. The right claims say nothing, but also 
play a beneficial role in marketing. 
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Retinol is another ingredient that works 
well, but there are side effects. Different 
products sell retinol in different forms and 
different percentages.  
Retinol as we’ve seen it is the last big discovery 
in the skin cream world. There are tons of 
variations, and each have unique advantages and 
disadvantages. Finding the right type for our 
product will likely take some research and trial 
& error. 
There’s a surprising number of products 
that don’t go through any form of rigorous 
testing. 
This goes back to the lack of regulations on 
products. A company can produce a cream and 
sell it the next day without putting any heavy 
time or resource into proving its safety or 
effectiveness. This may be what leads to 
products that don’t work, as well as products 
that aren’t necessarily safe. 
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Table 32: Cosmetic/Plastic Surgeon Interview Insights and Takeaways 
 
Major Questions/Insights/Comments Team Takeaways 
“I’m not a big believer in things that are 
out there”. Not much data to support 
topical creams 
In the professional realm, especially for 
surgeons, evidence of a cream being beneficial 
is vital. 
For scarring, we’ve got topical silicone 
tapes. 
There are other forms of competition to 
consider, such as medical products which 
currently exist to solve the same needs we are 
trying to address. Depending on our niche, it 
should be important to determine all possible 
competitors, including those outside of 
cosmetics. 
Ideally, I’d like a skin cream that could 
increase the rate of healing, and reduce 
the rate of scarring. 
While it wasn’t recommended to us to ask, 
“what would be the most ideal thing for you to 
have?”, mainly because the response we’d get 
would be something typically not practical, this 
response did show us insight that there isn’t any 
product out there that really shines in the wound 
healing department, or in scar prevention. Are 
the two problems one in the same? 
Think about what our product is beneficial 
for. Is it wound healing, or scarring? 
Not to be seen as an either/or. Same question 
was asked by dermatologists. Finding our 
product niche is very important. It helps to 
determine our consumer base, and also helps 
define the experiments needed to prove 
efficacy. 
Moisturizers - good for skin. Look at 
Lucederm™   (skin brightening cream) 
We’d already been looking into moisturizers 
because of their usefulness 
Look into Tretinoin, and TNS essential 
serum (collagen and elastin selling point) 
Good leads for products to research and 
determine/compare benefits and examine 
literature. 
Look into active serum by IS Clinical 
• Popular product that people seek 
out 
• Gentle exfoliant, brightens skin, 
reduces pore size 
This was marked as a sought-after product, as in 
consumers would readily ask for it. Might be 
useful to understand why. 
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Table 33: Cosmetic Marketing and Branding Interview Insights and Takeaways 
Major Questions/Insights/Comments Team Takeaways 
Key considerations of product marketing: 
• Target Audience 
• Distribution Strategy 
• Selling Proposition 
See below notes for breakdown of each key 
consideration takeaways. 
Target Audience: 
• Know who they are 
• Learn how they shop (online, stores, 
etc.) figure out their habits 
Much like researching the product, one has to 
research the consumer. Learning about 
shopping habits is critical, as placing product in 
line of where the target audience shops is key 
to getting them to buy 
Distribution Strategy 
• Where do you market the product? 
• Make it easy for audience to access 
This ties in with the last takeaway. Knowing 
where to distribute to is based on where your 
shoppers are. Making it easy for shoppers to 
buy is the next big task. The more seamless, the 
better the experience for new consumers. 
Selling Proposition: 
• What does our product address?  
• How does it address the people’s 
needs? 
• Fills a need that isn’t already met 
(optional) 
• Path of least resistance 
• Best product with most 
understandable story, succinct  
 
 
Selling Prop = Value Prop 
• Our product addresses wound 
healing/scarring (as we claim right now) 
• Unmet need? Novel + quality product 
for this type of problem 
The path of least resistance asks us “what’s the 
easiest way to get this product out the door”. 
We don’t know the answer to this yet. 
Fibrin needs a story that authenticates its 
approach into skin cream. 
Online Consumers 
• Surveys for online audience 
• ID demographic, age group, location 
in the country 
• Offer incentive to answer survey 
Online shopping is huge, but you can’t 
interview online shoppers, or can you? 
Surveymonkey is big. We can collect a lot of 
useful data from online surveying, and use that 
toward defining our target audience, our best 
means of distribution, and our selling prop 
Most people shop online nowadays, or they 
go to a brick and mortar store 
When shoppers are in need of something in a 
pinch, they’ll go to a store. Else they shop 
online. 
Find out what makes people shop online Again, online surveys. Also think like an online 
shopper: Doesn’t have to go to a store, can 
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research products they find via the internet, 
from the comfort of their desks. 
Good Product Branding: 
• A good brand stands throughout time 
• Broad enough appeal 
• Legit claims 
• Authentic story being told 
• Specific to skincare: backup those 
claims with evidence 
What’s a good brand for Fibrin-based skin 
cream? How can we craft our brand to be 
broadly appealing? Our claims will likely 
surround the use of fibrin; what are those 
claims? Again, back to that authentic story. 
What’s the story for fibrin? Finally, scientific 
evidence is a must. Repeat of dermatologists, 
and surgeons.  
Competing with other products 
• Don’t look at it as a competition 
• What are you doing different/ better? 
• What are you addressing? Is it 
different from what is currently 
being addressed? 
• Would this change people’s habits?  
 
 
How do we separate from our competitor’s 
products? Our address should be unique. 
Would the use of our product change the habits 
of our consumers in our benefit? 
Word of mouth - slow 
• Marketing campaign to incentivize 
this  
• Word of mouth starts with a small 
group of people 
• Small, independent brands have 
done well (Tri dynamics (San Fran) - 
look at marketing campaign) 
• Why do consumers buy a product? - 
usually word of mouth, based on 
friends/ family opinions 
While word of mouth is slow, it is also 
extremely effective. A major advertisement has 
far less effect than a personal friend or family 
member offering their own opinion. Our 
interviewer gave us examples of small 
independent brands to research. This may be 
great for getting started up. 
How does marketing work? 
• Not as hard to get clearance like a 
medical device company would 
• Look at competitive market 
• How are they marketing their 
products? 
• Sales 
• What’s our value 
proposition? 
Back to the regulations, where anything could 
be theoretically sold tomorrow. However, this 
theory did not originally take into marketing 
and means of selling. Once again, value 
proposition becomes very important. 
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• Go into stores - Sephora, Lord and 
Taylor, CVS/Walgreens → Ask 
what products sell the best, what 
kind of questions do they ask, what 
is your selling propositions  
• Research into 
salesmen/women - real world 
data on what customers are 
thinking 
• Department stores: Specific 
lines salesmen 
• CVS/Walgreens (also target) 
- array of products 
Interactions with salespeople and the everyday 
consumer is essential. The Accelerate Program 
itself pushed the “Get out of the building” 
mentality from the first class.  
 
High-end stores will sell and attract a different 
group of consumers than a low end (compare 
Sephora to CVS). While the differences may 
appear non-correlating, the truth is our product 
could potentially sell in one place, the other, or 
both. 
• How do you make money on a 
product? What should the structure 
of an SKU look like? 
• Distribution (based on where 
it’s being sold)  
• How much money do 
i have to spend on 
product and 
marketing? 
• What percentage flow 
to bottom line? 
There’s a complex mathematical equation that 
needs to be followed in order to answer the 
“how do we make money out of this?” 
question. However, one way of simplifying that 
question is to ignore the cost details of making 
the product and just envision the cost it would 
take to market and distribute first. Compare that 
to the general cost of making a product and 
figure out how much you would need to mark 
up to make money for yourself while paying 
everyone else along the way. 
 
Table 34: Low-End Store Interview Insights and Takeaways 
Interviews/Notes on Product Placement, Price, 
and/or Ingredients 
Major Takeaways 
Interview, Walgreens: Regular online shopper 
looking for all-natural face cream. All-natural 
component was most important to her. Price 
wasn’t a major factor. Normally shops online 
(bridgebox.com) but was in need of something 
immediately. 
This shopper normally purchases her 
products online, but that day she had run out 
of supplies and had to go on an 
“emergency” run. Out of the entire aisle of 
skincare products, she had spent at ten 
minutes looking at only a few of the 
products. She took careful note of the 
ingredients each time. This was a highly 
valuable interaction to observe and ask 
about. 
Product Placement, Walgreens: single aisle 
dedicated to skincare products. Depending on 
the product being sold, some product packaging 
The eye-appealing packages appeared to be 
the ones that were selling most. In the sea of 
skincare products out there, many had eerily 
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was more eye-catching, if not on part of the 
aisle that catches a lot of consumer attention. 
similar packaging color schemes. The 
product brands were taken note of to see if 
they could be found elsewhere on the 
shelves in other stores. 
Discussion, Store Manager, Walgreens: The 
store manager offered to help me make a 
purchase on a product. I explained my intent for 
being there and she offered some consumer 
insight. She said that most consumers don’t 
purchase skincare products at Walgreens. 
People more often buy these products a health 
food stores (e.g. Wegmans). 
This was an interesting comment from the 
store manager, considering the amount of 
products I saw on the shelves right next to 
me. It may be worthwhile in the future to 
check out places like Wegmans and scope 
out buyer habits. 
CVS interview: An older woman (60s) 
purchased a moisturizer from the small skincare 
section in the store. Upon asking her how she 
made her decision, she lifted up the product and 
read the “special ingredient” center labelled on 
the front. She laughed, admitting she has no 
idea what the ingredient really is. She wanted to 
moisturize the wrinkles on her face. 
Inexpensive, decent ingredients was what she 
claimed to be looking for. 
While there wasn’t much to choose from in 
the CVS, this woman made her purchase 
based on a label for an ingredient she knew 
nothing about. In truth, she may have just 
picked up the product and “this’ll do just 
fine”. Either way, this says a lot about 
consumer behavior. Hopeful to see this habit 
again. 
Product Placement, Rite Aid: As there was no 
one in this section as I visited, I took careful 
note of all the products on the shelves. Many of 
the product brands seen in other stores were 
also found at Rite Aid. For many of them, their 
product placements were the same. 
The fact that the products were found in the 
same or similar shelf spaces as in other 
stores tells us the amount of money some 
brands are paying to be at eye-level to the 
consumer. Hard to tell from the few visits 
made if this extra money for eye-level 
placement is working, but there is literature 
out there that backs this. 
Product Placement, Price, Shaw’s: Everything 
here was a little bit more expensive. There were 
also more options available in terms of product 
brands. Special note on some of the packaging: 
the more vibrant-color packaging, the more 
recognizable the brand (and also the more 
expensive) 
Shaw’s, like Rite Aid, had no foot traffic 
during my visit. Some of the new product 
brands that showed up, I had never seen 
before. The retail market appears to be 
packed with products, but at the end of the 
day it seems that marketing and packaging 
are playing a much larger role than the 
products themselves. 
Double Interview, CVS: Two Spanish women 
had coupons for higher-end products. When 
The appeal for higher-end products in what 
could be described as a low-end store was 
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asked if they regular buy the more normal 
products, they said no. 
met by discounts to purchase the products. 
For these women, cost was important, but so 
was the perceived quality of the product. 
Why settle for what seems inferior when 
you can match the price with coupons? In 
the end, who really wins? 
 
Table 35: Wholesale Manufacturer and Distributor Interview Insights and Takeaways 
Major Questions/Insights/Comments Team Takeaways 
Pain points with drug products: 
• Regulator environment is severe in 
terms of drug products 
• Less severe with products that 
don’t make a drug claim 
If a product has drug-like properties, and the 
producer of said product makes claims based on 
those properties, then regulation is guaranteed to 
be there. However, if no drug claim is made, then 
regulations aren’t as severe. Does this mean we 
can avoid making drug claims but still market a 
product with drug-like properties? 
Don’t market under therapeutic effect, 
pathologic indicator (cure disease) 
e.g. remove inflammation/redness Vs. 
Improve the way the skin looks and feels 
(marketing is important)  
Again going back to the above takeaway. Note 
the difference: One claim could be to remove 
inflammation/redness (which would incline that 
physical properties of the skin are being altered 
by direct means). On the other side, improving 
the way the skin looks and feels can address the 
same issue of inflammation and redness, but 
without directly targeting it. 
• Some Cosmetic ingredients are 
drugs, but marketed as a non-drug 
• Note: Claims are important in 
successfully marketing a cosmetic 
product as a nondrug 
Arguably the largest surprise for the team. Drug 
products are being marketed as non-drug. What 
does this mean with respect to fibrin-based skin 
cream? How are we going to base our claims? 
Marketing: 
• Fundamental questions: If there 
were no boundaries, what claims 
would i be able to make? 
 
The team had no idea how to answer this at the 
time. 
You can communicate information about 
the drug effects of the product as long as it 
is not communicated to the general public 
Provide data from established journals to 
professionals to back up our claims 
A prominent clarification point: as producers, we 
are able to express the benefits of a drug product 
so long as we do not relay that information out to 
the open public. How do we tell people without 
telling people? The answer: doctors 
(dermatologists/surgeons) 
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Prescription drug products and 
cosmetic products marketed to 
professionals, while cosmetic 
products only marketed to 
consumers 
To a professional, we are able to market a 
product as a drug product and as cosmetic. For 
consumers, only cosmetic. But, both the drug 
product, and the cosmetic, can be the exact same 
thing.  
Decision making process behind choosing 
ingredients: 
• Varies between professional and 
retail market 
• Evidence is more important 
for professional market 
• In order to create separation 
between 2 markets: 
credentialing the products 
for professional is more 
important than retail 
So it is possible to create a professional and 
cosmetic based product that are nearly identical. 
The professional product will likely be under a 
lot of scrutiny for its effectiveness and the 
science which backs that up. Keeping that in 
mind with the types of ingredients to choose in 
either case is vital for a lot of factors: cost, ease 
of production, scientific backing required, and so 
on. 
• Consumer: All about 
novelty, price conscious 
• Cost of materials/ 
drugs 
Points of differentiation 
Features/benefits 
• Evidence of how 
the product works 
Our big approach with fibrin is novelty. Price is 
something the team has not heavily considered as 
of yet. Price is also associated with a number of 
costs. Said costs include manufacturing, materials 
cost, and of course time and resource to validate 
efficacy.  
• Competitive Landscape 
• Research required to know 
competition/ what they are 
selling 
• Cost of entry into market 
and cost of competitors 
While it is great that our team is pursuing a novel 
product, we have to do our homework and see 
what the current competition is. 
Cell Culture Evidence: 
• Based on what we consider the 
features and benefits of our 
product 
• Approaches based on our claim, 
lead to substantiation of the final 
product 
• Simple studies and Clinical studies 
• Compare with competitor 
product: amount of people 
to enter clinical study to 
The science has to specifically back up the claims 
being made. Our team’s experiments need to 
follow along with our claims, which then have to 
compare against claims of a competitor. The 
experiments also have to compare against the 
science being used by the competitor. In any 
clinical study, population size is critical. As 
mentioned from one of the dermatologist 
interviews, some doctors won’t even look at a 
study if its population size isn’t above a certain 
number. 
176 
 
show effectiveness of the 
products 
• Go to individuals who do a lot of 
research with our type of products 
• Dermatologists 
• Can help define 
what are the best 
parameters to look 
at during our course 
of study 
 
Reaching out to researchers and dermatologists 
who current with the experimental processes of 
testing products should be contacted. 
• What is the market place looking 
for right now? 
• Different answers 
depending on the 
consumers/ professionals 
Based on our value proposition research, we 
believe the market is hungry for something new. 
That could mean anything, but it is a good start 
nonetheless. 
What is professional market looking for 
when it comes to aesthetic products? What 
would you like to have? What is missing? 
 
• Cosmetic product business: 
Different biological pathways to 
producing beneficial effect on the 
skin, ways to present anti-aging 
effects on the skin 
There is a lot of push to finding the most 
effective ways of delivering actives into the skin 
which cause desirable effects. The many 
difficulties have been discussed in the 
background section of this report. It is good to 
know that our approach with fibrin is one that is 
sought after in the industry. 
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Appendix III: Protocols for Fibrina Experiments 
Appendix IIIa Protocol for Composition Experiment 
Materials: 
1 small whisk 
16 oz. wide mouth jar, or recycled bottle/container (sterilized) [Glass Preferred] 
½ cup Grape Seed Oil 
 ¼ cup Emulsifying Wax 
 ¾ cup Water 
1 tbsp Glycerin 
¼ tsp Vitamin E 
12-15 drops Essential Oil 
 1/8 tsp Germall Plus 
For a 50% Water-Based Cream: 
Ingredient Non-SI units SI (in mls) % to total 
Grape Seed Oil ½ cup 118.294 31.5 
Emulsifying Wax ¼ cup 59.147 15.75 
Water ¾ cup 177.441 47.25 
Glycerin 1 tbsp 17.7582 4.73 
Vitamin E ¼ tsp 1.4798475 0.39 
Essential Oil 12-15 drops 0.7 0.19 
Germall Plus 1/8 tsp 0.73992375 0.2 
Note: Adjust water content as needed to create more/less viscous cream. 
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Procedure: 
1. In a small container such as a stainless steel measuring cup, combine emulsifying wax 
and grape seed oil.  
2. Heat the emulsifying wax and grape seed oil over a pan of simmering water till the wax 
melts and stir till ingredients are thoroughly combined.  
3. In the same pot of simmering water, but in a separate container warm the water so the oil 
and water reach approximately the same temperature. 
4. Slowly drip the oil mix into the hot water while blending with the stick blender till the oil 
and water are thoroughly emulsified.  
5. After it cools down to 120°F, blend in the optional additives. 
6. Pour into container(s) before the moisturizer gets a chance to thicken. 
 
Recommendations: 
The team recommends a 60% water-based skin cream. A 60% water-based cream provides ideal 
properties for testing. A 50% water-based cream proves to be too viscous, and any % above 60% 
appears to have issues with maintaining non-separation between water and oil phases. 
 
Appendix IIIb Protocol for Exploratory Degradation Experiment: 
Materials: 
• Fibrin powder (Grind fibrin threads into particles the size of grains using scissors other 
grinding method) 
• PBS Solution (Or any other neutral buffer) 
• Petri dishes 
• Protease (Bromelain, Serrapeptase, Nattokinase) 
• Microscope 
 
Procedure: 
1. Take 5 mls of PBS solution into each of the petri dishes to be used for the experiment 
2. Place 1, 2.5, 5, and 10 mgs of protease into separate petri dishes.  
3. Place the petri dishes onto an orbital shaker; else use a magnetic stirrer to continuously 
mix the solution. 
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4. Take images of the solutions every other hour beginning at the first hour (1,3,5,7, etc.). 
Images should be taken with a microscope using imaging software.  
5. Record any observations throughout the time periods. Take special note of the visible 
fibrin threads both through the microscope images and with the naked eye. 
Special Notes: Using too little protease will prevent the degradation reaction from continuing 
over time. Observations showing little to no change in degradation between time periods is 
normal/expected with the lower quantities of protease (1, 2.5 mg). 
Appendix IIIc Protocol for UV Spectroscopy Degradation Analysis Experiment 
Experiment Objective: 
 To quantify the rate of retinol-additive being release through the degradation of fibrin-
based particles via the use of protease. 
 
Materials: 
100mg – 100ul Retinol-infused fibrin-based particles 
20 - 60x15mm tissue culture dishes 
100ml – PBS solution 
200mg – protease in lyophilized powder form (bromelain, nattokinase, serrapeptase, plasmin, 
lumbrokinase) 
SpectraMax 250 UV Spectroscopy Plate Reader 
24-Well Plate 
96-Well Plate 
 
Procedure: 
1. Prepare 100mg of retinol-infused fibrin threads using the protocol for producing additive-
infused fibrin threads. 
2. Grind, pulverize, or chop threads into particles (grains). The particles can be anywhere 
from 500um to up to 2mm in length. Smaller particles preferred. Experimental set-up is 
shown in Figure 51 below. 
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Figure 51: Cutting of Threads into particles using small scissors. Threads cut onto weigh plate for measuring 
 
3. Add 5mg of the retinol-infused fibrin-based particles into each of the 20 tissue culture 
plates. Ensure as much of the fibrin particles are sitting in solution and not statically 
clung to the walls of the plate. 
4. Add 5ml PBS solution to each of the plates. Use a 1000ul Micropipetter to spray 
statically clung particles down to the bottom of the plate and into solution. Experimental 
set-up is shown in Figure 52 below. 
Figure 52: Tissue Culture Dishes all prepped with 5mg fibrin particles and 5ml PBS. On the Right: 
Eppendorf Tubes prepped with varying amounts of protease 
 
5. Introduce 6,7,8,9, and 10 mg of the chosen protease to 4 of the tissue culture plates.  
6. At 1,3,5, and 7 hours, take a 500ml sample of one of each of the 6,7,8,9 and 10 mg 
protease plates. Take images of the plates from which each of the samples just before 
prior to taking the sample.  
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7. Place the 500ml samples in the 24 well plate. Rake a clear sample from each plate; be 
careful not to take up any of the protease powder grains, nor any degrading fibrin 
particles. 
8. Take 3 100ul samples of each of the 500ml samples onto the 96 well plate.  
9. Create a standards group consisting of 1,3,5,10,20, and 30 ul of 25ug/ml retinol in 
ethanol solution within the 96-well plate.  
10. Create a control group consisting of PBS solution. 
11. Run the SpectraMax 250 UV Spectroscopy plate reader at a wavelength of 325nm. 
12. Record results on an excel sheet and observe the recorded quantities read by the plate 
reader for patterns. Experimental results are shown in Figure 53 below. 
Figure 53: Plate Reader Setup. 6,7,8,9 and mg protease degradation measured over 1,3,5, and 7 hours. Actual 
Standards used: 1,3,5,10,20 and 30 ul retinol in ethanol. Control group was PBS only 
 
Note: Fibrin-based Particles experience static cling and thus are difficult to transport from one 
container to another. When cutting/grinding threads into particles, be sure that the particles are 
being cut/ground into their final container of use if possible.  
 
Below in Tables 36 and 37 is experimental data for the standard curve and data for 
different concentrations of Bromelain at different concentrations over hours 1, 3, 5, and 7. 
 
Table 36: SpectraMax 250 Data Values for UV Spec. Analysis Experiment 
Bromelain 6 mg 7 mg 8 mg 9 mg 10 mg Control 
1 hour 0.243 0.244 0.242 0.238 0.251 0.216 
 0.244 0.238 0.243 0.245 0.265 0.222 
 0.238 0.235 0.249 0.233 0.255 0.224 
Average 0.2417 0.239 0.2447 0.2387 0.257 0.2207 
3 hour 0.257 0.245 0.258 0.238 0.253 0.221 
 0.262 0.241 0.257 0.25 0.263 0.225 
 0.246 0.241 0.245 0.253 0.251 0.23 
Average 0.255 0.2423 0.2533 0.247 0.2557 0.2253 
5 hour 0.278 0.297 0.287 0.306 0.31  
 0.295 0.295 0.288 0.306 0.307  
 0.299 0.283 0.283 0.756 0.289  
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Average 0.2907 0.2917 0.286 0.456 0.302  
7 hour 0.3 0.295 0.312 0.308 0.328  
 0.298 0.292 0.301 0.309 0.324  
 0.288 0.268 0.292 0.302 0.327  
Average 0.2953 0.285 0.3017 0.3063 0.3263  
 
Table 37: Standard Curve Values for Retinol in Ethanol Solutions within PBS Solution 
Standard 
Curve:    Avg. 
1 0.295 0.289 0.284 0.2893 
3 0.394 0.403 0.402 0.3997 
5 0.515 0.512 0.508 0.5117 
10 0.898 0.923 0.908 0.9097 
20 1.575 1.635 1.634 1.6147 
30 2.067 2.134 2.113 2.1047 
 
Appendix IV: Data and Results from Fibrina Experiments 
Appendix IVa: Fibrin Exploratory Experiment Images 
No PBS hour 0 
Results displayed in Figures 54 to 58. 
General Notes: Without PBS as a medium, bromelain powder is inactive to the fibrin particles.  
Figure 54: Fibrin Control Hour 0, Pre-PBS 
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Figure 55: Fibrin 1mg Hour 0, Pre-PBS 
 
Figure 56: Fibrin 2.5mg Hour 0, Pre-PBS 
 
Figure 57: Fibrin 5mg Hour 0, No PBS 
184 
 
 
Figure 58: Fibrin 10mg Hour 0, No PBS 
PBS Hour 0 
Observations: With the introduction of PBS, the fibrin particles immediately begin to swell. No 
immediate notice of degradation among fibrin threads except from the 10mg dish, which works 
very fast towards complete fibrin degradation. Results are shown in Figures 59-63. 
 
Figure 59: Fibrin Control Hour 0 
 
Figure 60: Fibrin 1mg Hour 0 
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Figure 61: Fibrin 2.5mg Hour 0 
 
Figure 62: Fibrin 5mg Hour 0, PBS Added 
 
Figure 63: Fibrin 10mg Hour 0, PBS Added 
PBS Hour 1 
Observations: Fibrin particles are beginning to degrade across all plates, with the exception of 
the control. The 10mg dish showcases particles which are showing prominent signs of 
degradation. From the naked eye, it was noted that some of the smaller particles in each of the 
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plates has degraded. This occurrence was noticed much more prevalently when going up in 
concentration. Results are shown in Figure 64-68. 
 
Figure 64: Fibrin Control Hour 1 
 
Figure 65: Fibrin 1mg Hour 1 
 
Figure 66: Fibrin 2.5mg Hour 1 
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Figure 67: Fibrin 5 mg Hour 1 
 
Figure 68: Fibrin 10mg Hour 1 
PBS Hour 3 
Observations: The 10 mg dish has completely broken down all fibrin particles. The 5mg dish is 
almost complete as well. The 1mg dish appears to have shown little progress in particle 
degradation. Hard to determine where the 2.5mg dish is in terms of whether it is continuing to 
degrade or not. Within all of the non-control dishes, it is difficult to determine whether floating 
particles are smaller fibrin particulate or if they are particulate from the bromelain powder that is 
slowly solubilizing. Results are shown in Figures 69-73.  
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Figure 69: Fibrin Control Hour 3 
 
Figure 70: Fibrin 1mg Hour 3 
 
Figure 71: Fibrin 2.5mg Hour 3 
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Figure 72: Fibrin 5mg Hour 3 
 
Figure 73: Fibrin 10mg Hour 3 
PBS Hour 5 
Observations: Both the 5mg and 10mg dishes are now fully degraded. The 2.5 mg dish has made 
more progress but appears to be slowing down. The 1mg dish has made very little progress since 
hour 3. Results are shown in Figures 74-78. 
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Figure 74: Fibrin Control Hour 5 
 
Figure 75: Fibrin 1mg Hour 5 
 
Figure 76: Fibrin 2.5mg Hour 5 
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Figure 77: Fibrin 5mg Hour 5 
 
Figure 78: Fibrin 10mg Hour 5 
PBS Overnight Observations 
Observations: At this point, all of the dishes have sat for over 12 hours. The resulting images 
appear drastically different due to unforeseen evaporation of PBS. The control dish showcases 
fibrin particles that appear to be entrapped in a light film that is presumably PBS? Each of the 
other dishes lack this film-like appearance, but are significantly evaporated. Both the 1mg and 
2.5mg plates still show some fibrin particles. There is still nearly the same amount of particles in 
the 1mg plate as there was the night prior. The 2.5mg plate has also shown little change. Two 
images were taken to showcase different areas of the dish. In one area, a fibrin particle can still 
be seen, whereas in another there appears to be nothing more than mixed particulate that could 
be fibrin or bromelain.  The 5mg and 10mg plates have shown no change since the previous 
night. Results are shown in Figures 79-84. 
192 
 
 
Figure 79: Fibrin Control Overnight 
 
Figure 80: Fibrin 1mg Overnight 
 
Figure 81: Fibrin 2.5mg Overnight (Image 1) 
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Figure 82: Fibrin 2.5mg Overnight (Image 2) 
 
Figure 83: Fibrin 5mg Overnight 
 
Figure 84: Fibrin 10mg Overnight 
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Appendix IVb: UV Spectroscopy Data 
Table 38: Raw UV Spectroscopy data from UV spectroscopy experiment 
Bromelain 6 mg 7 mg 8 mg 9 mg 10 mg Control 
0 Hour 0.222 0.230 0.231 0.236 0.224 0.220  
0.232 0.232 0.233 0.240 0.225 0.223  
0.225 0.230 0.235 0.237 0.220 0.217 
Average 0.226 0.231 0.233 0.238 0.223 0.220 
1 hour 0.243 0.244 0.242 0.238 0.251 0.216  
0.244 0.238 0.243 0.245 0.265 0.222  
0.238 0.235 0.249 0.233 0.255 0.224 
Average 0.242 0.239 0.245 0.239 0.257 0.221 
3 hour 0.257 0.245 0.258 0.238 0.253 0.221  
0.262 0.241 0.257 0.250 0.263 0.225  
0.246 0.241 0.245 0.253 0.251 0.230 
Average 0.255 0.242 0.253 0.247 0.256 0.225 
5 hour 0.278 0.297 0.287 0.306 0.310 0.220  
0.295 0.295 0.288 0.306 0.307 0.223  
0.299 0.283 0.283 0.756 0.289 0.218 
Average 0.291 0.292 0.286 0.456 0.302 0.220 
7 hour 0.300 0.295 0.312 0.308 0.328 0.221  
0.298 0.292 0.301 0.309 0.324 0.220  
0.288 0.268 0.292 0.302 0.327 0.222 
Average 0.295 0.285 0.302 0.306 0.326 0.221 
 
Table 39: Corresponding data to Figure 32 from UV Spectroscopy Results 
Hour Control 6mg 7mg 8mg 9mg 10mg 
0 0.220 0.226 0.233 0.238 0.223 0.220 
1 0.222 0.242 0.239 0.245 0.239 0.257 
3 0.224 0.255 0.242 0.253 0.247 0.256 
5 0.221 0.291 0.292 0.286 0.456 0.302 
7 0.221 0.295 0.285 0.302 0.306 0.326 
 
Table 40: Corresponding data to Figure 34 from UV Spectroscopy Standard Curve 
Standard Curve: 
   
Avg. 
0 0.221 0.220 0.225 0.222 
1 0.295 0.289 0.284 0.289 
3 0.394 0.403 0.402 0.400 
5 0.515 0.512 0.508 0.512 
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10 0.898 0.923 0.908 0.910 
20 1.575 1.635 1.634 1.615 
30 2.067 2.134 2.113 2.105 
 
Code for UV Spectroscopy Statistical Analysis 
%% MATLAB Data Analysis MQP 
%% Two Way ANOVA Analysis - UV Spec 
  
UV_Spec = [0.243    0.244   0.242   0.238   0.251   0.216; 
0.244   0.238   0.243   0.245   0.265   0.222; 
0.238   0.235   0.249   0.233   0.255   0.224; 
0.257   0.245   0.258   0.238   0.253   0.221; 
0.262   0.241   0.257   0.25    0.263   0.225; 
0.246   0.241   0.245   0.253   0.251   0.23; 
0.278   0.297   0.287   0.306   0.31    0.234; 
0.295   0.295   0.288   0.306   0.307   0.237; 
0.299   0.283   0.283   0.756   0.289   0.239; 
0.3 0.295   0.312   0.308   0.328   0.241; 
0.298   0.292   0.301   0.309   0.324   0.246; 
0.288   0.268   0.292   0.302   0.327   0.249;]; 
  
  
[p, tbl] = anova2(UV_Spec,3);  
 
Appendix IVc: AFM Surface Roughness Images 
Results of the AFM surface roughness are shown in Figures 85-98. 
Figure 85: AFM Top-down image of Fibrin Particle Sample Plate 
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Figure 86: Side Image of Fibrin Particle Sample Plate under AFM 
 
Figure 87: AFM image of Fibrin Particle with Data Info 
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Figure 88: Derived Data of the AFM image in Figure 79, with Area Roughness Calculation for near-center 
cross section. 
 
Figure 89: Derived Data of the AFM image in Figure 79, with Area Roughness Calculation for lower-left 
cross section. 
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Figure 90: Near-center area roughness calculations from backward scan of Figure 79 
 
Figure 91: Near-Edge area roughness calculations from forward scan of Figure 79 
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Figure 92: Center cross section area roughness analysis on forward scan of Figure 79 
  
Figure 93: Near Center cross-section area roughness calculations from backward scan 
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Figure 94: Top-Right Cross section area roughness calculations from backward scan 
  
Figure 95: Whole image area roughness calculations for forward scan 
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Figure 96: Whole Image area roughness calculations from backwards scan 
 
Figure 97: Unreadable imaging of cut face of Fibrin Particle 
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Figure 98: Attempted area roughness calculation for cut face particle 
 
Appendix IVd: Channels UV Sub-Experiment Results  
Objective: 
- Identify whether retinol is seeping out of threads during extrusion or not.  
Hypothesis: Given the ratio of retinol to HEPES during the drawing of a singular thread, the 
overall concentration gradient is forcing the retinol to disperse out into the HEPES and not stay 
into thread. 
Materials: 
- Retinol-Infused Fibrin Microthreads (25mg/ml retinol in ethanol solution, 100ul ROL in EtOH 
for one batch)  
- HEPES 
- 5ml multi-channel tub  
 -Specs: 19 wells, well radius: 7mm. Well length: 180mm. Max Volume: 14 mls (Half-
Cylinder) 
- SpectraMax 250 
- Bromelain Powder 
 
Procedures: 
Part 1: Drawing and Collecting Samples 
1. Produce a single batch of retinol-infused fibrin microthreads using the protocol for 
producing additive infused fibrin threads. Please note that instead of using the regular 
500ml tub, instead use a series of small channels as individual tubs, much like the one 
seen in Figure 99 below: 
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Figure 99: A custom 3D Printed multi-channel design (has 19 channels) 
 
Use 5ml of HEPES for each channel. 
2. Draw a single thread into as many of the wells as possible. As a rule of thumb, take about 
15 seconds drawing within each well. 
3. Remove the threads from the channels once they are ready to be removed. DO NOT 
empty the channels for cleaning. 
4. Allow the threads to dry. Bonus: collect droplets from the threads as they are drying or 
during any part of their removal from the channels (i.e. when you are lifting them from 
the channels using tweezers and they are suspended in mid-air. 
Part 2: Prepping Samples and Controls 
5. Collect the 5ml HEPES from each of the channels separately and place them in a 12-well 
plate (use as many as needed). See Set-up in Figure 100.  
6. Create controls using retinol in ethanol solution (0,10,25,50,100ul respectively) and 
HEPES (fill to 5mls). See Set-up in Figure 101. 
7. Once the threads are dried, bundle them, and weigh them in milligrams. Write down the 
weight before placing the bundled threads into a single 5ml well of HEPES. Hint: the 
bundled threads can be kneaded into a ball with your fingers to make placement into the 
well easier.  
8. Based on the weight (in mg) of the batch of retinol-infused fibrin threads, add 10x 
bromelain powder to the fibrin batch well*. 
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9. Create a separate control of just HEPES and the same quantity of bromelain powder used 
in step 8. 
10. Create a final well using the collected droplets from the drying threads (we used 100ul) 
and fill the rest up to 5mls with HEPES. 
11. Place the wells on a horizontal orbital shaker for 3 hours. 
*Based on the results of the exploratory fibrin degradation experiment, where it takes around 3 
hours to fully degrade 1mg of fibrin with 10mg of bromelain.  
Part 3: UV Spectroscopy Data Collection 
12. After waiting for 3 hours, examine each of the wells and write down observations.  
13. Take 100ul samples of each sample and control (in triplicate) and organize them onto a 
96-well plate for reading. 
14. Take readings for each sample on the 96-well plate using the Spectra Max 250 plate 
reader. Results are shown in Figures 102-103. 
15. Transfer the results from the plate reader over to an excel file for further statistical 
analysis. 
Results: 
 
Figure 100: Channels 1-12 transferred over to a 12-well plate 
205 
 
 
Figure 101: Top-row:Channels 13-16;  
Mid-row starting from Left: 0,10,25,50ul ROL in EtOH standards;  
Bottom-row from Left: 100ul ROL in EtOH, 37mg fibrin batch + 370mg bromelain, 100ul collected droplets 
from hung threads, 370mg bromelain 
 
Figure 102: SpectraMax 250 template for UV Spec testing; CH - Channel; C# - Control/Standard, amount of 
ROL in EtOH (ul); T - Threads+Bromelain; M - Droplets from threads; B - 370mg Bromelain 
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Figure 103: Results from UV Spectroscopy reading 
 
Appendix V: CAD drawings for Automated Fibrin Microthread Production 
Mechanism 
  
Figure 104: CAD image for Automated Fibrin Microthread Production Mechanism Final Design 
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Figure 105: CAD of 80/20 Frame 
 
 
Figure 106: CAD of Chain Guiding Platform 
 
 
Figure 107: CAD of Stepper Motor 1 Holster 
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Figure 108: CAD Assembly of Drive Shaft Bracket and Ball Roller Bearing 
 
Figure 109: CAD Assembly of Drive Shaft Bearing Assembly, Sprockets, and Hex Bar 
 
 
Figure 110: CAD Assembly of Bearing, Bracket, and Sprocket 
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Figure 111: CAD Assembly of Chain and Magnetic Clamps 
 
Figure 112: CAD of 80/20 Gantry Frame 
 
Figure 113: CAD of Slider for Extruder 
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Figure 114: CAD of Holster for Stepper Motor 2 
 
Figure 115: CAD Assembly of Tub and Conveyor 
 
 
Figure 116: CAD Assembly of Conveyor 
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Figure 117: CAD of L-frame 1 
 
 
Figure 118: CAD of L-frame 2 
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Figure 119: CAD of Bearing for Conveyor Roller 
 
Figure 120: CAD of Urethane Conveyor Belt 
 
Figure 121: CAD of PVC for Conveyor Roller Assembly 
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Figure 122: CAD of Threaded Rod for Conveyor Drive Roller Assembly 
 
Figure 123: CAD of 3/8 in Hex Bolt 
 
Figure 124: CAD of 3/8 in Hex Nut 
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Figure 125: CAD of 3/8 in Washer 
 
Figure 126: CAD for Rubber Bung to Provide Friction Between Threaded Rod and PVC of Conveyor Drive 
Roller 
 
 
Figure 127: CAD of Acrylic Tub 
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Figure 128: CAD of Pulley for Conveyor Drive Roller for Coupling with Hex Bar 
 
Figure 129: CAD of Pulley for Hex Bar Drive Shaft 
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Appendix VI: Conversion Preliminary Testing Results and Design Analysis 
Table 41 shows the initial imaging analysis of the different conversion methods. The 
teammates’ Design Analysis of the conversion mechanism are shown in Figures 42-43 
respectively.  
 Table 41: Initial Testing Conversion Method Image Analysis - Fibrin Particle Length Measurements 
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Table 43: Pairwise Comparison Charts for the other Teammates 
Table 42: Design Matrices for the other teammates 
